vencortex/NewsPress · Datasets at Hugging Face

source stringlengths 2 222	date stringlengths 19 19	url stringlengths 22 853 ⌀	text stringlengths 0 10k ⌀	title stringlengths 0 701	context_id stringlengths 1 9	document_id stringclasses 2 values	document_type stringclasses 2 values
Press Release 0 2CRSI.PA 1 2CRSI.PA 2 2CRSI.PA 3 2CRSI.PA 4 2CRSI.PA ... 83 ZYXI 84 ZYXI 85 ZYXI 0 ZZZ.TO 1 ZZZ.TO Name: symbol, Length: 320040, dtype: object	2022-01-19 16:15:00	null	VANCOUVER, BRITISH COLUMBIA & SEATTLE--(BUSINESS WIRE)--ZYMEWORKS INC. (NYSE: ZYME), A CLINICAL-STAGE BIOPHARMACEUTICAL COMPANY DEVELOPING MULTIFUNCTIONAL BIOTHERAPEUTICS, TODAY PROVIDED A CORPORATE UPDATE ON ITS KEY STRATEGIC PRIORITIES FOR 2022 AND 2023 IN ADDITION TO CONFIRMING ITS UPCOMING CLINICAL DEVELOPMENT MILE...	ZYMEWORKS PROVIDES CORPORATE UPDATE ON KEY STRATEGIC PRIORITIES AND OUTLOOK FOR 2022	ZYME	a5c0a04e-eb88-4264-9cb2-fb3140e63537	PressRelease
Press Release 0 2CRSI.PA 1 2CRSI.PA 2 2CRSI.PA 3 2CRSI.PA 4 2CRSI.PA ... 83 ZYXI 84 ZYXI 85 ZYXI 0 ZZZ.TO 1 ZZZ.TO Name: symbol, Length: 320040, dtype: object	2022-01-15 08:30:00	null	VANCOUVER, BRITISH COLUMBIA & SEATTLE--(BUSINESS WIRE)--ZYMEWORKS INC. (NYSE: ZYME), A CLINICAL-STAGE BIOPHARMACEUTICAL COMPANY DEVELOPING MULTIFUNCTIONAL BIOTHERAPEUTICS, TODAY REPORTED, AS REQUIRED BY THE NEW YORK STOCK EXCHANGE LISTED COMPANY MANUAL RULE 303A.08 (THE “NYSE RULE”), AN EQUITY INDUCEMENT AWARD TO MR. K...	ZYMEWORKS REPORTS INDUCEMENT GRANT UNDER NEW YORK STOCK EXCHANGE LISTED COMPANY MANUAL RULE	ZYME	a5c0a04e-eb88-4264-9cb2-fb3140e63537	PressRelease
Press Release 0 2CRSI.PA 1 2CRSI.PA 2 2CRSI.PA 3 2CRSI.PA 4 2CRSI.PA ... 83 ZYXI 84 ZYXI 85 ZYXI 0 ZZZ.TO 1 ZZZ.TO Name: symbol, Length: 320040, dtype: object	2022-01-05 16:30:00	null	VANCOUVER, BRITISH COLUMBIA & SEATTLE--(BUSINESS WIRE)--ZYMEWORKS NAMES BIOTECHNOLOGY INDUSTRY LEADER KENNETH GALBRAITH AS CHAIR AND CEO TO SUCCEED DR. ALI TEHRANI	ZYMEWORKS NAMES BIOTECHNOLOGY INDUSTRY LEADER KENNETH GALBRAITH AS CHAIR AND CEO TO SUCCEED DR. ALI TEHRANI	ZYME	a5c0a04e-eb88-4264-9cb2-fb3140e63537	PressRelease
Press Release 0 2CRSI.PA 1 2CRSI.PA 2 2CRSI.PA 3 2CRSI.PA 4 2CRSI.PA ... 83 ZYXI 84 ZYXI 85 ZYXI 0 ZZZ.TO 1 ZZZ.TO Name: symbol, Length: 320040, dtype: object	2021-12-09 08:30:00	null	VANCOUVER, BRITISH COLUMBIA--(BUSINESS WIRE)--ZYMEWORKS INC. (NYSE: ZYME), A CLINICAL-STAGE BIOPHARMACEUTICAL COMPANY DEVELOPING MULTIFUNCTIONAL BIOTHERAPEUTICS, TODAY ANNOUNCED THAT ITS COLLABORATOR, BEIGENE, LTD., HAS DOSED THE FIRST PATIENT IN SOUTH KOREA IN THE HERIZON‑GEA‑01 TRIAL. AS A RESULT OF THIS DEVELOPMENT ...	ZYMEWORKS ANNOUNCES EXPANSION OF ZANIDATAMAB PIVOTAL TRIAL IN ASIA IN COLLABORATION WITH BEIGENE AND ASSOCIATED MILESTONE PAYMENT	ZYME	a5c0a04e-eb88-4264-9cb2-fb3140e63537	PressRelease
Press Release 0 2CRSI.PA 1 2CRSI.PA 2 2CRSI.PA 3 2CRSI.PA 4 2CRSI.PA ... 83 ZYXI 84 ZYXI 85 ZYXI 0 ZZZ.TO 1 ZZZ.TO Name: symbol, Length: 320040, dtype: object	2021-12-08 18:00:00	null	VANCOUVER, BRITISH COLUMBIA--(BUSINESS WIRE)--ZANIDATAMAB DATA PRESENTED AT THE SAN ANTONIO BREAST CANCER SYMPOSIUM (SABCS) DEMONSTRATE ENCOURAGING ANTITUMOR ACTIVITY	ZANIDATAMAB DATA PRESENTED AT THE SAN ANTONIO BREAST CANCER SYMPOSIUM (SABCS) DEMONSTRATE ENCOURAGING ANTITUMOR ACTIVITY IN HEAVILY PRETREATED PATIENTS WITH HER2-POSITIVE BREAST CANCER	ZYME	a5c0a04e-eb88-4264-9cb2-fb3140e63537	PressRelease
Press Release 0 2CRSI.PA 1 2CRSI.PA 2 2CRSI.PA 3 2CRSI.PA 4 2CRSI.PA ... 83 ZYXI 84 ZYXI 85 ZYXI 0 ZZZ.TO 1 ZZZ.TO Name: symbol, Length: 320040, dtype: object	2021-11-19 09:21:00	null	VANCOUVER, BRITISH COLUMBIA--(BUSINESS WIRE)--ZYMEWORKS ANNOUNCES ABSTRACT FOR ZANIDATAMAB IN LATE-LINE HER2-POSITIVE BREAST CANCER AT THE SAN ANTONIO BREAST CANCER SYMPOSIUM (SABCS)	ZYMEWORKS ANNOUNCES ABSTRACT FOR ZANIDATAMAB IN LATE-LINE HER2-POSITIVE BREAST CANCER AT THE SAN ANTONIO BREAST CANCER SYMPOSIUM (SABCS)	ZYME	a5c0a04e-eb88-4264-9cb2-fb3140e63537	PressRelease
Press Release 0 2CRSI.PA 1 2CRSI.PA 2 2CRSI.PA 3 2CRSI.PA 4 2CRSI.PA ... 83 ZYXI 84 ZYXI 85 ZYXI 0 ZZZ.TO 1 ZZZ.TO Name: symbol, Length: 320040, dtype: object	2021-11-09 08:30:00	null	VANCOUVER, BRITISH COLUMBIA--(BUSINESS WIRE)--ZYMEWORKS LAUNCHES GLOBAL PHASE 3 ZANIDATAMAB TRIAL IN FIRST-LINE HER2 POSITIVE GASTROESOPHAGEAL ADENOCARCINOMA (GEA)	ZYMEWORKS LAUNCHES GLOBAL PHASE 3 ZANIDATAMAB TRIAL IN FIRST-LINE HER2‑POSITIVE GASTROESOPHAGEAL ADENOCARCINOMA (GEA)	ZYME	a5c0a04e-eb88-4264-9cb2-fb3140e63537	PressRelease
Press Release 0 2CRSI.PA 1 2CRSI.PA 2 2CRSI.PA 3 2CRSI.PA 4 2CRSI.PA ... 83 ZYXI 84 ZYXI 85 ZYXI 0 ZZZ.TO 1 ZZZ.TO Name: symbol, Length: 320040, dtype: object	2021-09-16 05:30:00	null	VANCOUVER, BRITISH COLUMBIA--(BUSINESS WIRE)--ZYMEWORKS INC. (NYSE: ZYME), A CLINICAL-STAGE BIOPHARMACEUTICAL COMPANY DEVELOPING MULTIFUNCTIONAL BIOTHERAPEUTICS, TODAY ANNOUNCED THAT NEW CLINICAL DATA FOR ZANIDATAMAB, A HER2‑TARGETED BISPECIFIC ANTIBODY, DEMONSTRATE PROMISING RESPONSE RATES AND DURABILITY IN FIRST-LINE...	ZANIDATAMAB PHASE 2 CLINICAL TRIAL DEMONSTRATES PROMISING RESPONSE RATE AND DURABILITY IN FIRST-LINE HER2-POSITIVE GASTROESOPHAGEAL ADENOCARCINOMA (GEA) AT THE EUROPEAN SOCIETY FOR MEDICAL ONCOLOGY (ESMO) ANNUAL CONGRESS	ZYME	a5c0a04e-eb88-4264-9cb2-fb3140e63537	PressRelease
Press Release 0 2CRSI.PA 1 2CRSI.PA 2 2CRSI.PA 3 2CRSI.PA 4 2CRSI.PA ... 83 ZYXI 84 ZYXI 85 ZYXI 0 ZZZ.TO 1 ZZZ.TO Name: symbol, Length: 320040, dtype: object	2021-09-12 18:49:00	null	VANCOUVER, BRITISH COLUMBIA--(BUSINESS WIRE)--THIS PRESS RELEASE ANNOUNCES THE AVAILABILITY OF AN ABSTRACT THAT ZYMEWORKS IS PRESENTING AT THE UPCOMING ESMO CONGRESS	ZYMEWORKS ANNOUNCES ABSTRACT FOR ZANIDATAMAB IN FIRST-LINE HER2-EXPRESSING GASTROESOPHAGEAL CANCERS (GEA) AT THE EUROPEAN SOCIETY FOR MEDICAL ONCOLOGY (ESMO) ANNUAL CONGRESS	ZYME	a5c0a04e-eb88-4264-9cb2-fb3140e63537	PressRelease
Press Release 0 2CRSI.PA 1 2CRSI.PA 2 2CRSI.PA 3 2CRSI.PA 4 2CRSI.PA ... 83 ZYXI 84 ZYXI 85 ZYXI 0 ZZZ.TO 1 ZZZ.TO Name: symbol, Length: 320040, dtype: object	2021-08-04 16:15:00	null	VANCOUVER, BRITISH COLUMBIA--(BUSINESS WIRE)--ZYMEWORKS INC. (NYSE: ZYME), A CLINICAL-STAGE BIOPHARMACEUTICAL COMPANY DEVELOPING MULTIFUNCTIONAL BIOTHERAPEUTICS, TODAY REPORTED FINANCIAL RESULTS FOR THE SECOND QUARTER ENDED JUNE 30, 2021. “THE SECOND HALF OF 2021 IS AN EXCITING TIME AT ZYMEWORKS AS WE PREPARE TO PRESEN...	ZYMEWORKS REPORTS 2021 SECOND QUARTER FINANCIAL RESULTS	ZYME	a5c0a04e-eb88-4264-9cb2-fb3140e63537	PressRelease
Press Release 0 2CRSI.PA 1 2CRSI.PA 2 2CRSI.PA 3 2CRSI.PA 4 2CRSI.PA ... 83 ZYXI 84 ZYXI 85 ZYXI 0 ZZZ.TO 1 ZZZ.TO Name: symbol, Length: 320040, dtype: object	2021-08-03 08:30:00	null	VANCOUVER, BRITISH COLUMBIA--(BUSINESS WIRE)--ZYMEWORKS ANNOUNCES MILESTONE PAYMENT AS JANSSEN ACHIEVES FIRST PATIENT DOSED FOR ITS BISPECIFIC ANTIBODY UTILIZING ZYMEWORKS' THERAPEUTIC PLATFORMS	ZYMEWORKS ANNOUNCES MILESTONE PAYMENT AS JANSSEN ACHIEVES FIRST PATIENT DOSED FOR ITS BISPECIFIC ANTIBODY UTILIZING ZYMEWORKS' AZYMETRIC™ AND EFECT™ THERAPEUTIC PLATFORMS	ZYME	a5c0a04e-eb88-4264-9cb2-fb3140e63537	PressRelease
Press Release 0 2CRSI.PA 1 2CRSI.PA 2 2CRSI.PA 3 2CRSI.PA 4 2CRSI.PA ... 83 ZYXI 84 ZYXI 85 ZYXI 0 ZZZ.TO 1 ZZZ.TO Name: symbol, Length: 320040, dtype: object	2021-07-28 08:30:00	null	VANCOUVER, BRITISH COLUMBIA--(BUSINESS WIRE)--ZYMEWORKS ANNOUNCES FIRST PATIENT WITH ADVANCED HER2-POSITIVE BREAST CANCER DOSED WITH ZANIDATAMAB IN COMBINATION WITH TUKYSA® AND CHEMOTHERAPY	ZYMEWORKS ANNOUNCES FIRST PATIENT WITH ADVANCED HER2-POSITIVE BREAST CANCER DOSED WITH ZANIDATAMAB IN COMBINATION WITH TUKYSA® (TUCATINIB) AND CHEMOTHERAPY	ZYME	a5c0a04e-eb88-4264-9cb2-fb3140e63537	PressRelease
Press Release 0 2CRSI.PA 1 2CRSI.PA 2 2CRSI.PA 3 2CRSI.PA 4 2CRSI.PA ... 83 ZYXI 84 ZYXI 85 ZYXI 0 ZZZ.TO 1 ZZZ.TO Name: symbol, Length: 320040, dtype: object	2021-04-19 08:30:00	null	VANCOUVER, BRITISH COLUMBIA--(BUSINESS WIRE)--ZYMEWORKS INC. (NYSE: ZYME), A CLINICAL-STAGE BIOPHARMACEUTICAL COMPANY DEVELOPING MULTIFUNCTIONAL BIOTHERAPEUTICS, TODAY ANNOUNCED THAT DIANA HAUSMAN, M.D., WILL BE TRANSITIONING OUT OF HER ROLE AS ZYMEWORKS' CHIEF MEDICAL OFFICER (CMO) AND ASSUMING AN EXECUTIVE ADVISORY R...	ZYMEWORKS ANNOUNCES SUCCESSION PLAN FOR CHIEF MEDICAL OFFICER	ZYME	a5c0a04e-eb88-4264-9cb2-fb3140e63537	PressRelease
Press Release 0 2CRSI.PA 1 2CRSI.PA 2 2CRSI.PA 3 2CRSI.PA 4 2CRSI.PA ... 83 ZYXI 84 ZYXI 85 ZYXI 0 ZZZ.TO 1 ZZZ.TO Name: symbol, Length: 320040, dtype: object	2021-04-10 08:30:00	null	VANCOUVER, BRITISH COLUMBIA--(BUSINESS WIRE)--ZYMEWORKS SHOWCASES PRECLINICAL ASSETS, INCLUDING NEW THERAPEUTIC PLATFORM, PROTECT™, AND ZANIDATAMAB MECHANISMS OF ACTION AT AACR ANNUAL MEETING	ZYMEWORKS SHOWCASES PRECLINICAL ASSETS, INCLUDING NEW THERAPEUTIC PLATFORM, PROTECT™, AND ZANIDATAMAB MECHANISMS OF ACTION AT AACR ANNUAL MEETING	ZYME	a5c0a04e-eb88-4264-9cb2-fb3140e63537	PressRelease
Press Release 0 2CRSI.PA 1 2CRSI.PA 2 2CRSI.PA 3 2CRSI.PA 4 2CRSI.PA ... 83 ZYXI 84 ZYXI 85 ZYXI 0 ZZZ.TO 1 ZZZ.TO Name: symbol, Length: 320040, dtype: object	2021-03-10 17:27:00	null	VANCOUVER, BRITISH COLUMBIA--(BUSINESS WIRE)--ZYMEWORKS INC. (NYSE: ZYME), A CLINICAL-STAGE BIOPHARMACEUTICAL COMPANY DEVELOPING MULTIFUNCTIONAL BIOTHERAPEUTICS, TODAY ANNOUNCED THE ACCEPTANCE OF FIVE ABSTRACTS FOR POSTER PRESENTATION AT THE UPCOMING AMERICAN ASSOCIATION FOR CANCER RESEARCH (AACR) ANNUAL MEETING 2021 T...	ZYMEWORKS ANNOUNCES FIVE PRESENTATIONS AT THE AMERICAN ASSOCIATION FOR CANCER RESEARCH (AACR) ANNUAL MEETING 2021	ZYME	a5c0a04e-eb88-4264-9cb2-fb3140e63537	PressRelease
Press Release 0 2CRSI.PA 1 2CRSI.PA 2 2CRSI.PA 3 2CRSI.PA 4 2CRSI.PA ... 83 ZYXI 84 ZYXI 85 ZYXI 0 ZZZ.TO 1 ZZZ.TO Name: symbol, Length: 320040, dtype: object	2021-02-24 16:15:00	null	VANCOUVER, CANADA--(BUSINESS WIRE)--ZYMEWORKS INC. (NYSE: ZYME), A CLINICAL-STAGE BIOPHARMACEUTICAL COMPANY DEVELOPING MULTIFUNCTIONAL BIOTHERAPEUTICS, TODAY REPORTED FINANCIAL RESULTS FOR THE YEAR ENDED DECEMBER 31, 2020 AND PROVIDED A SUMMARY OF RECENT BUSINESS AND CLINICAL HIGHLIGHTS. “THROUGHOUT 2020, WE INITIATED ...	ZYMEWORKS REPORTS 2020 YEAR-END FINANCIAL RESULTS	ZYME	a5c0a04e-eb88-4264-9cb2-fb3140e63537	PressRelease
Press Release 0 2CRSI.PA 1 2CRSI.PA 2 2CRSI.PA 3 2CRSI.PA 4 2CRSI.PA ... 83 ZYXI 84 ZYXI 85 ZYXI 0 ZZZ.TO 1 ZZZ.TO Name: symbol, Length: 320040, dtype: object	2021-02-09 16:30:00	null	VANCOUVER, BRITISH COLUMBIA--(BUSINESS WIRE)--ZYMEWORKS INC. (NYSE: ZYME), A CLINICAL-STAGE BIOPHARMACEUTICAL COMPANY DEVELOPING MULTIFUNCTIONAL BIOTHERAPEUTICS, TODAY ANNOUNCED THAT JAMES PRIOUR, FORMER SENIOR VICE PRESIDENT, COMMERCIAL, HAS BEEN PROMOTED TO CHIEF COMMERCIAL OFFICER AND NAMED TO THE COMPANY'S EXECUTIV...	ZYMEWORKS EXPANDS COMMERCIAL TEAM AND CREATES NEW R&D ROLE	ZYME	a5c0a04e-eb88-4264-9cb2-fb3140e63537	PressRelease
Press Release 0 2CRSI.PA 1 2CRSI.PA 2 2CRSI.PA 3 2CRSI.PA 4 2CRSI.PA ... 83 ZYXI 84 ZYXI 85 ZYXI 0 ZZZ.TO 1 ZZZ.TO Name: symbol, Length: 320040, dtype: object	2021-01-27 17:15:00	null	VANCOUVER, BRITISH COLUMBIA--(BUSINESS WIRE)--ZYMEWORKS INC. (NYSE: ZYME), A CLINICAL-STAGE BIOPHARMACEUTICAL COMPANY DEVELOPING MULTIFUNCTIONAL BIOTHERAPEUTICS, ANNOUNCED TODAY THAT THE COMPANY HAS BEGUN ENROLLING PATIENTS INTO THE EXPANSION COHORT PORTION OF THE ONGOING PHASE 1 CLINICAL TRIAL FOR ZW49, ITS NOVEL HER2...	ZYMEWORKS ADVANCES HER2 BISPECIFIC ANTIBODY-DRUG CONJUGATE, ZW49, INTO EXPANSION COHORT STAGE OF CLINICAL DEVELOPMENT	ZYME	a5c0a04e-eb88-4264-9cb2-fb3140e63537	PressRelease
Press Release 0 2CRSI.PA 1 2CRSI.PA 2 2CRSI.PA 3 2CRSI.PA 4 2CRSI.PA ... 83 ZYXI 84 ZYXI 85 ZYXI 0 ZZZ.TO 1 ZZZ.TO Name: symbol, Length: 320040, dtype: object	2021-01-15 08:30:00	null	VANCOUVER, BRITISH COLUMBIA--(BUSINESS WIRE)--ZYMEWORKS INC. (NYSE: ZYME), A CLINICAL-STAGE BIOPHARMACEUTICAL COMPANY DEVELOPING MULTIFUNCTIONAL BIOTHERAPEUTICS, TODAY ANNOUNCED NEW AND UPDATED CLINICAL DATA FOR THE HER2‑TARGETED BISPECIFIC ANTIBODY ZANIDATAMAB, IN BOTH HER2-EXPRESSING BILIARY TRACT CANCER (BTC) AND GA...	ZANIDATAMAB DATA HIGHLIGHT DURABLE ANTITUMOR ACTIVITY IN HER2‑EXPRESSING BILIARY TRACT AND GASTROESOPHAGEAL CANCERS AT ASCO GASTROINTESTINAL CANCERS SYMPOSIUM	ZYME	a5c0a04e-eb88-4264-9cb2-fb3140e63537	PressRelease
Press Release 0 2CRSI.PA 1 2CRSI.PA 2 2CRSI.PA 3 2CRSI.PA 4 2CRSI.PA ... 83 ZYXI 84 ZYXI 85 ZYXI 0 ZZZ.TO 1 ZZZ.TO Name: symbol, Length: 320040, dtype: object	2021-01-11 08:00:00	null	VANCOUVER, BRITISH COLUMBIA--(BUSINESS WIRE)--ZYMEWORKS INC. (NYSE: ZYME), A CLINICAL-STAGE BIOPHARMACEUTICAL COMPANY DEVELOPING MULTIFUNCTIONAL BIOTHERAPEUTICS, TODAY HIGHLIGHTED ITS KEY ACCOMPLISHMENTS IN 2020 AND UPDATED ITS CORPORATE PRIORITIES. “2020 WAS A LEAP FORWARD FOR OUR LEAD CLINICAL PROGRAM IN TERMS OF A P...	ZYMEWORKS HIGHLIGHTS 2020 ACHIEVEMENTS AND ANNOUNCES CORPORATE PRIORITIES	ZYME	a5c0a04e-eb88-4264-9cb2-fb3140e63537	PressRelease
Press Release 0 2CRSI.PA 1 2CRSI.PA 2 2CRSI.PA 3 2CRSI.PA 4 2CRSI.PA ... 83 ZYXI 84 ZYXI 85 ZYXI 0 ZZZ.TO 1 ZZZ.TO Name: symbol, Length: 320040, dtype: object	2020-12-10 08:30:00	null	VANCOUVER, BRITISH COLUMBIA--(BUSINESS WIRE)--ZYMEWORKS INC. (NYSE: ZYME), A CLINICAL-STAGE BIOPHARMACEUTICAL COMPANY DEVELOPING MULTIFUNCTIONAL BIOTHERAPEUTICS, TODAY ANNOUNCED THE SELECTION OF THREE ABSTRACTS FOR PRESENTATION AT THE AMERICAN SOCIETY OF CLINICAL ONCOLOGY (ASCO) GASTROINTESTINAL CANCERS SYMPOSIUM, TAKI...	ZANIDATAMAB CLINICAL DATA SELECTED FOR ORAL PRESENTATION AT THE AMERICAN SOCIETY OF CLINICAL ONCOLOGY (ASCO) GASTROINTESTINAL CANCERS SYMPOSIUM	ZYME	a5c0a04e-eb88-4264-9cb2-fb3140e63537	PressRelease
Press Release 0 2CRSI.PA 1 2CRSI.PA 2 2CRSI.PA 3 2CRSI.PA 4 2CRSI.PA ... 83 ZYXI 84 ZYXI 85 ZYXI 0 ZZZ.TO 1 ZZZ.TO Name: symbol, Length: 320040, dtype: object	2020-11-19 08:30:00	null	VANCOUVER, BRITISH COLUMBIA--(BUSINESS WIRE)--ZYMEWORKS INC. (NYSE:ZYME), A CLINICAL-STAGE BIOPHARMACEUTICAL COMPANY DEVELOPING MULTIFUNCTIONAL BIOTHERAPEUTICS, TODAY ANNOUNCED THAT THE EUROPEAN COMMISSION (EC) HAS GRANTED ORPHAN DRUG DESIGNATION FOR ZANIDATAMAB, THE COMPANY'S INVESTIGATIONAL HER2-TARGETED BISPECIFIC A...	ZYMEWORKS RECEIVES ORPHAN DRUG DESIGNATION FROM THE EUROPEAN COMMISSION FOR HER2-TARGETED BISPECIFIC ANTIBODY ZANIDATAMAB IN PATIENTS WITH GASTRIC CANCER	ZYME	a5c0a04e-eb88-4264-9cb2-fb3140e63537	PressRelease
Press Release 0 2CRSI.PA 1 2CRSI.PA 2 2CRSI.PA 3 2CRSI.PA 4 2CRSI.PA ... 83 ZYXI 84 ZYXI 85 ZYXI 0 ZZZ.TO 1 ZZZ.TO Name: symbol, Length: 320040, dtype: object	2020-11-16 16:15:00	null	VANCOUVER, BRITISH COLUMBIA & BURLINGAME, CALIF.--(BUSINESS WIRE)--ZYMEWORKS INC. (NYSE: ZYME), A CLINICAL-STAGE BIOPHARMACEUTICAL COMPANY DEVELOPING MULTIFUNCTIONAL BIOTHERAPEUTICS, AND ALX ONCOLOGY HOLDINGS INC. (NASDAQ: ALXO), A CLINICAL-STAGE IMMUNO-ONCOLOGY COMPANY DEVELOPING THERAPIES THAT BLOCK THE CD47 CHECKPOI...	ZYMEWORKS AND ALX ONCOLOGY ANNOUNCE CLINICAL COLLABORATION EVALUATING ZANIDATAMAB WITH THE CD47 BLOCKER ALX148 IN PATIENTS WITH ADVANCED HER2‑EXPRESSING BREAST CANCER	ZYME	a5c0a04e-eb88-4264-9cb2-fb3140e63537	PressRelease
Press Release 0 2CRSI.PA 1 2CRSI.PA 2 2CRSI.PA 3 2CRSI.PA 4 2CRSI.PA ... 83 ZYXI 84 ZYXI 85 ZYXI 0 ZZZ.TO 1 ZZZ.TO Name: symbol, Length: 320040, dtype: object	2020-11-03 16:15:00	null	VANCOUVER, BRITISH COLUMBIA--(BUSINESS WIRE)--ZYMEWORKS INC. (NYSE: ZYME), A CLINICAL-STAGE BIOPHARMACEUTICAL COMPANY DEVELOPING MULTIFUNCTIONAL BIOTHERAPEUTICS, TODAY REPORTED FINANCIAL RESULTS FOR THE QUARTER ENDED SEPTEMBER 30, 2020. “ZANIDATAMAB'S CLINICAL DEVELOPMENT CONTINUED TO EXPAND THIS QUARTER, HAVING OPENED...	ZYMEWORKS REPORTS 2020 THIRD QUARTER FINANCIAL RESULTS	ZYME	a5c0a04e-eb88-4264-9cb2-fb3140e63537	PressRelease
Press Release 0 2CRSI.PA 1 2CRSI.PA 2 2CRSI.PA 3 2CRSI.PA 4 2CRSI.PA ... 83 ZYXI 84 ZYXI 85 ZYXI 0 ZZZ.TO 1 ZZZ.TO Name: symbol, Length: 320040, dtype: object	2020-08-05 18:30:00	null	ZYMEWORKS REPORTS 2020 SECOND QUARTER FINANCIAL RESULTS.Q2 REVENUE $12.4 MILLION VERSUS $7.9 MILLION.QTRLY LOSS PER SHARE $0.77.	ZYMEWORKS REPORTS QTRLY LOSS PER SHARE $0.77	ZYME	a5c0a04e-eb88-4264-9cb2-fb3140e63537	PressRelease
Press Release 0 2CRSI.PA 1 2CRSI.PA 2 2CRSI.PA 3 2CRSI.PA 4 2CRSI.PA ... 83 ZYXI 84 ZYXI 85 ZYXI 0 ZZZ.TO 1 ZZZ.TO Name: symbol, Length: 320040, dtype: object	2020-07-08 19:30:00	null	ZYMEWORKS - CO & MERCK SIGNED NEW LICENSE AGREEMENT.ZYMEWORKS - AGREEMENT GRANTS MERCK RIGHT TO DEVELOP ADDITIONAL MULTISPECIFIC ANTIBODY THERAPEUTIC CANDIDATES USING CO'S AZYMETRIC & EFECT PLATFORMS.ZYMEWORKS - TO PROVIDE MERCK WORLDWIDE, ROYALTY-BEARING LICENSE TO RESEARCH, COMMERCIALIZE UP TO 3 NEW MULTISPECIFIC ANT...	ZYMEWORKS & MERCK SIGN NEW LICENSE AGREEMENT	ZYME	a5c0a04e-eb88-4264-9cb2-fb3140e63537	PressRelease
Press Release 0 2CRSI.PA 1 2CRSI.PA 2 2CRSI.PA 3 2CRSI.PA 4 2CRSI.PA ... 83 ZYXI 84 ZYXI 85 ZYXI 0 ZZZ.TO 1 ZZZ.TO Name: symbol, Length: 320040, dtype: object	2020-05-07 19:30:00	null	ZYMEWORKS REPORTS 2020 FIRST QUARTER FINANCIAL RESULTS.Q1 REVENUE $8.3 MILLION VERSUS $11.9 MILLION.EXPECTS TO HAVE CASH TO FUND RESEARCH AND DEVELOPMENT PROGRAMS AND OPERATIONS INTO 2022 AND POTENTIALLY BEYOND.QTRLY LOSS PER SHARE $0.64.	ZYMEWORKS POSTS QUARTERLY LOSS PER SHARE OF $0.64	ZYME	a5c0a04e-eb88-4264-9cb2-fb3140e63537	PressRelease
Press Release 0 2CRSI.PA 1 2CRSI.PA 2 2CRSI.PA 3 2CRSI.PA 4 2CRSI.PA ... 83 ZYXI 84 ZYXI 85 ZYXI 0 ZZZ.TO 1 ZZZ.TO Name: symbol, Length: 320040, dtype: object	2020-01-21 20:30:00	null	ZYMEWORKS FILES PRELIMINARY PROSPECTUS SUPPLEMENTS FOR OFFERING OF COMMON SHARES AND PRE-FUNDED WARRANTS.	ZYMEWORKS FILES PRELIMINARY PROSPECTUS SUPPLEMENTS FOR OFFERING OF COMMON SHARES AND PRE-FUNDED WARRANTS	ZYME	a5c0a04e-eb88-4264-9cb2-fb3140e63537	PressRelease
Press Release 0 2CRSI.PA 1 2CRSI.PA 2 2CRSI.PA 3 2CRSI.PA 4 2CRSI.PA ... 83 ZYXI 84 ZYXI 85 ZYXI 0 ZZZ.TO 1 ZZZ.TO Name: symbol, Length: 320040, dtype: object	2020-01-12 13:30:00	null	ZYMEWORKS ANNOUNCES AGREEMENT WITH PFIZER AND INITIATION OF A NEW PHASE 2 TRIAL EVALUATING ZW25 IN COMBINATION WITH IBRANCE® (PALBOCICLIB).ZYMEWORKS WILL SPONSOR STUDY, AND PFIZER WILL PROVIDE PALBOCICLIB..PLANS TO INITIATE A REGISTRATION-ENABLING PHASE 2 TRIAL IN PREVIOUSLY-TREATED OR RECURRENT HER2-POSITIVE BILIARY T...	ZYMEWORKS ANNOUNCES AGREEMENT WITH PFIZER	ZYME	a5c0a04e-eb88-4264-9cb2-fb3140e63537	PressRelease
Press Release 0 2CRSI.PA 1 2CRSI.PA 2 2CRSI.PA 3 2CRSI.PA 4 2CRSI.PA ... 83 ZYXI 84 ZYXI 85 ZYXI 0 ZZZ.TO 1 ZZZ.TO Name: symbol, Length: 320040, dtype: object	2019-11-21 22:30:00	null	ZYMEWORKS INC. ANNOUNCED UPDATED PHASE 1 DATA FOR SINGLE AGENT ZW25 IN HEAVILY PRETREATED PATIENTS WITH HER2-EXPRESSING SOLID TUMORS IN A MINI ORAL PRESENTATION BY DR. DO-YOUN OH, STUDY INVESTIGATOR AND PROFESSOR AT SEOUL NATIONAL UNIVERSITY, AT THE ESMO ASIA 2019 CONGRESS, TAKING PLACE NOVEMBER 22 - 24 IN SINGAPORE. Z...	ZYMEWORKS INC. ANNOUNCES UPDATED PHASE 1 DATA FOR SINGLE AGENT ZW25	ZYME	a5c0a04e-eb88-4264-9cb2-fb3140e63537	PressRelease
Press Release 0 2CRSI.PA 1 2CRSI.PA 2 2CRSI.PA 3 2CRSI.PA 4 2CRSI.PA ... 83 ZYXI 84 ZYXI 85 ZYXI 0 ZZZ.TO 1 ZZZ.TO Name: symbol, Length: 320040, dtype: object	2019-11-17 22:30:00	null	ZYMEWORKS INC. ANNOUNCED THE SELECTION OF AN ABSTRACT HIGHLIGHTING UPDATED SINGLE AGENT DATA FROM THE PHASE 1 CLINICAL TRIAL EVALUATING THE HER2-TARGETED BISPECIFIC ANTIBODY, ZW25, IN PATIENTS WITH HER2-EXPRESSING SOLID TUMORS FOR A MINI ORAL PRESENTATION AT THE ESMO ASIA 2019 CONGRESS, TAKING PLACE NOVEMBER 22 - 24 IN...	ZYMEWORKS INC. ANNOUNCES SELECTION OF ZW25 ABSTRACT FOR MINI ORAL PRESENTATION AT THE EUROPEAN SOCIETY FOR MEDICAL ONCOLOGY ASIA (ESMO ASIA) CONGRESS	ZYME	a5c0a04e-eb88-4264-9cb2-fb3140e63537	PressRelease
Press Release 0 2CRSI.PA 1 2CRSI.PA 2 2CRSI.PA 3 2CRSI.PA 4 2CRSI.PA ... 83 ZYXI 84 ZYXI 85 ZYXI 0 ZZZ.TO 1 ZZZ.TO Name: symbol, Length: 320040, dtype: object	2019-11-05 21:30:00	null	ZYMEWORKS INC FILES FOR OFFERING OF UP TO $75.0 MILLION OF COMMON SHARES - SEC FILING.	ZYMEWORKS INC FILES FOR OFFERING OF UP TO $75 MLN OF COMMON SHARES	ZYME	a5c0a04e-eb88-4264-9cb2-fb3140e63537	PressRelease
Press Release 0 2CRSI.PA 1 2CRSI.PA 2 2CRSI.PA 3 2CRSI.PA 4 2CRSI.PA ... 83 ZYXI 84 ZYXI 85 ZYXI 0 ZZZ.TO 1 ZZZ.TO Name: symbol, Length: 320040, dtype: object	2019-11-05 19:30:00	null	ZYMEWORKS REPORTS 2019 THIRD QUARTER FINANCIAL RESULTS.Q3 REVENUE $7.9 MILLION VERSUS $2.1 MILLION.QTRLY LOSS PER SHARE $0.70.AS OF SEPTEMBER 30, 2019, ZYMEWORKS HAD $335.1 MILLION IN CASH AND CASH EQUIVALENTS AND SHORT-TERM INVESTMENTS.	ZYMEWORKS REPORTS 2019 THIRD QUARTER FINANCIAL RESULTS	ZYME	a5c0a04e-eb88-4264-9cb2-fb3140e63537	PressRelease
Press Release 0 2CRSI.PA 1 2CRSI.PA 2 2CRSI.PA 3 2CRSI.PA 4 2CRSI.PA ... 83 ZYXI 84 ZYXI 85 ZYXI 0 ZZZ.TO 1 ZZZ.TO Name: symbol, Length: 320040, dtype: object	2019-11-04 22:30:00	null	ZYMEWORKS INC. HAS FILED A SHELF REGISTRATION.	ZYMEWORKS INC. HAS FILED A SHELF REGISTRATION.	ZYME	a5c0a04e-eb88-4264-9cb2-fb3140e63537	PressRelease
Press Release 0 2CRSI.PA 1 2CRSI.PA 2 2CRSI.PA 3 2CRSI.PA 4 2CRSI.PA ... 83 ZYXI 84 ZYXI 85 ZYXI 0 ZZZ.TO 1 ZZZ.TO Name: symbol, Length: 320040, dtype: object	2019-10-27 22:30:00	null	ZYMEWORKS INC. ANNOUNCED THE FIRST DATA FROM ITS PHASE 1 STUDY EVALUATING NOVEL BISPECIFIC ANTIBODY ZW25 IN COMBINATION WITH CHEMOTHERAPY IN HER2-EXPRESSING GASTROESOPHAGEAL ADENOCARCINOMA (GEA) IN A POSTER PRESENTATION AT THE AACR-NCI-EORTC INTERNATIONAL CONFERENCE ON MOLECULAR TARGETS AND CANCER THERAPEUTICS, TAKING ...	ZYMEWORKS INC. ANNOUNCES PHASE 1 DATA FOR ZW25 IN COMBINATION WITH CHEMOTHERAPY IN ADVANCED GASTROESOPHAGEAL ADENOCARCINOMA AT AACR-NCI-EORTC INTERNATIONAL CONFERENCE	ZYME	a5c0a04e-eb88-4264-9cb2-fb3140e63537	PressRelease
Press Release 0 2CRSI.PA 1 2CRSI.PA 2 2CRSI.PA 3 2CRSI.PA 4 2CRSI.PA ... 83 ZYXI 84 ZYXI 85 ZYXI 0 ZZZ.TO 1 ZZZ.TO Name: symbol, Length: 320040, dtype: object	2019-10-24 22:30:00	null	ZYMEWORKS INC. PRESENTS AT PROTEIN & ANTIBODY ENGINEERING SUMMIT 2019, NOV-18-2019 . VENUE: LISBON CONGRESS CENTER, LISBON, PORTUGAL.	ZYMEWORKS INC. PRESENTS AT PROTEIN & ANTIBODY ENGINEERING SUMMIT 2019, NOV-18-2019	ZYME	a5c0a04e-eb88-4264-9cb2-fb3140e63537	PressRelease
Press Release 0 2CRSI.PA 1 2CRSI.PA 2 2CRSI.PA 3 2CRSI.PA 4 2CRSI.PA ... 83 ZYXI 84 ZYXI 85 ZYXI 0 ZZZ.TO 1 ZZZ.TO Name: symbol, Length: 320040, dtype: object	2019-10-16 22:30:00	null	ZYMEWORKS INC. PRESENTS AT STIFEL 2019 HEALTHCARE CONFERENCE, NOV-19-2019 08:00 AM. VENUE: LOTTE NEW YORK PALACE HOTEL, NEW YORK, NEW YORK, UNITED STATES.	ZYMEWORKS INC. PRESENTS AT STIFEL 2019 HEALTHCARE CONFERENCE, NOV-19-2019 08:00 AM	ZYME	a5c0a04e-eb88-4264-9cb2-fb3140e63537	PressRelease
Press Release 0 2CRSI.PA 1 2CRSI.PA 2 2CRSI.PA 3 2CRSI.PA 4 2CRSI.PA ... 83 ZYXI 84 ZYXI 85 ZYXI 0 ZZZ.TO 1 ZZZ.TO Name: symbol, Length: 320040, dtype: object	2019-10-15 22:30:00	null	ZYMEWORKS INC. ANNOUNCED THE APPOINTMENT OF KATHRYN O’DRISCOLL TO THE EXECUTIVE TEAM AS CHIEF PEOPLE OFFICER (CPO). MS. O'DRISCOLL BRINGS OVER 20 YEARS OF EXPERIENCE AS AN EXECUTIVE-LEVEL HUMAN RESOURCES LEADER ACROSS LARGE GLOBAL ORGANIZATIONS IN THE TECHNOLOGY AND NON-PROFIT SECTORS. IN HER NEW ROLE AS ZYMEWORKS’ CPO...	ZYMEWORKS INC. APPOINTS KATHRYN O’DRISCOLL AS CHIEF PEOPLE OFFICER	ZYME	a5c0a04e-eb88-4264-9cb2-fb3140e63537	PressRelease
Press Release 0 2CRSI.PA 1 2CRSI.PA 2 2CRSI.PA 3 2CRSI.PA 4 2CRSI.PA ... 83 ZYXI 84 ZYXI 85 ZYXI 0 ZZZ.TO 1 ZZZ.TO Name: symbol, Length: 320040, dtype: object	2019-09-27 22:30:00	null	ZYMEWORKS INC. ANNOUNCED UPDATED DATA FROM THE ONGOING MULTI-CENTER PHASE 1 CLINICAL TRIAL EVALUATING ZW25 IN PATIENTS WITH HER2-EXPRESSING SOLID TUMORS, INCLUDING BILIARY TRACT CANCER (BTC), COLORECTAL CANCER (CRC), GYNECOLOGICAL CANCERS, AND GASTROESOPHAGEAL ADENOCARCINOMA (GEA), IN A POSTER DISCUSSION PRESENTATION A...	ZYMEWORKS INC. ANNOUNCES UPDATED SINGLE AGENT DATA FOR HER2-TARGETED BISPECIFIC ANTIBODY ZW25 AT EUROPEAN SOCIETY FOR MEDICAL ONCOLOGY (ESMO) CONGRESS	ZYME	a5c0a04e-eb88-4264-9cb2-fb3140e63537	PressRelease
Press Release 0 2CRSI.PA 1 2CRSI.PA 2 2CRSI.PA 3 2CRSI.PA 4 2CRSI.PA ... 83 ZYXI 84 ZYXI 85 ZYXI 0 ZZZ.TO 1 ZZZ.TO Name: symbol, Length: 320040, dtype: object	2023-06-28 16:05:00	null	ANNUAL MEETING RECONVENED AND ADJOURNED WITHOUT CONDUCTING BUSINESS MEETING TO RECONVENE ON JULY 27, 2023 AT 9:00 AM EDT DEVON, PA., JUNE 28, 2023 (GLOBE NEWSWIRE) -- ZYNERBA PHARMACEUTICALS, INC. (NASDAQ: ZYNE) (THE “COMPANY”), THE LEADER IN INNOVATIVE PHARMACEUTICALLY-PRODUCED TRANSDERMAL CANNABINOID THERAPIES FOR OR...	ZYNERBA PHARMACEUTICALS ANNOUNCES FURTHER ADJOURNMENT OF ANNUAL MEETING	ZYNE	a5c0a04e-eb88-4264-9cb2-fb3140e63537	PressRelease
Press Release 0 2CRSI.PA 1 2CRSI.PA 2 2CRSI.PA 3 2CRSI.PA 4 2CRSI.PA ... 83 ZYXI 84 ZYXI 85 ZYXI 0 ZZZ.TO 1 ZZZ.TO Name: symbol, Length: 320040, dtype: object	2023-06-13 16:05:00	null	MEETING ADJOURNED WITH RESPECT TO PROPOSAL 2, REVERSE STOCK SPLIT; COMPANY ENCOURAGES ADDITIONAL STOCKHOLDERS OF RECORD TO VOTE BEFORE RECONVENED MEETING ON JUNE 28, 2023	ZYNERBA PHARMACEUTICALS ANNOUNCES PARTIAL ADJOURNMENT OF ANNUAL MEETING	ZYNE	a5c0a04e-eb88-4264-9cb2-fb3140e63537	PressRelease
Press Release 0 2CRSI.PA 1 2CRSI.PA 2 2CRSI.PA 3 2CRSI.PA 4 2CRSI.PA ... 83 ZYXI 84 ZYXI 85 ZYXI 0 ZZZ.TO 1 ZZZ.TO Name: symbol, Length: 320040, dtype: object	2023-05-23 07:00:00	null	DEVON, PA., MAY 23, 2023 (GLOBE NEWSWIRE) -- ZYNERBA PHARMACEUTICALS, INC. (NASDAQ: ZYNE), THE LEADER IN INNOVATIVE PHARMACEUTICALLY-PRODUCED TRANSDERMAL CANNABINOID THERAPIES FOR ORPHAN NEUROPSYCHIATRIC DISORDERS, TODAY ANNOUNCED AN ORAL PODIUM PRESENTATION AND POSTER PRESENTATIONS AT THE AMERICAN SOCIETY OF CLINICAL ...	ZYNERBA PHARMACEUTICALS ANNOUNCES PODIUM AND POSTER PRESENTATIONS AT THE AMERICAN SOCIETY OF CLINICAL PSYCHOPHARMACOLOGY ANNUAL MEETING	ZYNE	a5c0a04e-eb88-4264-9cb2-fb3140e63537	PressRelease
Press Release 0 2CRSI.PA 1 2CRSI.PA 2 2CRSI.PA 3 2CRSI.PA 4 2CRSI.PA ... 83 ZYXI 84 ZYXI 85 ZYXI 0 ZZZ.TO 1 ZZZ.TO Name: symbol, Length: 320040, dtype: object	2023-05-15 07:00:00	null	ENROLLMENT CONTINUES IN RECONNECT, A CONFIRMATORY PIVOTAL PHASE 3 TRIAL OF ZYGEL™ IN PATIENTS WITH FRAGILE X SYNDROME; TOPLINE RESULTS EXPECTED FIRST-HALF 2024	ZYNERBA PHARMACEUTICALS REPORTS FIRST QUARTER 2023 FINANCIAL RESULTS AND OPERATIONAL HIGHLIGHTS	ZYNE	a5c0a04e-eb88-4264-9cb2-fb3140e63537	PressRelease
Press Release 0 2CRSI.PA 1 2CRSI.PA 2 2CRSI.PA 3 2CRSI.PA 4 2CRSI.PA ... 83 ZYXI 84 ZYXI 85 ZYXI 0 ZZZ.TO 1 ZZZ.TO Name: symbol, Length: 320040, dtype: object	2023-04-12 07:30:00	null	ZYGEL CONTINUED TO BE WELL-TOLERATED WITH LONG-TERM ADMINISTRATION AND MAINTAINED CLINICALLY MEANINGFUL IMPROVEMENTS IN CHILDREN AND ADOLESCENTS WITH FRAGILE X SYNDROME	ZYNERBA PHARMACEUTICALS PRESENTS DATA ON ZYGEL™ AT THE 55TH GATLINBURG CONFERENCE	ZYNE	a5c0a04e-eb88-4264-9cb2-fb3140e63537	PressRelease
Press Release 0 2CRSI.PA 1 2CRSI.PA 2 2CRSI.PA 3 2CRSI.PA 4 2CRSI.PA ... 83 ZYXI 84 ZYXI 85 ZYXI 0 ZZZ.TO 1 ZZZ.TO Name: symbol, Length: 320040, dtype: object	2023-04-05 07:30:00	null	DEVON, PA., APRIL 05, 2023 (GLOBE NEWSWIRE) -- ZYNERBA PHARMACEUTICALS, INC. (NASDAQ: ZYNE), THE LEADER IN INNOVATIVE PHARMACEUTICALLY-PRODUCED TRANSDERMAL CANNABINOID THERAPIES FOR ORPHAN NEUROPSYCHIATRIC DISORDERS, TODAY ANNOUNCED THE PRESENTATION OF TWO POSTERS AT THE 55TH GATLINBURG CONFERENCE, BEING HELD APRIL 10-...	ZYNERBA PHARMACEUTICALS ANNOUNCES POSTER PRESENTATIONS AT THE 55TH GATLINBURG CONFERENCE	ZYNE	a5c0a04e-eb88-4264-9cb2-fb3140e63537	PressRelease
Press Release 0 2CRSI.PA 1 2CRSI.PA 2 2CRSI.PA 3 2CRSI.PA 4 2CRSI.PA ... 83 ZYXI 84 ZYXI 85 ZYXI 0 ZZZ.TO 1 ZZZ.TO Name: symbol, Length: 320040, dtype: object	2023-03-28 07:30:00	null	ENROLLMENT CONTINUES IN RECONNECT, A CONFIRMATORY PIVOTAL PHASE 3 TRIAL OF ZYGEL™ IN PATIENTS WITH FRAGILE X SYNDROME; TOPLINE RESULTS EXPECTED FIRST-HALF 2024	ZYNERBA PHARMACEUTICALS REPORTS FOURTH QUARTER AND FULL YEAR 2022 FINANCIAL RESULTS AND OPERATIONAL HIGHLIGHTS	ZYNE	a5c0a04e-eb88-4264-9cb2-fb3140e63537	PressRelease
Press Release 0 2CRSI.PA 1 2CRSI.PA 2 2CRSI.PA 3 2CRSI.PA 4 2CRSI.PA ... 83 ZYXI 84 ZYXI 85 ZYXI 0 ZZZ.TO 1 ZZZ.TO Name: symbol, Length: 320040, dtype: object	2023-03-13 16:15:00	null	DEVON, PA., MARCH 13, 2023 (GLOBE NEWSWIRE) -- ZYNERBA PHARMACEUTICALS, INC. (NASDAQ: ZYNE), THE LEADER IN INNOVATIVE PHARMACEUTICALLY-PRODUCED TRANSDERMAL CANNABINOID THERAPIES FOR ORPHAN NEUROPSYCHIATRIC DISORDERS, TODAY ISSUED A STATEMENT CONFIRMING THAT IT DOES NOT HOLD CASH DEPOSITS OR SECURITIES AT SILICON VALLEY...	ZYNERBA PHARMACEUTICALS CONFIRMS NOT HOLDING CASH DEPOSITS OR SECURITIES AT SILICON VALLEY BANK	ZYNE	a5c0a04e-eb88-4264-9cb2-fb3140e63537	PressRelease
Press Release 0 2CRSI.PA 1 2CRSI.PA 2 2CRSI.PA 3 2CRSI.PA 4 2CRSI.PA ... 83 ZYXI 84 ZYXI 85 ZYXI 0 ZZZ.TO 1 ZZZ.TO Name: symbol, Length: 320040, dtype: object	2023-01-11 08:30:00	null	COMPREHENSIVE DATA REVIEW SUGGESTS A CENTRAL ROLE FOR THE ENDOCANNABINOID SYSTEM (ECS) IN NEURONAL DEVELOPMENT, COGNITIVE FUNCTION AND IN THE PATHOGENESIS OF FRAGILE X SYNDROME (FXS)	ZYNERBA PHARMACEUTICALS ANNOUNCES PUBLICATION IN THE JOURNAL OF NEURODEVELOPMENTAL DISORDERS DESCRIBING THE ROLE OF THE ENDOCANNABINOID SYSTEM AND CANNABIDIOL THERAPY IN FRAGILE X SYNDROME	ZYNE	a5c0a04e-eb88-4264-9cb2-fb3140e63537	PressRelease
Press Release 0 2CRSI.PA 1 2CRSI.PA 2 2CRSI.PA 3 2CRSI.PA 4 2CRSI.PA ... 83 ZYXI 84 ZYXI 85 ZYXI 0 ZZZ.TO 1 ZZZ.TO Name: symbol, Length: 320040, dtype: object	2022-12-21 07:00:00	null	RECONNECT INITIAL SCREENING VISITS ARE BEING ADVERSELY IMPACTED BY ENVIRONMENTAL FACTORS, SUCH AS THE “TRIPLEDEMIC” (HIGH RATES OF RSV, INFLUENZA AND COVID-19); TOPLINE RESULTS NOW EXPECTED FIRST HALF OF 2024	ZYNERBA PHARMACEUTICALS ANNOUNCES UPDATE ON RECONNECT, THE PIVOTAL PHASE 3 TRIAL OF ZYGEL™ IN FRAGILE X SYNDROME	ZYNE	a5c0a04e-eb88-4264-9cb2-fb3140e63537	PressRelease
Press Release 0 2CRSI.PA 1 2CRSI.PA 2 2CRSI.PA 3 2CRSI.PA 4 2CRSI.PA ... 83 ZYXI 84 ZYXI 85 ZYXI 0 ZZZ.TO 1 ZZZ.TO Name: symbol, Length: 320040, dtype: object	2022-12-05 07:30:00	null	ZYGEL™ ACHIEVED STATISTICALLY SIGNIFICANT AND CLINICALLY MEANINGFUL IMPROVEMENTS FROM BASELINE IN MULTIPLE EFFICACY ASSESSMENTS AND WAS GENERALLY WELL-TOLERATED THROUGH 38 WEEKS OF TREATMENT	ZYNERBA PHARMACEUTICALS ANNOUNCES POSITIVE LONG-TERM DATA FROM PHASE 2 INSPIRE TRIAL IN 22Q11.2 DELETION SYNDROME AT THE ANNUAL MEETING OF THE AMERICAN COLLEGE OF NEUROPSYCHOPHARMACOLOGY	ZYNE	a5c0a04e-eb88-4264-9cb2-fb3140e63537	PressRelease
Press Release 0 2CRSI.PA 1 2CRSI.PA 2 2CRSI.PA 3 2CRSI.PA 4 2CRSI.PA ... 83 ZYXI 84 ZYXI 85 ZYXI 0 ZZZ.TO 1 ZZZ.TO Name: symbol, Length: 320040, dtype: object	2022-11-29 07:00:00	null	DEVON, PA., NOV. 29, 2022 (GLOBE NEWSWIRE) -- ZYNERBA PHARMACEUTICALS, INC. (NASDAQ: ZYNE), THE LEADER IN INNOVATIVE PHARMACEUTICALLY-PRODUCED TRANSDERMAL CANNABINOID THERAPIES FOR ORPHAN NEUROPSYCHIATRIC DISORDERS, TODAY ANNOUNCED THE PRESENTATION OF A POSTER AT THE 61ST ANNUAL MEETING OF THE AMERICAN COLLEGE OF NEURO...	ZYNERBA PHARMACEUTICALS ANNOUNCES POSTER PRESENTATION AT THE ANNUAL MEETING OF THE AMERICAN COLLEGE OF NEUROPSYCHOPHARMACOLOGY	ZYNE	a5c0a04e-eb88-4264-9cb2-fb3140e63537	PressRelease
Press Release 0 2CRSI.PA 1 2CRSI.PA 2 2CRSI.PA 3 2CRSI.PA 4 2CRSI.PA ... 83 ZYXI 84 ZYXI 85 ZYXI 0 ZZZ.TO 1 ZZZ.TO Name: symbol, Length: 320040, dtype: object	2022-11-28 07:30:00	null	STUDY FINDS PATIENTS WITH FRAGILE X WHO HAVE A HIGHLY METHYLATED FMR1 GENE THAT WERE TREATED WITH ZYGEL SHOWED A SIGNIFICANT REDUCTION IN BEHAVIORAL SYMPTOMS COMPARED TO THOSE TREATED WITH PLACEBO	ZYNERBA PHARMACEUTICALS ANNOUNCES PUBLICATION OF DATA FROM PHASE 3 CONNECT-FX STUDY OF ZYGEL™ IN THE JOURNAL OF NEURODEVELOPMENTAL DISORDERS	ZYNE	a5c0a04e-eb88-4264-9cb2-fb3140e63537	PressRelease
Press Release 0 2CRSI.PA 1 2CRSI.PA 2 2CRSI.PA 3 2CRSI.PA 4 2CRSI.PA ... 83 ZYXI 84 ZYXI 85 ZYXI 0 ZZZ.TO 1 ZZZ.TO Name: symbol, Length: 320040, dtype: object	2022-11-15 07:30:00	null	DEVON, PA., NOV. 15, 2022 (GLOBE NEWSWIRE) -- ZYNERBA PHARMACEUTICALS, INC. (NASDAQ: ZYNE), THE LEADER IN INNOVATIVE PHARMACEUTICALLY-PRODUCED TRANSDERMAL CANNABINOID THERAPIES FOR ORPHAN NEUROPSYCHIATRIC DISORDERS, TODAY ANNOUNCED THAT THE EUROPEAN COMMISSION (EC) HAS GRANTED ORPHAN DRUG DESIGNATION TO CANNABIDIOL, TH...	ZYNERBA PHARMACEUTICALS ANNOUNCES EUROPEAN COMMISSION HAS GRANTED ORPHAN DRUG DESIGNATION FOR ZYGEL™ IN 22Q11.2 DELETION SYNDROME	ZYNE	a5c0a04e-eb88-4264-9cb2-fb3140e63537	PressRelease
Press Release 0 2CRSI.PA 1 2CRSI.PA 2 2CRSI.PA 3 2CRSI.PA 4 2CRSI.PA ... 83 ZYXI 84 ZYXI 85 ZYXI 0 ZZZ.TO 1 ZZZ.TO Name: symbol, Length: 320040, dtype: object	2022-11-14 07:30:00	null	ENROLLMENT CONTINUES IN RECONNECT, A CONFIRMATORY PIVOTAL PHASE 3 TRIAL OF ZYGEL™ IN PATIENTS WITH FRAGILE X SYNDROME (FXS); TOPLINE RESULTS EXPECTED SECOND-HALF 2023	ZYNERBA PHARMACEUTICALS REPORTS THIRD QUARTER 2022 FINANCIAL RESULTS AND OPERATIONAL HIGHLIGHTS	ZYNE	a5c0a04e-eb88-4264-9cb2-fb3140e63537	PressRelease
Press Release 0 2CRSI.PA 1 2CRSI.PA 2 2CRSI.PA 3 2CRSI.PA 4 2CRSI.PA ... 83 ZYXI 84 ZYXI 85 ZYXI 0 ZZZ.TO 1 ZZZ.TO Name: symbol, Length: 320040, dtype: object	2022-11-02 07:30:00	null	DEVON, PA., NOV. 02, 2022 (GLOBE NEWSWIRE) -- ZYNERBA PHARMACEUTICALS, INC. (NASDAQ: ZYNE), THE LEADER IN INNOVATIVE PHARMACEUTICALLY-PRODUCED TRANSDERMAL CANNABINOID THERAPIES FOR ORPHAN NEUROPSYCHIATRIC DISORDERS, TODAY ANNOUNCED THAT THE U.S. PATENT AND TRADEMARK OFFICE HAS ISSUED PATENT NO. 11,458,109, TITLED “TREA...	ZYNERBA PHARMACEUTICALS ANNOUNCES ISSUANCE OF NEW U.S. PATENT FOR ZYGEL™ FOR THE TREATMENT OF 22Q11.2 DELETION SYNDROME	ZYNE	a5c0a04e-eb88-4264-9cb2-fb3140e63537	PressRelease
Press Release 0 2CRSI.PA 1 2CRSI.PA 2 2CRSI.PA 3 2CRSI.PA 4 2CRSI.PA ... 83 ZYXI 84 ZYXI 85 ZYXI 0 ZZZ.TO 1 ZZZ.TO Name: symbol, Length: 320040, dtype: object	2022-10-10 07:00:00	null	DEVON, PA., OCT. 10, 2022 (GLOBE NEWSWIRE) -- ZYNERBA PHARMACEUTICALS, INC. (NASDAQ: ZYNE), THE LEADER IN INNOVATIVE PHARMACEUTICALLY-PRODUCED TRANSDERMAL CANNABINOID THERAPIES FOR ORPHAN NEUROPSYCHIATRIC DISORDERS, TODAY ANNOUNCED THE PRESENTATION OF A POSTER AT THE 2022 NATIONAL ORGANIZATION FOR RARE DISORDERS (NORD)...	ZYNERBA PHARMACEUTICALS ANNOUNCES POSTER PRESENTATION AT THE NATIONAL ORGANIZATION FOR RARE DISORDERS (NORD) RARE DISEASES AND ORPHAN PRODUCTS BREAKTHROUGH SUMMIT	ZYNE	a5c0a04e-eb88-4264-9cb2-fb3140e63537	PressRelease
Press Release 0 2CRSI.PA 1 2CRSI.PA 2 2CRSI.PA 3 2CRSI.PA 4 2CRSI.PA ... 83 ZYXI 84 ZYXI 85 ZYXI 0 ZZZ.TO 1 ZZZ.TO Name: symbol, Length: 320040, dtype: object	2022-10-06 07:00:00	null	DEVON, PA., OCT. 06, 2022 (GLOBE NEWSWIRE) -- ZYNERBA PHARMACEUTICALS, INC. (NASDAQ: ZYNE), THE LEADER IN INNOVATIVE PHARMACEUTICALLY-PRODUCED TRANSDERMAL CANNABINOID THERAPIES FOR ORPHAN NEUROPSYCHIATRIC DISORDERS, TODAY ANNOUNCED THAT THE U.S. PATENT AND TRADEMARK OFFICE HAS ISSUED PATENT NO. 11,458,110, TITLED “TREA...	ZYNERBA PHARMACEUTICALS ANNOUNCES ISSUANCE OF NEW U.S. PATENT FOR ZYGEL™	ZYNE	a5c0a04e-eb88-4264-9cb2-fb3140e63537	PressRelease
Press Release 0 2CRSI.PA 1 2CRSI.PA 2 2CRSI.PA 3 2CRSI.PA 4 2CRSI.PA ... 83 ZYXI 84 ZYXI 85 ZYXI 0 ZZZ.TO 1 ZZZ.TO Name: symbol, Length: 320040, dtype: object	2022-09-29 07:00:00	null	DEVON, PA., SEPT. 29, 2022 (GLOBE NEWSWIRE) -- ZYNERBA PHARMACEUTICALS, INC. (NASDAQ: ZYNE), THE LEADER IN INNOVATIVE PHARMACEUTICALLY-PRODUCED TRANSDERMAL CANNABINOID THERAPIES FOR ORPHAN NEUROPSYCHIATRIC DISORDERS, TODAY ANNOUNCED THAT STEPHEN O'QUINN, PHARM.D., VICE PRESIDENT, MEDICAL AFFAIRS, ZYNERBA PHARMACEUTICAL...	ZYNERBA PHARMACEUTICALS TO PARTICIPATE IN THE CANTOR NEUROLOGY & PSYCHIATRY CONFERENCE	ZYNE	a5c0a04e-eb88-4264-9cb2-fb3140e63537	PressRelease
Press Release 0 2CRSI.PA 1 2CRSI.PA 2 2CRSI.PA 3 2CRSI.PA 4 2CRSI.PA ... 83 ZYXI 84 ZYXI 85 ZYXI 0 ZZZ.TO 1 ZZZ.TO Name: symbol, Length: 320040, dtype: object	2022-09-08 09:15:00	null	INSPIRE TRIAL IN 22Q ACHIEVED STATISTICALLY SIGNIFICANT AND CLINICALLY MEANINGFUL IMPROVEMENTS FROM BASELINE IN MULTIPLE EFFICACY ASSESSMENTS, WITH EXCELLENT TOLERABILITY PROFILE INSPIRE TRIAL IN 22Q ACHIEVED STATISTICALLY SIGNIFICANT AND CLINICALLY MEANINGFUL IMPROVEMENTS FROM BASELINE IN MULTIPLE EFFICACY ASSESSMENTS...	ZYNERBA PHARMACEUTICALS PRESENTS POSITIVE DATA FROM PHASE 2 INSPIRE TRIAL IN 22Q AT THE SOCIETY FOR THE STUDY OF BEHAVIOURAL PHENOTYPES (SSBP) 24TH INTERNATIONAL RESEARCH SYMPOSIUM	ZYNE	a5c0a04e-eb88-4264-9cb2-fb3140e63537	PressRelease
Press Release 0 2CRSI.PA 1 2CRSI.PA 2 2CRSI.PA 3 2CRSI.PA 4 2CRSI.PA ... 83 ZYXI 84 ZYXI 85 ZYXI 0 ZZZ.TO 1 ZZZ.TO Name: symbol, Length: 320040, dtype: object	2022-08-31 07:00:00	null	DEVON, PA., AUG. 31, 2022 (GLOBE NEWSWIRE) -- ZYNERBA PHARMACEUTICALS, INC. (NASDAQ: ZYNE), THE LEADER IN INNOVATIVE PHARMACEUTICALLY-PRODUCED TRANSDERMAL CANNABINOID THERAPIES FOR ORPHAN NEUROPSYCHIATRIC DISORDERS, TODAY ANNOUNCED THE ACCEPTANCE OF AN ORAL PRESENTATION AT THE SOCIETY FOR THE STUDY OF BEHAVIOURAL PHENO...	ZYNERBA PHARMACEUTICALS ANNOUNCES ORAL PRESENTATION AT THE SOCIETY FOR THE STUDY OF BEHAVIOURAL PHENOTYPES (SSBP) 24TH INTERNATIONAL RESEARCH SYMPOSIUM	ZYNE	a5c0a04e-eb88-4264-9cb2-fb3140e63537	PressRelease
Press Release 0 2CRSI.PA 1 2CRSI.PA 2 2CRSI.PA 3 2CRSI.PA 4 2CRSI.PA ... 83 ZYXI 84 ZYXI 85 ZYXI 0 ZZZ.TO 1 ZZZ.TO Name: symbol, Length: 320040, dtype: object	2022-08-10 07:00:00	null	ENROLLMENT CONTINUES IN RECONNECT, A CONFIRMATORY PIVOTAL PHASE 3 TRIAL OF ZYGEL™ IN PATIENTS WITH FRAGILE X SYNDROME (FXS); TOPLINE RESULTS EXPECTED SECOND-HALF 2023	ZYNERBA PHARMACEUTICALS REPORTS SECOND QUARTER 2022 FINANCIAL RESULTS AND OPERATIONAL HIGHLIGHTS	ZYNE	a5c0a04e-eb88-4264-9cb2-fb3140e63537	PressRelease
Press Release 0 2CRSI.PA 1 2CRSI.PA 2 2CRSI.PA 3 2CRSI.PA 4 2CRSI.PA ... 83 ZYXI 84 ZYXI 85 ZYXI 0 ZZZ.TO 1 ZZZ.TO Name: symbol, Length: 320040, dtype: object	2022-07-21 07:00:00	null	DEVON, PA., JULY 21, 2022 (GLOBE NEWSWIRE) -- ZYNERBA PHARMACEUTICALS, INC. (NASDAQ: ZYNE), THE LEADER IN INNOVATIVE PHARMACEUTICALLY-PRODUCED TRANSDERMAL CANNABINOID THERAPIES FOR ORPHAN NEUROPSYCHIATRIC DISORDERS, TODAY ANNOUNCED IT HAS ENTERED INTO AN EQUITY PURCHASE AGREEMENT FOR UP TO $20 MILLION WITH LINCOLN PARK...	ZYNERBA PHARMACEUTICALS ENTERS INTO EQUITY PURCHASE AGREEMENT FOR UP TO $20 MILLION WITH LINCOLN PARK CAPITAL	ZYNE	a5c0a04e-eb88-4264-9cb2-fb3140e63537	PressRelease
Press Release 0 2CRSI.PA 1 2CRSI.PA 2 2CRSI.PA 3 2CRSI.PA 4 2CRSI.PA ... 83 ZYXI 84 ZYXI 85 ZYXI 0 ZZZ.TO 1 ZZZ.TO Name: symbol, Length: 320040, dtype: object	2022-07-07 07:00:00	null	DEVON, PA., JULY 07, 2022 (GLOBE NEWSWIRE) -- ZYNERBA PHARMACEUTICALS, INC. (NASDAQ: ZYNE), THE LEADER IN INNOVATIVE PHARMACEUTICALLY-PRODUCED TRANSDERMAL CANNABINOID THERAPIES FOR RARE AND NEAR-RARE NEUROPSYCHIATRIC DISORDERS, TODAY ANNOUNCED TWO POSTER PRESENTATIONS AT THE 18TH NFXF INTERNATIONAL FRAGILE X CONFERENCE...	ZYNERBA PHARMACEUTICALS ANNOUNCES PANEL PRESENTATION AND POSTER PRESENTATIONS AT THE NFXF INTERNATIONAL FRAGILE X CONFERENCE	ZYNE	a5c0a04e-eb88-4264-9cb2-fb3140e63537	PressRelease
Press Release 0 2CRSI.PA 1 2CRSI.PA 2 2CRSI.PA 3 2CRSI.PA 4 2CRSI.PA ... 83 ZYXI 84 ZYXI 85 ZYXI 0 ZZZ.TO 1 ZZZ.TO Name: symbol, Length: 320040, dtype: object	2022-06-21 20:05:00	null	– THE INSPIRE TRIAL ACHIEVED STATISTICALLY SIGNIFICANT AND CLINICALLY MEANINGFUL IMPROVEMENTS FROM BASELINE IN MULTIPLE EFFICACY ASSESSMENTS –	ZYNERBA PHARMACEUTICALS ANNOUNCES POSITIVE TOP LINE RESULTS FROM OPEN-LABEL PHASE 2 INSPIRE TRIAL OF ZYGEL™ IN 22Q11.2 DELETION SYNDROME	ZYNE	a5c0a04e-eb88-4264-9cb2-fb3140e63537	PressRelease
Press Release 0 2CRSI.PA 1 2CRSI.PA 2 2CRSI.PA 3 2CRSI.PA 4 2CRSI.PA ... 83 ZYXI 84 ZYXI 85 ZYXI 0 ZZZ.TO 1 ZZZ.TO Name: symbol, Length: 320040, dtype: object	2022-06-01 07:00:00	null	– POSTER PRESENTATION HIGHLIGHTS DESIGN ENHANCEMENTS INCORPORATED INTO PIVOTAL RECONNECT TRIAL –	ZYNERBA PHARMACEUTICALS PRESENTS DATA ON ZYGEL™ AT THE AMERICAN SOCIETY OF CLINICAL PSYCHOPHARMACOLOGY ANNUAL MEETING	ZYNE	a5c0a04e-eb88-4264-9cb2-fb3140e63537	PressRelease
Press Release 0 2CRSI.PA 1 2CRSI.PA 2 2CRSI.PA 3 2CRSI.PA 4 2CRSI.PA ... 83 ZYXI 84 ZYXI 85 ZYXI 0 ZZZ.TO 1 ZZZ.TO Name: symbol, Length: 320040, dtype: object	2022-05-16 07:00:00	null	– ENROLLMENT CONTINUES IN RECONNECT, A CONFIRMATORY PIVOTAL PHASE 3 TRIAL OF ZYGEL™ IN PATIENTS WITH FRAGILE X SYNDROME (FXS); TOPLINE RESULTS EXPECTED SECOND-HALF 2023 –	ZYNERBA PHARMACEUTICALS REPORTS FIRST QUARTER 2022 FINANCIAL RESULTS AND OPERATIONAL HIGHLIGHTS	ZYNE	a5c0a04e-eb88-4264-9cb2-fb3140e63537	PressRelease
Press Release 0 2CRSI.PA 1 2CRSI.PA 2 2CRSI.PA 3 2CRSI.PA 4 2CRSI.PA ... 83 ZYXI 84 ZYXI 85 ZYXI 0 ZZZ.TO 1 ZZZ.TO Name: symbol, Length: 320040, dtype: object	2022-05-11 13:30:00	null	– DATA SUPPORT THE LONG-TERM SAFETY AND EFFECTIVENESS OF ZYGEL –	ZYNERBA PHARMACEUTICALS PRESENTS LONG-TERM SAFETY AND EFFICACY DATA OF ZYGEL™ IN CHILDREN AND ADOLESCENTS WITH FRAGILE X SYNDROME (FXS) AT THE INTERNATIONAL SOCIETY FOR AUTISM RESEARCH ANNUAL MEETING	ZYNE	a5c0a04e-eb88-4264-9cb2-fb3140e63537	PressRelease
Press Release 0 2CRSI.PA 1 2CRSI.PA 2 2CRSI.PA 3 2CRSI.PA 4 2CRSI.PA ... 83 ZYXI 84 ZYXI 85 ZYXI 0 ZZZ.TO 1 ZZZ.TO Name: symbol, Length: 320040, dtype: object	2022-05-09 16:57:00	null	DEVON, PA., MAY 09, 2022 (GLOBE NEWSWIRE) -- ZYNERBA PHARMACEUTICALS, INC. (NASDAQ: ZYNE), THE LEADER IN INNOVATIVE PHARMACEUTICALLY-PRODUCED TRANSDERMAL CANNABINOID THERAPIES FOR RARE AND NEAR-RARE NEUROPSYCHIATRIC DISORDERS, TODAY ANNOUNCED AN ORAL PODIUM PRESENTATION AT THE INTERNATIONAL SOCIETY FOR AUTISM RESEARCH ...	ZYNERBA PHARMACEUTICALS ANNOUNCES PODIUM PRESENTATION AT THE INTERNATIONAL SOCIETY FOR AUTISM RESEARCH ANNUAL MEETING	ZYNE	a5c0a04e-eb88-4264-9cb2-fb3140e63537	PressRelease
Press Release 0 2CRSI.PA 1 2CRSI.PA 2 2CRSI.PA 3 2CRSI.PA 4 2CRSI.PA ... 83 ZYXI 84 ZYXI 85 ZYXI 0 ZZZ.TO 1 ZZZ.TO Name: symbol, Length: 320040, dtype: object	2022-05-02 07:00:00	null	DEVON, PA., MAY 02, 2022 (GLOBE NEWSWIRE) -- ZYNERBA PHARMACEUTICALS, INC. (NASDAQ: ZYNE), THE LEADER IN INNOVATIVE PHARMACEUTICALLY-PRODUCED TRANSDERMAL CANNABINOID THERAPIES FOR RARE AND NEAR-RARE NEUROPSYCHIATRIC DISORDERS, PRESENTED A POSTER AT THE 2022 SOCIETY OF BIOLOGICAL PSYCHIATRY (SOBP) ANNUAL MEETING, HELD A...	ZYNERBA PHARMACEUTICALS PRESENTS LONG-TERM SAFETY AND EFFICACY DATA OF ZYGEL™ IN CHILDREN AND ADOLESCENTS WITH FRAGILE X SYNDROME (FXS) AT THE 2022 SOCIETY OF BIOLOGICAL PSYCHIATRY ANNUAL MEETING	ZYNE	a5c0a04e-eb88-4264-9cb2-fb3140e63537	PressRelease
Press Release 0 2CRSI.PA 1 2CRSI.PA 2 2CRSI.PA 3 2CRSI.PA 4 2CRSI.PA ... 83 ZYXI 84 ZYXI 85 ZYXI 0 ZZZ.TO 1 ZZZ.TO Name: symbol, Length: 320040, dtype: object	2022-04-21 07:00:00	null	DEVON, PA., APRIL 21, 2022 (GLOBE NEWSWIRE) -- ZYNERBA PHARMACEUTICALS, INC. (NASDAQ: ZYNE), THE LEADER IN INNOVATIVE PHARMACEUTICALLY-PRODUCED TRANSDERMAL CANNABINOID THERAPIES FOR RARE AND NEAR-RARE NEUROPSYCHIATRIC DISORDERS, TODAY ANNOUNCED THE PRESENTATION OF A POSTER AT THE 2022 SOCIETY OF BIOLOGICAL PSYCHIATRY (...	ZYNERBA PHARMACEUTICALS ANNOUNCES PRESENTATION OF POSTER AT THE 2022 SOCIETY OF BIOLOGICAL PSYCHIATRY ANNUAL MEETING	ZYNE	a5c0a04e-eb88-4264-9cb2-fb3140e63537	PressRelease
Press Release 0 2CRSI.PA 1 2CRSI.PA 2 2CRSI.PA 3 2CRSI.PA 4 2CRSI.PA ... 83 ZYXI 84 ZYXI 85 ZYXI 0 ZZZ.TO 1 ZZZ.TO Name: symbol, Length: 320040, dtype: object	2022-03-22 07:00:00	null	DEVON, PA., MARCH 22, 2022 (GLOBE NEWSWIRE) -- ZYNERBA PHARMACEUTICALS, INC. (NASDAQ: ZYNE), THE LEADER IN INNOVATIVE PHARMACEUTICALLY-PRODUCED TRANSDERMAL CANNABINOID THERAPIES FOR RARE AND NEAR-RARE NEUROPSYCHIATRIC DISORDERS, TODAY ANNOUNCED THAT STEPHEN O'QUINN, VICE PRESIDENT, MEDICAL AFFAIRS, ZYNERBA PHARMACEUTIC...	ZYNERBA PHARMACEUTICALS TO PARTICIPATE IN THE CANTOR RARE ORPHAN DISEASE SUMMIT	ZYNE	a5c0a04e-eb88-4264-9cb2-fb3140e63537	PressRelease
Press Release 0 2CRSI.PA 1 2CRSI.PA 2 2CRSI.PA 3 2CRSI.PA 4 2CRSI.PA ... 83 ZYXI 84 ZYXI 85 ZYXI 0 ZZZ.TO 1 ZZZ.TO Name: symbol, Length: 320040, dtype: object	2022-03-01 06:00:00	null	– EUROPEAN COMMISSION GRANTED ORPHAN DRUG DESIGNATION FOR ZYGEL™ IN FRAGILE X SYNDROME (FXS) –	ZYNERBA PHARMACEUTICALS REPORTS FOURTH QUARTER AND FULL YEAR 2021 FINANCIAL RESULTS AND OPERATIONAL HIGHLIGHTS	ZYNE	a5c0a04e-eb88-4264-9cb2-fb3140e63537	PressRelease
Press Release 0 2CRSI.PA 1 2CRSI.PA 2 2CRSI.PA 3 2CRSI.PA 4 2CRSI.PA ... 83 ZYXI 84 ZYXI 85 ZYXI 0 ZZZ.TO 1 ZZZ.TO Name: symbol, Length: 320040, dtype: object	2022-02-28 07:00:00	null	TOPLINE DATA FROM PHASE 2 INSPIRE TRIAL EXPECTED MID-YEAR 2022 TOPLINE DATA FROM PHASE 2 INSPIRE TRIAL EXPECTED MID-YEAR 2022	ZYNERBA PHARMACEUTICALS ANNOUNCES COMPLETION OF ENROLLMENT IN PHASE 2 TRIAL OF ZYGEL™ IN 22Q11.2 DELETION SYNDROME	ZYNE	a5c0a04e-eb88-4264-9cb2-fb3140e63537	PressRelease
Press Release 0 2CRSI.PA 1 2CRSI.PA 2 2CRSI.PA 3 2CRSI.PA 4 2CRSI.PA ... 83 ZYXI 84 ZYXI 85 ZYXI 0 ZZZ.TO 1 ZZZ.TO Name: symbol, Length: 320040, dtype: object	2022-02-15 07:00:00	null	DEVON, PA., FEB. 15, 2022 (GLOBE NEWSWIRE) -- ZYNERBA PHARMACEUTICALS, INC. (NASDAQ: ZYNE), THE LEADER IN INNOVATIVE PHARMACEUTICALLY-PRODUCED TRANSDERMAL CANNABINOID THERAPIES FOR RARE AND NEAR-RARE NEUROPSYCHIATRIC DISORDERS, TODAY ANNOUNCED THE APPOINTMENT OF ALBERT P. PARKER, AN ACCOMPLISHED INDUSTRY EXECUTIVE WITH...	ZYNERBA PHARMACEUTICALS ANNOUNCES PLANNED RETIREMENT OF SUZANNE HANLON AND APPOINTS ALBERT P. PARKER AS CHIEF LEGAL OFFICER	ZYNE	a5c0a04e-eb88-4264-9cb2-fb3140e63537	PressRelease
Press Release 0 2CRSI.PA 1 2CRSI.PA 2 2CRSI.PA 3 2CRSI.PA 4 2CRSI.PA ... 83 ZYXI 84 ZYXI 85 ZYXI 0 ZZZ.TO 1 ZZZ.TO Name: symbol, Length: 320040, dtype: object	2022-01-04 16:05:00	null	– COMPANY PLANS TO FOCUS DEVELOPMENT OF ZYGEL™ IN FXS, ASD AND 22Q –	ZYNERBA PHARMACEUTICALS ANNOUNCES CLINICAL DEVELOPMENT UPDATES FOR FXS, ASD, 22Q AND DEE	ZYNE	a5c0a04e-eb88-4264-9cb2-fb3140e63537	PressRelease
Press Release 0 2CRSI.PA 1 2CRSI.PA 2 2CRSI.PA 3 2CRSI.PA 4 2CRSI.PA ... 83 ZYXI 84 ZYXI 85 ZYXI 0 ZZZ.TO 1 ZZZ.TO Name: symbol, Length: 320040, dtype: object	2021-12-06 07:00:00	null	DEVON, PA., DEC. 06, 2021 (GLOBE NEWSWIRE) -- ZYNERBA PHARMACEUTICALS, INC. (NASDAQ: ZYNE), THE LEADER IN INNOVATIVE PHARMACEUTICALLY-PRODUCED TRANSDERMAL CANNABINOID THERAPIES FOR RARE AND NEAR-RARE NEUROPSYCHIATRIC DISORDERS, TODAY ANNOUNCED PRESENTATION DETAILS FOR THE BRAIN FOUNDATION SYNCHRONY 2021 SYMPOSIUM, BEIN...	ZYNERBA PHARMACEUTICALS ANNOUNCES PRESENTATION AT THE BRAIN FOUNDATION SYNCHRONY 2021 SYMPOSIUM	ZYNE	a5c0a04e-eb88-4264-9cb2-fb3140e63537	PressRelease
Press Release 0 2CRSI.PA 1 2CRSI.PA 2 2CRSI.PA 3 2CRSI.PA 4 2CRSI.PA ... 83 ZYXI 84 ZYXI 85 ZYXI 0 ZZZ.TO 1 ZZZ.TO Name: symbol, Length: 320040, dtype: object	2021-11-22 07:00:00	null	DEVON, PA., NOV. 22, 2021 (GLOBE NEWSWIRE) -- ZYNERBA PHARMACEUTICALS, INC. (NASDAQ: ZYNE), THE LEADER IN INNOVATIVE PHARMACEUTICALLY-PRODUCED TRANSDERMAL CANNABINOID THERAPIES FOR RARE AND NEAR-RARE NEUROPSYCHIATRIC DISORDERS, TODAY ANNOUNCED THAT THE EUROPEAN PATENT OFFICE HAS ISSUED PATENT NO. 3687513, TITLED “TREAT...	ZYNERBA PHARMACEUTICALS ANNOUNCES ISSUANCE OF NEW PATENT IN EU FOR ZYGEL™	ZYNE	a5c0a04e-eb88-4264-9cb2-fb3140e63537	PressRelease
Press Release 0 2CRSI.PA 1 2CRSI.PA 2 2CRSI.PA 3 2CRSI.PA 4 2CRSI.PA ... 83 ZYXI 84 ZYXI 85 ZYXI 0 ZZZ.TO 1 ZZZ.TO Name: symbol, Length: 320040, dtype: object	2021-10-21 07:00:00	null	DEVON, PA., OCT. 21, 2021 (GLOBE NEWSWIRE) -- ZYNERBA PHARMACEUTICALS, INC. (NASDAQ: ZYNE), THE LEADER IN INNOVATIVE PHARMACEUTICALLY-PRODUCED TRANSDERMAL CANNABINOID THERAPIES FOR RARE AND NEAR-RARE NEUROPSYCHIATRIC DISORDERS, TODAY ANNOUNCED ORAL AND POSTER PRESENTATIONS AT THE SOCIETY FOR DEVELOPMENTAL & BEHAVIORAL ...	ZYNERBA PHARMACEUTICALS ANNOUNCES PRESENTATIONS AT TWO UPCOMING SCIENTIFIC CONFERENCES IN OCTOBER	ZYNE	a5c0a04e-eb88-4264-9cb2-fb3140e63537	PressRelease
Press Release 0 2CRSI.PA 1 2CRSI.PA 2 2CRSI.PA 3 2CRSI.PA 4 2CRSI.PA ... 83 ZYXI 84 ZYXI 85 ZYXI 0 ZZZ.TO 1 ZZZ.TO Name: symbol, Length: 320040, dtype: object	2021-10-19 16:15:00	null	DEVON, PA., OCT. 19, 2021 (GLOBE NEWSWIRE) -- ZYNERBA PHARMACEUTICALS, INC. (NASDAQ: ZYNE), THE LEADER IN INNOVATIVE PHARMACEUTICALLY-PRODUCED TRANSDERMAL CANNABINOID THERAPIES FOR RARE AND NEAR-RARE NEUROPSYCHIATRIC DISORDERS, TODAY ANNOUNCED THE PRESENTATION OF A POSTER AT THE 2021 NATIONAL ORGANIZATION FOR RARE DISO...	ZYNERBA PHARMACEUTICALS ANNOUNCES PRESENTATION OF POSTER AT THE NATIONAL ORGANIZATION FOR RARE DISORDERS (NORD) RARE DISEASES AND ORPHAN PRODUCTS BREAKTHROUGH SUMMIT	ZYNE	a5c0a04e-eb88-4264-9cb2-fb3140e63537	PressRelease
Press Release 0 2CRSI.PA 1 2CRSI.PA 2 2CRSI.PA 3 2CRSI.PA 4 2CRSI.PA ... 83 ZYXI 84 ZYXI 85 ZYXI 0 ZZZ.TO 1 ZZZ.TO Name: symbol, Length: 320040, dtype: object	2021-10-08 07:30:00	null	DEVON, PA., OCT. 08, 2021 (GLOBE NEWSWIRE) -- ZYNERBA PHARMACEUTICALS, INC. (NASDAQ: ZYNE), THE LEADER IN INNOVATIVE PHARMACEUTICALLY-PRODUCED TRANSDERMAL CANNABINOID THERAPIES FOR RARE AND NEAR-RARE NEUROPSYCHIATRIC DISORDERS, TODAY ANNOUNCED THE PRESENTATION OF A POSTER AT THE 2021 AMERICAN ACADEMY OF PEDIATRICS (AAP...	ZYNERBA PHARMACEUTICALS ANNOUNCES PRESENTATION OF POSTER AT THE 2021 AMERICAN ACADEMY OF PEDIATRICS NATIONAL CONFERENCE & EXHIBITION	ZYNE	a5c0a04e-eb88-4264-9cb2-fb3140e63537	PressRelease
Press Release 0 2CRSI.PA 1 2CRSI.PA 2 2CRSI.PA 3 2CRSI.PA 4 2CRSI.PA ... 83 ZYXI 84 ZYXI 85 ZYXI 0 ZZZ.TO 1 ZZZ.TO Name: symbol, Length: 320040, dtype: object	2021-09-20 07:00:00	null	DEVON, PA., SEPT. 20, 2021 (GLOBE NEWSWIRE) -- ZYNERBA PHARMACEUTICALS, INC. (NASDAQ: ZYNE), THE LEADER IN INNOVATIVE PHARMACEUTICALLY-PRODUCED TRANSDERMAL CANNABINOID THERAPIES FOR RARE AND NEAR-RARE NEUROPSYCHIATRIC DISORDERS, TODAY ANNOUNCED THAT ARMANDO ANIDO, CHAIRMAN AND CHIEF EXECUTIVE OFFICER OF ZYNERBA, WILL P...	ZYNERBA PHARMACEUTICALS TO PRESENT AT THE CANTOR VIRTUAL GLOBAL HEALTHCARE CONFERENCE	ZYNE	a5c0a04e-eb88-4264-9cb2-fb3140e63537	PressRelease
Press Release 0 2CRSI.PA 1 2CRSI.PA 2 2CRSI.PA 3 2CRSI.PA 4 2CRSI.PA ... 83 ZYXI 84 ZYXI 85 ZYXI 0 ZZZ.TO 1 ZZZ.TO Name: symbol, Length: 320040, dtype: object	2021-09-09 07:00:00	null	DEVON, PA., SEPT. 09, 2021 (GLOBE NEWSWIRE) -- ZYNERBA PHARMACEUTICALS, INC. (NASDAQ: ZYNE), THE LEADER IN INNOVATIVE PHARMACEUTICALLY-PRODUCED TRANSDERMAL CANNABINOID THERAPIES FOR RARE AND NEAR-RARE NEUROPSYCHIATRIC DISORDERS, TODAY PRESENTED DATA FROM THE PHASE 2 BRIGHT TRIAL DESCRIBING TOLERABILITY AND EFFICACY OF ...	ZYNERBA PHARMACEUTICALS PRESENTS LONGER TERM TOLERABILITY AND EFFICACY DATA OF ZYGEL™ IN CHILDREN AND ADOLESCENTS WITH AUTISM SPECTRUM DISORDER (ASD) AT THE SOCIETY FOR THE STUDY OF BEHAVIOURAL PHENOTYPES (SSBP) CONFERENCE 2021	ZYNE	a5c0a04e-eb88-4264-9cb2-fb3140e63537	PressRelease
Press Release 0 2CRSI.PA 1 2CRSI.PA 2 2CRSI.PA 3 2CRSI.PA 4 2CRSI.PA ... 83 ZYXI 84 ZYXI 85 ZYXI 0 ZZZ.TO 1 ZZZ.TO Name: symbol, Length: 320040, dtype: object	2021-09-02 07:30:00	null	DEVON, PA., SEPT. 02, 2021 (GLOBE NEWSWIRE) -- ZYNERBA PHARMACEUTICALS, INC. (NASDAQ: ZYNE), THE LEADER IN INNOVATIVE PHARMACEUTICALLY-PRODUCED TRANSDERMAL CANNABINOID THERAPIES FOR RARE AND NEAR-RARE NEUROPSYCHIATRIC DISORDERS, TODAY ANNOUNCED THAT ARMANDO ANIDO, CHAIRMAN AND CHIEF EXECUTIVE OFFICER OF ZYNERBA, WILL P...	ZYNERBA PHARMACEUTICALS TO PRESENT AT THE H.C. WAINWRIGHT GLOBAL INVESTMENT CONFERENCE	ZYNE	a5c0a04e-eb88-4264-9cb2-fb3140e63537	PressRelease
Press Release 0 2CRSI.PA 1 2CRSI.PA 2 2CRSI.PA 3 2CRSI.PA 4 2CRSI.PA ... 83 ZYXI 84 ZYXI 85 ZYXI 0 ZZZ.TO 1 ZZZ.TO Name: symbol, Length: 320040, dtype: object	2021-08-09 07:00:00	null	DEVON, PA., AUG. 09, 2021 (GLOBE NEWSWIRE) -- ZYNERBA PHARMACEUTICALS, INC. (NASDAQ: ZYNE), THE LEADER IN INNOVATIVE PHARMACEUTICALLY-PRODUCED TRANSDERMAL CANNABINOID THERAPIES FOR RARE AND NEAR-RARE NEUROPSYCHIATRIC DISORDERS, TODAY REPORTED FINANCIAL RESULTS FOR THE SECOND QUARTER ENDED JUNE 30, 2021, AND PROVIDED AN...	ZYNERBA PHARMACEUTICALS REPORTS SECOND QUARTER 2021 FINANCIAL RESULTS AND OPERATIONAL HIGHLIGHTS	ZYNE	a5c0a04e-eb88-4264-9cb2-fb3140e63537	PressRelease
Press Release 0 2CRSI.PA 1 2CRSI.PA 2 2CRSI.PA 3 2CRSI.PA 4 2CRSI.PA ... 83 ZYXI 84 ZYXI 85 ZYXI 0 ZZZ.TO 1 ZZZ.TO Name: symbol, Length: 320040, dtype: object	2021-08-04 07:30:00	null	DEVON, PA., AUG. 04, 2021 (GLOBE NEWSWIRE) -- ZYNERBA PHARMACEUTICALS, INC. (NASDAQ: ZYNE), THE LEADER IN INNOVATIVE PHARMACEUTICALLY-PRODUCED TRANSDERMAL CANNABINOID THERAPIES FOR RARE AND NEAR-RARE NEUROPSYCHIATRIC DISORDERS, TODAY ANNOUNCED THAT COMPANY MANAGEMENT WILL PARTICIPATE IN A FIRESIDE CHAT DURING THE CANAC...	ZYNERBA PHARMACEUTICALS TO PRESENT AT THE CANACCORD GENUITY 41ST ANNUAL GROWTH CONFERENCE	ZYNE	a5c0a04e-eb88-4264-9cb2-fb3140e63537	PressRelease
Press Release 0 2CRSI.PA 1 2CRSI.PA 2 2CRSI.PA 3 2CRSI.PA 4 2CRSI.PA ... 83 ZYXI 84 ZYXI 85 ZYXI 0 ZZZ.TO 1 ZZZ.TO Name: symbol, Length: 320040, dtype: object	2021-07-07 07:30:00	null	DEVON, PA., JULY 07, 2021 (GLOBE NEWSWIRE) -- ZYNERBA PHARMACEUTICALS, INC. (NASDAQ: ZYNE), THE LEADER IN INNOVATIVE PHARMACEUTICALLY-PRODUCED TRANSDERMAL CANNABINOID THERAPIES FOR RARE AND NEAR-RARE NEUROPSYCHIATRIC DISORDERS, TODAY ANNOUNCED THAT ARMANDO ANIDO, CHAIRMAN AND CHIEF EXECUTIVE OFFICER OF ZYNERBA, WILL PR...	ZYNERBA PHARMACEUTICALS TO PRESENT AT THE LADENBURG THALMANN VIRTUAL HEALTHCARE CONFERENCE	ZYNE	a5c0a04e-eb88-4264-9cb2-fb3140e63537	PressRelease
Press Release 0 2CRSI.PA 1 2CRSI.PA 2 2CRSI.PA 3 2CRSI.PA 4 2CRSI.PA ... 83 ZYXI 84 ZYXI 85 ZYXI 0 ZZZ.TO 1 ZZZ.TO Name: symbol, Length: 320040, dtype: object	2021-06-11 12:30:00	null	DEVON, PA., JUNE 11, 2021 (GLOBE NEWSWIRE) -- ZYNERBA PHARMACEUTICALS, INC. (NASDAQ: ZYNE), THE LEADER IN INNOVATIVE PHARMACEUTICALLY-PRODUCED TRANSDERMAL CANNABINOID THERAPIES FOR RARE AND NEAR-RARE NEUROPSYCHIATRIC DISORDERS, PRESENTED A POSTER TODAY AT SLEEP 2021, THE 35TH ANNUAL MEETING OF THE ASSOCIATED PROFESSION...	ZYNERBA PHARMACEUTICALS PRESENTS SLEEP DATA FROM STUDY OF ZYGEL™ IN CHILDREN AND ADOLESCENTS WITH BOTH DEVELOPMENTAL AND EPILEPTIC ENCEPHALOPATHIES (DEE) AND AUTISM SPECTRUM DISORDER (ASD) AT THE ASSOCIATED PROFESSIONAL SLEEP SOCIETIES SLEEP 2021 ANNUAL MEETING	ZYNE	a5c0a04e-eb88-4264-9cb2-fb3140e63537	PressRelease
Press Release 0 2CRSI.PA 1 2CRSI.PA 2 2CRSI.PA 3 2CRSI.PA 4 2CRSI.PA ... 83 ZYXI 84 ZYXI 85 ZYXI 0 ZZZ.TO 1 ZZZ.TO Name: symbol, Length: 320040, dtype: object	2021-06-09 16:05:00	null	– 46.4% OF SHARES VOTED, QUORUM NOT ESTABLISHED TO HOLD ANNUAL MEETING –	ZYNERBA PHARMACEUTICALS ANNOUNCES ADJOURNMENT OF ANNUAL MEETING	ZYNE	a5c0a04e-eb88-4264-9cb2-fb3140e63537	PressRelease
Press Release 0 2CRSI.PA 1 2CRSI.PA 2 2CRSI.PA 3 2CRSI.PA 4 2CRSI.PA ... 83 ZYXI 84 ZYXI 85 ZYXI 0 ZZZ.TO 1 ZZZ.TO Name: symbol, Length: 320040, dtype: object	2021-06-04 07:30:00	null	DEVON, PA., JUNE 04, 2021 (GLOBE NEWSWIRE) -- ZYNERBA PHARMACEUTICALS, INC. (NASDAQ: ZYNE), THE LEADER IN INNOVATIVE PHARMACEUTICALLY-PRODUCED TRANSDERMAL CANNABINOID THERAPIES FOR RARE AND NEAR-RARE NEUROPSYCHIATRIC DISORDERS, TODAY ANNOUNCED THE ACCEPTANCE AND PRESENTATION DETAILS OF A POSTER AT SLEEP 2021, THE 35TH ...	ZYNERBA PHARMACEUTICALS ANNOUNCES ACCEPTANCE OF POSTER AT THE ASSOCIATED PROFESSIONAL SLEEP SOCIETIES SLEEP 2021 ANNUAL MEETING	ZYNE	a5c0a04e-eb88-4264-9cb2-fb3140e63537	PressRelease
Press Release 0 2CRSI.PA 1 2CRSI.PA 2 2CRSI.PA 3 2CRSI.PA 4 2CRSI.PA ... 83 ZYXI 84 ZYXI 85 ZYXI 0 ZZZ.TO 1 ZZZ.TO Name: symbol, Length: 320040, dtype: object	2021-06-03 10:00:00	null	DEVON, PA., JUNE 03, 2021 (GLOBE NEWSWIRE) -- ZYNERBA PHARMACEUTICALS, INC. (NASDAQ: ZYNE), THE LEADER IN INNOVATIVE PHARMACEUTICALLY-PRODUCED TRANSDERMAL CANNABINOID THERAPIES FOR RARE AND NEAR-RARE NEUROPSYCHIATRIC DISORDERS, IS PRESENTING A POSTER TODAY FROM 10:00 A.M. – 11:00 A.M. ET IN POSTER SESSION II AT THE 202...	ZYNERBA PHARMACEUTICALS ANNOUNCES PRESENTATION OF EFFICACY AND SAFETY FINDINGS IN CHILDREN AND ADOLESCENTS WITH AUTISM SPECTRUM DISORDER (ASD) AND RELATED DISORDERS AT THE 2021 AMERICAN SOCIETY OF CLINICAL PSYCHOPHARMACOLOGY (ASCP) ANNUAL MEETING	ZYNE	a5c0a04e-eb88-4264-9cb2-fb3140e63537	PressRelease
Press Release 0 2CRSI.PA 1 2CRSI.PA 2 2CRSI.PA 3 2CRSI.PA 4 2CRSI.PA ... 83 ZYXI 84 ZYXI 85 ZYXI 0 ZZZ.TO 1 ZZZ.TO Name: symbol, Length: 320040, dtype: object	2021-05-27 07:30:00	null	DEVON, PA., MAY 27, 2021 (GLOBE NEWSWIRE) -- ZYNERBA PHARMACEUTICALS, INC. (NASDAQ: ZYNE), THE LEADER IN INNOVATIVE PHARMACEUTICALLY-PRODUCED TRANSDERMAL CANNABINOID THERAPIES FOR RARE AND NEAR-RARE NEUROPSYCHIATRIC DISORDERS, TODAY ANNOUNCED THE ACCEPTANCE AND PRESENTATION DETAILS OF A POSTER AT THE 2021 AMERICAN SOCI...	ZYNERBA PHARMACEUTICALS ANNOUNCES ACCEPTANCE OF POSTER AT THE 2021 AMERICAN SOCIETY OF CLINICAL PSYCHOPHARMACOLOGY (ASCP) ANNUAL MEETING	ZYNE	a5c0a04e-eb88-4264-9cb2-fb3140e63537	PressRelease
Press Release 0 2CRSI.PA 1 2CRSI.PA 2 2CRSI.PA 3 2CRSI.PA 4 2CRSI.PA ... 83 ZYXI 84 ZYXI 85 ZYXI 0 ZZZ.TO 1 ZZZ.TO Name: symbol, Length: 320040, dtype: object	2021-05-26 07:30:00	null	DEVON, PA., MAY 26, 2021 (GLOBE NEWSWIRE) -- ZYNERBA PHARMACEUTICALS, INC. (NASDAQ: ZYNE), THE LEADER IN INNOVATIVE PHARMACEUTICALLY-PRODUCED TRANSDERMAL CANNABINOID THERAPIES FOR RARE AND NEAR-RARE NEUROPSYCHIATRIC DISORDERS, TODAY ANNOUNCED THAT ARMANDO ANIDO, CHAIRMAN AND CHIEF EXECUTIVE OFFICER OF ZYNERBA, WILL PRE...	ZYNERBA PHARMACEUTICALS TO PRESENT AT THE JEFFERIES VIRTUAL HEALTHCARE CONFERENCE	ZYNE	a5c0a04e-eb88-4264-9cb2-fb3140e63537	PressRelease
Press Release 0 2CRSI.PA 1 2CRSI.PA 2 2CRSI.PA 3 2CRSI.PA 4 2CRSI.PA ... 83 ZYXI 84 ZYXI 85 ZYXI 0 ZZZ.TO 1 ZZZ.TO Name: symbol, Length: 320040, dtype: object	2021-04-29 14:00:00	null	DEVON, PA., APRIL 29, 2021 (GLOBE NEWSWIRE) -- ZYNERBA PHARMACEUTICALS, INC. (NASDAQ: ZYNE), THE LEADER IN INNOVATIVE PHARMACEUTICALLY-PRODUCED TRANSDERMAL CANNABINOID THERAPIES FOR RARE AND NEAR-RARE NEUROPSYCHIATRIC DISORDERS, IS PRESENTING TWO POSTERS AT THE SOCIETY OF BIOLOGICAL PSYCHIATRY (SOBP) 2021 VIRTUAL MEETI...	ZYNERBA PHARMACEUTICALS PRESENTS TWO POSTERS AT THE SOCIETY OF BIOLOGICAL PSYCHIATRY 2021 VIRTUAL MEETING	ZYNE	a5c0a04e-eb88-4264-9cb2-fb3140e63537	PressRelease
Press Release 0 2CRSI.PA 1 2CRSI.PA 2 2CRSI.PA 3 2CRSI.PA 4 2CRSI.PA ... 83 ZYXI 84 ZYXI 85 ZYXI 0 ZZZ.TO 1 ZZZ.TO Name: symbol, Length: 320040, dtype: object	2021-04-15 07:30:00	null	DEVON, PA., APRIL 15, 2021 (GLOBE NEWSWIRE) -- ZYNERBA PHARMACEUTICALS, INC. (NASDAQ: ZYNE), THE LEADER IN INNOVATIVE PHARMACEUTICALLY-PRODUCED TRANSDERMAL CANNABINOID THERAPIES FOR RARE AND NEAR-RARE NEUROPSYCHIATRIC DISORDERS, TODAY ANNOUNCED THE ACCEPTANCE AND PRESENTATION DETAILS OF TWO POSTERS AT THE SOCIETY OF BI...	ZYNERBA PHARMACEUTICALS ANNOUNCES THE ACCEPTANCE OF TWO POSTERS AT THE SOCIETY OF BIOLOGICAL PSYCHIATRY 2021 VIRTUAL MEETING	ZYNE	a5c0a04e-eb88-4264-9cb2-fb3140e63537	PressRelease
Press Release 0 2CRSI.PA 1 2CRSI.PA 2 2CRSI.PA 3 2CRSI.PA 4 2CRSI.PA ... 83 ZYXI 84 ZYXI 85 ZYXI 0 ZZZ.TO 1 ZZZ.TO Name: symbol, Length: 320040, dtype: object	2021-04-06 07:30:00	null	DEVON, PA., APRIL 06, 2021 (GLOBE NEWSWIRE) -- ZYNERBA PHARMACEUTICALS, INC. (NASDAQ: ZYNE), THE LEADER IN INNOVATIVE PHARMACEUTICALLY-PRODUCED TRANSDERMAL CANNABINOID THERAPIES FOR RARE AND NEAR-RARE NEUROPSYCHIATRIC DISORDERS, TODAY ANNOUNCED THAT ARMANDO ANIDO, CHIEF EXECUTIVE OFFICER OF ZYNERBA, WILL PRESENT A COMP...	ZYNERBA PHARMACEUTICALS TO PRESENT AT THE NEEDHAM VIRTUAL HEALTHCARE CONFERENCE	ZYNE	a5c0a04e-eb88-4264-9cb2-fb3140e63537	PressRelease
Press Release 0 2CRSI.PA 1 2CRSI.PA 2 2CRSI.PA 3 2CRSI.PA 4 2CRSI.PA ... 83 ZYXI 84 ZYXI 85 ZYXI 0 ZZZ.TO 1 ZZZ.TO Name: symbol, Length: 320040, dtype: object	2021-03-28 08:15:00	null	SAN DIEGO, MARCH 28, 2021 /PRNEWSWIRE/ -- JOHNSON FISTEL, LLP IS INVESTIGATING POTENTIAL CLAIMS ON BEHALF OF ZYNERBA PHARMACEUTICALS, INC. (NASDAQ: ZYNE) ("ZYNERBA " OR THE "COMPANY") AGAINST CERTAIN OF ITS OFFICERS AND DIRECTORS. SPECIFICALLY, A CLASS-ACTION LAWSUIT PENDING IN THE EASTERN DISTRICT OF PENNSYLVANIA AGAI...	ZYNERBA (ZYNE) ALERT: SHAREHOLDER CLASS ACTION SURVIVES MOTION TO DISMISS; SHOULD MANAGEMENT BE HELD ACCOUNTABLE FOR INVESTORS LOSSES? CONTACT JOHNSON FISTEL	ZYNE	a5c0a04e-eb88-4264-9cb2-fb3140e63537	PressRelease
Press Release 0 2CRSI.PA 1 2CRSI.PA 2 2CRSI.PA 3 2CRSI.PA 4 2CRSI.PA ... 83 ZYXI 84 ZYXI 85 ZYXI 0 ZZZ.TO 1 ZZZ.TO Name: symbol, Length: 320040, dtype: object	2021-03-10 06:45:00	null	DEVON, PA., MARCH 10, 2021 (GLOBE NEWSWIRE) -- ZYNERBA PHARMACEUTICALS, INC. (NASDAQ: ZYNE), THE LEADER IN INNOVATIVE PHARMACEUTICALLY-PRODUCED TRANSDERMAL CANNABINOID THERAPIES FOR RARE AND NEAR-RARE NEUROPSYCHIATRIC DISORDERS, TODAY REPORTED FINANCIAL RESULTS FOR THE FOURTH QUARTER AND FULL YEAR ENDED DECEMBER 31, 20...	ZYNERBA PHARMACEUTICALS REPORTS FOURTH QUARTER AND FULL YEAR 2020 FINANCIAL RESULTS AND OPERATIONAL HIGHLIGHTS	ZYNE	a5c0a04e-eb88-4264-9cb2-fb3140e63537	PressRelease
Press Release 0 2CRSI.PA 1 2CRSI.PA 2 2CRSI.PA 3 2CRSI.PA 4 2CRSI.PA ... 83 ZYXI 84 ZYXI 85 ZYXI 0 ZZZ.TO 1 ZZZ.TO Name: symbol, Length: 320040, dtype: object	2021-03-04 08:00:00	null	DEVON, PA., MARCH 04, 2021 (GLOBE NEWSWIRE) -- ZYNERBA PHARMACEUTICALS, INC. (NASDAQ: ZYNE), THE LEADER IN INNOVATIVE PHARMACEUTICALLY-PRODUCED TRANSDERMAL CANNABINOID THERAPIES FOR RARE AND NEAR-RARE NEUROPSYCHIATRIC DISORDERS, TODAY ANNOUNCED THAT COMPANY MANAGEMENT WILL PARTICIPATE IN THE 33RD ANNUAL ROTH CONFERENCE...	ZYNERBA PHARMACEUTICALS TO PARTICIPATE IN THE 33RD ANNUAL ROTH CONFERENCE	ZYNE	a5c0a04e-eb88-4264-9cb2-fb3140e63537	PressRelease
Press Release 0 2CRSI.PA 1 2CRSI.PA 2 2CRSI.PA 3 2CRSI.PA 4 2CRSI.PA ... 83 ZYXI 84 ZYXI 85 ZYXI 0 ZZZ.TO 1 ZZZ.TO Name: symbol, Length: 320040, dtype: object	2020-12-17 06:30:00	null	- SINGLE TRIAL TO BE CONDUCTED IN PATIENTS WITH FRAGILE X SYNDROME TO CONFIRM POSITIVE RESULTS SEEN IN THE POPULATION OF RESPONDERS IN THE CONNECT-FX TRIAL -	ZYNERBA PHARMACEUTICALS PROVIDES REGULATORY UPDATE ON ZYGEL™ IN FRAGILE X SYNDROME	ZYNE	a5c0a04e-eb88-4264-9cb2-fb3140e63537	PressRelease
Press Release 0 2CRSI.PA 1 2CRSI.PA 2 2CRSI.PA 3 2CRSI.PA 4 2CRSI.PA ... 83 ZYXI 84 ZYXI 85 ZYXI 0 ZZZ.TO 1 ZZZ.TO Name: symbol, Length: 320040, dtype: object	2020-12-09 15:49:00	null	DENVER--(BUSINESS WIRE)--SHUMAN, GLENN & STECKER INVESTIGATES ZYNERBA PHARMACEUTICALS, INC. (ZYNE)	SHUMAN, GLENN & STECKER INVESTIGATES ZYNERBA PHARMACEUTICALS, INC.	ZYNE	a5c0a04e-eb88-4264-9cb2-fb3140e63537	PressRelease

Press Release 0 2CRSI.PA 1 2CRSI.PA 2 2CRSI.PA 3 2CRSI.PA 4 2CRSI.PA ... 83 ZYXI 84 ZYXI 85 ZYXI 0 ZZZ.TO 1 ZZZ.TO Name: symbol, Length: 320040, dtype: object

2022-01-19 16:15:00

null

VANCOUVER, BRITISH COLUMBIA & SEATTLE--(BUSINESS WIRE)--ZYMEWORKS INC. (NYSE: ZYME), A CLINICAL-STAGE BIOPHARMACEUTICAL COMPANY DEVELOPING MULTIFUNCTIONAL BIOTHERAPEUTICS, TODAY PROVIDED A CORPORATE UPDATE ON ITS KEY STRATEGIC PRIORITIES FOR 2022 AND 2023 IN ADDITION TO CONFIRMING ITS UPCOMING CLINICAL DEVELOPMENT MILE...

ZYMEWORKS PROVIDES CORPORATE UPDATE ON KEY STRATEGIC PRIORITIES AND OUTLOOK FOR 2022

ZYME

a5c0a04e-eb88-4264-9cb2-fb3140e63537

PressRelease

Press Release 0 2CRSI.PA 1 2CRSI.PA 2 2CRSI.PA 3 2CRSI.PA 4 2CRSI.PA ... 83 ZYXI 84 ZYXI 85 ZYXI 0 ZZZ.TO 1 ZZZ.TO Name: symbol, Length: 320040, dtype: object

2022-01-15 08:30:00

null

VANCOUVER, BRITISH COLUMBIA & SEATTLE--(BUSINESS WIRE)--ZYMEWORKS INC. (NYSE: ZYME), A CLINICAL-STAGE BIOPHARMACEUTICAL COMPANY DEVELOPING MULTIFUNCTIONAL BIOTHERAPEUTICS, TODAY REPORTED, AS REQUIRED BY THE NEW YORK STOCK EXCHANGE LISTED COMPANY MANUAL RULE 303A.08 (THE “NYSE RULE”), AN EQUITY INDUCEMENT AWARD TO MR. K...

ZYMEWORKS REPORTS INDUCEMENT GRANT UNDER NEW YORK STOCK EXCHANGE LISTED COMPANY MANUAL RULE

ZYME

a5c0a04e-eb88-4264-9cb2-fb3140e63537

PressRelease

Press Release 0 2CRSI.PA 1 2CRSI.PA 2 2CRSI.PA 3 2CRSI.PA 4 2CRSI.PA ... 83 ZYXI 84 ZYXI 85 ZYXI 0 ZZZ.TO 1 ZZZ.TO Name: symbol, Length: 320040, dtype: object

2022-01-05 16:30:00

null

VANCOUVER, BRITISH COLUMBIA & SEATTLE--(BUSINESS WIRE)--ZYMEWORKS NAMES BIOTECHNOLOGY INDUSTRY LEADER KENNETH GALBRAITH AS CHAIR AND CEO TO SUCCEED DR. ALI TEHRANI

ZYMEWORKS NAMES BIOTECHNOLOGY INDUSTRY LEADER KENNETH GALBRAITH AS CHAIR AND CEO TO SUCCEED DR. ALI TEHRANI

ZYME

a5c0a04e-eb88-4264-9cb2-fb3140e63537

PressRelease

Press Release 0 2CRSI.PA 1 2CRSI.PA 2 2CRSI.PA 3 2CRSI.PA 4 2CRSI.PA ... 83 ZYXI 84 ZYXI 85 ZYXI 0 ZZZ.TO 1 ZZZ.TO Name: symbol, Length: 320040, dtype: object

2021-12-09 08:30:00

null

VANCOUVER, BRITISH COLUMBIA--(BUSINESS WIRE)--ZYMEWORKS INC. (NYSE: ZYME), A CLINICAL-STAGE BIOPHARMACEUTICAL COMPANY DEVELOPING MULTIFUNCTIONAL BIOTHERAPEUTICS, TODAY ANNOUNCED THAT ITS COLLABORATOR, BEIGENE, LTD., HAS DOSED THE FIRST PATIENT IN SOUTH KOREA IN THE HERIZON‑GEA‑01 TRIAL. AS A RESULT OF THIS DEVELOPMENT ...

ZYMEWORKS ANNOUNCES EXPANSION OF ZANIDATAMAB PIVOTAL TRIAL IN ASIA IN COLLABORATION WITH BEIGENE AND ASSOCIATED MILESTONE PAYMENT

ZYME

a5c0a04e-eb88-4264-9cb2-fb3140e63537

PressRelease

Press Release 0 2CRSI.PA 1 2CRSI.PA 2 2CRSI.PA 3 2CRSI.PA 4 2CRSI.PA ... 83 ZYXI 84 ZYXI 85 ZYXI 0 ZZZ.TO 1 ZZZ.TO Name: symbol, Length: 320040, dtype: object

2021-12-08 18:00:00

null

VANCOUVER, BRITISH COLUMBIA--(BUSINESS WIRE)--ZANIDATAMAB DATA PRESENTED AT THE SAN ANTONIO BREAST CANCER SYMPOSIUM (SABCS) DEMONSTRATE ENCOURAGING ANTITUMOR ACTIVITY

ZANIDATAMAB DATA PRESENTED AT THE SAN ANTONIO BREAST CANCER SYMPOSIUM (SABCS) DEMONSTRATE ENCOURAGING ANTITUMOR ACTIVITY IN HEAVILY PRETREATED PATIENTS WITH HER2-POSITIVE BREAST CANCER

ZYME

a5c0a04e-eb88-4264-9cb2-fb3140e63537

PressRelease

Press Release 0 2CRSI.PA 1 2CRSI.PA 2 2CRSI.PA 3 2CRSI.PA 4 2CRSI.PA ... 83 ZYXI 84 ZYXI 85 ZYXI 0 ZZZ.TO 1 ZZZ.TO Name: symbol, Length: 320040, dtype: object

2021-11-19 09:21:00

null

VANCOUVER, BRITISH COLUMBIA--(BUSINESS WIRE)--ZYMEWORKS ANNOUNCES ABSTRACT FOR ZANIDATAMAB IN LATE-LINE HER2-POSITIVE BREAST CANCER AT THE SAN ANTONIO BREAST CANCER SYMPOSIUM (SABCS)

ZYMEWORKS ANNOUNCES ABSTRACT FOR ZANIDATAMAB IN LATE-LINE HER2-POSITIVE BREAST CANCER AT THE SAN ANTONIO BREAST CANCER SYMPOSIUM (SABCS)

ZYME

a5c0a04e-eb88-4264-9cb2-fb3140e63537

PressRelease

Press Release 0 2CRSI.PA 1 2CRSI.PA 2 2CRSI.PA 3 2CRSI.PA 4 2CRSI.PA ... 83 ZYXI 84 ZYXI 85 ZYXI 0 ZZZ.TO 1 ZZZ.TO Name: symbol, Length: 320040, dtype: object

2021-11-09 08:30:00

null

VANCOUVER, BRITISH COLUMBIA--(BUSINESS WIRE)--ZYMEWORKS LAUNCHES GLOBAL PHASE 3 ZANIDATAMAB TRIAL IN FIRST-LINE HER2 POSITIVE GASTROESOPHAGEAL ADENOCARCINOMA (GEA)

ZYMEWORKS LAUNCHES GLOBAL PHASE 3 ZANIDATAMAB TRIAL IN FIRST-LINE HER2‑POSITIVE GASTROESOPHAGEAL ADENOCARCINOMA (GEA)

ZYME

a5c0a04e-eb88-4264-9cb2-fb3140e63537

PressRelease

Press Release 0 2CRSI.PA 1 2CRSI.PA 2 2CRSI.PA 3 2CRSI.PA 4 2CRSI.PA ... 83 ZYXI 84 ZYXI 85 ZYXI 0 ZZZ.TO 1 ZZZ.TO Name: symbol, Length: 320040, dtype: object

2021-09-16 05:30:00

null

VANCOUVER, BRITISH COLUMBIA--(BUSINESS WIRE)--ZYMEWORKS INC. (NYSE: ZYME), A CLINICAL-STAGE BIOPHARMACEUTICAL COMPANY DEVELOPING MULTIFUNCTIONAL BIOTHERAPEUTICS, TODAY ANNOUNCED THAT NEW CLINICAL DATA FOR ZANIDATAMAB, A HER2‑TARGETED BISPECIFIC ANTIBODY, DEMONSTRATE PROMISING RESPONSE RATES AND DURABILITY IN FIRST-LINE...

ZANIDATAMAB PHASE 2 CLINICAL TRIAL DEMONSTRATES PROMISING RESPONSE RATE AND DURABILITY IN FIRST-LINE HER2-POSITIVE GASTROESOPHAGEAL ADENOCARCINOMA (GEA) AT THE EUROPEAN SOCIETY FOR MEDICAL ONCOLOGY (ESMO) ANNUAL CONGRESS

ZYME

a5c0a04e-eb88-4264-9cb2-fb3140e63537

PressRelease

Press Release 0 2CRSI.PA 1 2CRSI.PA 2 2CRSI.PA 3 2CRSI.PA 4 2CRSI.PA ... 83 ZYXI 84 ZYXI 85 ZYXI 0 ZZZ.TO 1 ZZZ.TO Name: symbol, Length: 320040, dtype: object

2021-09-12 18:49:00

null

VANCOUVER, BRITISH COLUMBIA--(BUSINESS WIRE)--THIS PRESS RELEASE ANNOUNCES THE AVAILABILITY OF AN ABSTRACT THAT ZYMEWORKS IS PRESENTING AT THE UPCOMING ESMO CONGRESS

ZYMEWORKS ANNOUNCES ABSTRACT FOR ZANIDATAMAB IN FIRST-LINE HER2-EXPRESSING GASTROESOPHAGEAL CANCERS (GEA) AT THE EUROPEAN SOCIETY FOR MEDICAL ONCOLOGY (ESMO) ANNUAL CONGRESS

ZYME

a5c0a04e-eb88-4264-9cb2-fb3140e63537

PressRelease

Press Release 0 2CRSI.PA 1 2CRSI.PA 2 2CRSI.PA 3 2CRSI.PA 4 2CRSI.PA ... 83 ZYXI 84 ZYXI 85 ZYXI 0 ZZZ.TO 1 ZZZ.TO Name: symbol, Length: 320040, dtype: object

2021-08-04 16:15:00

null

VANCOUVER, BRITISH COLUMBIA--(BUSINESS WIRE)--ZYMEWORKS INC. (NYSE: ZYME), A CLINICAL-STAGE BIOPHARMACEUTICAL COMPANY DEVELOPING MULTIFUNCTIONAL BIOTHERAPEUTICS, TODAY REPORTED FINANCIAL RESULTS FOR THE SECOND QUARTER ENDED JUNE 30, 2021. “THE SECOND HALF OF 2021 IS AN EXCITING TIME AT ZYMEWORKS AS WE PREPARE TO PRESEN...

ZYMEWORKS REPORTS 2021 SECOND QUARTER FINANCIAL RESULTS

ZYME

a5c0a04e-eb88-4264-9cb2-fb3140e63537

PressRelease

Press Release 0 2CRSI.PA 1 2CRSI.PA 2 2CRSI.PA 3 2CRSI.PA 4 2CRSI.PA ... 83 ZYXI 84 ZYXI 85 ZYXI 0 ZZZ.TO 1 ZZZ.TO Name: symbol, Length: 320040, dtype: object

2021-08-03 08:30:00

null

VANCOUVER, BRITISH COLUMBIA--(BUSINESS WIRE)--ZYMEWORKS ANNOUNCES MILESTONE PAYMENT AS JANSSEN ACHIEVES FIRST PATIENT DOSED FOR ITS BISPECIFIC ANTIBODY UTILIZING ZYMEWORKS' THERAPEUTIC PLATFORMS

ZYMEWORKS ANNOUNCES MILESTONE PAYMENT AS JANSSEN ACHIEVES FIRST PATIENT DOSED FOR ITS BISPECIFIC ANTIBODY UTILIZING ZYMEWORKS' AZYMETRIC™ AND EFECT™ THERAPEUTIC PLATFORMS

ZYME

a5c0a04e-eb88-4264-9cb2-fb3140e63537

PressRelease

Press Release 0 2CRSI.PA 1 2CRSI.PA 2 2CRSI.PA 3 2CRSI.PA 4 2CRSI.PA ... 83 ZYXI 84 ZYXI 85 ZYXI 0 ZZZ.TO 1 ZZZ.TO Name: symbol, Length: 320040, dtype: object

2021-07-28 08:30:00

null

VANCOUVER, BRITISH COLUMBIA--(BUSINESS WIRE)--ZYMEWORKS ANNOUNCES FIRST PATIENT WITH ADVANCED HER2-POSITIVE BREAST CANCER DOSED WITH ZANIDATAMAB IN COMBINATION WITH TUKYSA® AND CHEMOTHERAPY

ZYMEWORKS ANNOUNCES FIRST PATIENT WITH ADVANCED HER2-POSITIVE BREAST CANCER DOSED WITH ZANIDATAMAB IN COMBINATION WITH TUKYSA® (TUCATINIB) AND CHEMOTHERAPY

ZYME

a5c0a04e-eb88-4264-9cb2-fb3140e63537

PressRelease

Press Release 0 2CRSI.PA 1 2CRSI.PA 2 2CRSI.PA 3 2CRSI.PA 4 2CRSI.PA ... 83 ZYXI 84 ZYXI 85 ZYXI 0 ZZZ.TO 1 ZZZ.TO Name: symbol, Length: 320040, dtype: object

2021-04-19 08:30:00

null

VANCOUVER, BRITISH COLUMBIA--(BUSINESS WIRE)--ZYMEWORKS INC. (NYSE: ZYME), A CLINICAL-STAGE BIOPHARMACEUTICAL COMPANY DEVELOPING MULTIFUNCTIONAL BIOTHERAPEUTICS, TODAY ANNOUNCED THAT DIANA HAUSMAN, M.D., WILL BE TRANSITIONING OUT OF HER ROLE AS ZYMEWORKS' CHIEF MEDICAL OFFICER (CMO) AND ASSUMING AN EXECUTIVE ADVISORY R...

ZYMEWORKS ANNOUNCES SUCCESSION PLAN FOR CHIEF MEDICAL OFFICER

ZYME

a5c0a04e-eb88-4264-9cb2-fb3140e63537

PressRelease

Press Release 0 2CRSI.PA 1 2CRSI.PA 2 2CRSI.PA 3 2CRSI.PA 4 2CRSI.PA ... 83 ZYXI 84 ZYXI 85 ZYXI 0 ZZZ.TO 1 ZZZ.TO Name: symbol, Length: 320040, dtype: object

2021-04-10 08:30:00

null

VANCOUVER, BRITISH COLUMBIA--(BUSINESS WIRE)--ZYMEWORKS SHOWCASES PRECLINICAL ASSETS, INCLUDING NEW THERAPEUTIC PLATFORM, PROTECT™, AND ZANIDATAMAB MECHANISMS OF ACTION AT AACR ANNUAL MEETING

ZYMEWORKS SHOWCASES PRECLINICAL ASSETS, INCLUDING NEW THERAPEUTIC PLATFORM, PROTECT™, AND ZANIDATAMAB MECHANISMS OF ACTION AT AACR ANNUAL MEETING

ZYME

a5c0a04e-eb88-4264-9cb2-fb3140e63537

PressRelease

Press Release 0 2CRSI.PA 1 2CRSI.PA 2 2CRSI.PA 3 2CRSI.PA 4 2CRSI.PA ... 83 ZYXI 84 ZYXI 85 ZYXI 0 ZZZ.TO 1 ZZZ.TO Name: symbol, Length: 320040, dtype: object

2021-03-10 17:27:00

null

VANCOUVER, BRITISH COLUMBIA--(BUSINESS WIRE)--ZYMEWORKS INC. (NYSE: ZYME), A CLINICAL-STAGE BIOPHARMACEUTICAL COMPANY DEVELOPING MULTIFUNCTIONAL BIOTHERAPEUTICS, TODAY ANNOUNCED THE ACCEPTANCE OF FIVE ABSTRACTS FOR POSTER PRESENTATION AT THE UPCOMING AMERICAN ASSOCIATION FOR CANCER RESEARCH (AACR) ANNUAL MEETING 2021 T...

ZYMEWORKS ANNOUNCES FIVE PRESENTATIONS AT THE AMERICAN ASSOCIATION FOR CANCER RESEARCH (AACR) ANNUAL MEETING 2021

ZYME

a5c0a04e-eb88-4264-9cb2-fb3140e63537

PressRelease

Press Release 0 2CRSI.PA 1 2CRSI.PA 2 2CRSI.PA 3 2CRSI.PA 4 2CRSI.PA ... 83 ZYXI 84 ZYXI 85 ZYXI 0 ZZZ.TO 1 ZZZ.TO Name: symbol, Length: 320040, dtype: object

2021-02-24 16:15:00

null

VANCOUVER, CANADA--(BUSINESS WIRE)--ZYMEWORKS INC. (NYSE: ZYME), A CLINICAL-STAGE BIOPHARMACEUTICAL COMPANY DEVELOPING MULTIFUNCTIONAL BIOTHERAPEUTICS, TODAY REPORTED FINANCIAL RESULTS FOR THE YEAR ENDED DECEMBER 31, 2020 AND PROVIDED A SUMMARY OF RECENT BUSINESS AND CLINICAL HIGHLIGHTS. “THROUGHOUT 2020, WE INITIATED ...

ZYMEWORKS REPORTS 2020 YEAR-END FINANCIAL RESULTS

ZYME

a5c0a04e-eb88-4264-9cb2-fb3140e63537

PressRelease

Press Release 0 2CRSI.PA 1 2CRSI.PA 2 2CRSI.PA 3 2CRSI.PA 4 2CRSI.PA ... 83 ZYXI 84 ZYXI 85 ZYXI 0 ZZZ.TO 1 ZZZ.TO Name: symbol, Length: 320040, dtype: object

2021-02-09 16:30:00

null

VANCOUVER, BRITISH COLUMBIA--(BUSINESS WIRE)--ZYMEWORKS INC. (NYSE: ZYME), A CLINICAL-STAGE BIOPHARMACEUTICAL COMPANY DEVELOPING MULTIFUNCTIONAL BIOTHERAPEUTICS, TODAY ANNOUNCED THAT JAMES PRIOUR, FORMER SENIOR VICE PRESIDENT, COMMERCIAL, HAS BEEN PROMOTED TO CHIEF COMMERCIAL OFFICER AND NAMED TO THE COMPANY'S EXECUTIV...

ZYMEWORKS EXPANDS COMMERCIAL TEAM AND CREATES NEW R&D ROLE

ZYME

a5c0a04e-eb88-4264-9cb2-fb3140e63537

PressRelease

Press Release 0 2CRSI.PA 1 2CRSI.PA 2 2CRSI.PA 3 2CRSI.PA 4 2CRSI.PA ... 83 ZYXI 84 ZYXI 85 ZYXI 0 ZZZ.TO 1 ZZZ.TO Name: symbol, Length: 320040, dtype: object

2021-01-27 17:15:00

null

VANCOUVER, BRITISH COLUMBIA--(BUSINESS WIRE)--ZYMEWORKS INC. (NYSE: ZYME), A CLINICAL-STAGE BIOPHARMACEUTICAL COMPANY DEVELOPING MULTIFUNCTIONAL BIOTHERAPEUTICS, ANNOUNCED TODAY THAT THE COMPANY HAS BEGUN ENROLLING PATIENTS INTO THE EXPANSION COHORT PORTION OF THE ONGOING PHASE 1 CLINICAL TRIAL FOR ZW49, ITS NOVEL HER2...

ZYMEWORKS ADVANCES HER2 BISPECIFIC ANTIBODY-DRUG CONJUGATE, ZW49, INTO EXPANSION COHORT STAGE OF CLINICAL DEVELOPMENT

ZYME

a5c0a04e-eb88-4264-9cb2-fb3140e63537

PressRelease

Press Release 0 2CRSI.PA 1 2CRSI.PA 2 2CRSI.PA 3 2CRSI.PA 4 2CRSI.PA ... 83 ZYXI 84 ZYXI 85 ZYXI 0 ZZZ.TO 1 ZZZ.TO Name: symbol, Length: 320040, dtype: object

2021-01-15 08:30:00

null

VANCOUVER, BRITISH COLUMBIA--(BUSINESS WIRE)--ZYMEWORKS INC. (NYSE: ZYME), A CLINICAL-STAGE BIOPHARMACEUTICAL COMPANY DEVELOPING MULTIFUNCTIONAL BIOTHERAPEUTICS, TODAY ANNOUNCED NEW AND UPDATED CLINICAL DATA FOR THE HER2‑TARGETED BISPECIFIC ANTIBODY ZANIDATAMAB, IN BOTH HER2-EXPRESSING BILIARY TRACT CANCER (BTC) AND GA...

ZANIDATAMAB DATA HIGHLIGHT DURABLE ANTITUMOR ACTIVITY IN HER2‑EXPRESSING BILIARY TRACT AND GASTROESOPHAGEAL CANCERS AT ASCO GASTROINTESTINAL CANCERS SYMPOSIUM

ZYME

a5c0a04e-eb88-4264-9cb2-fb3140e63537

PressRelease

Press Release 0 2CRSI.PA 1 2CRSI.PA 2 2CRSI.PA 3 2CRSI.PA 4 2CRSI.PA ... 83 ZYXI 84 ZYXI 85 ZYXI 0 ZZZ.TO 1 ZZZ.TO Name: symbol, Length: 320040, dtype: object

2021-01-11 08:00:00

null

VANCOUVER, BRITISH COLUMBIA--(BUSINESS WIRE)--ZYMEWORKS INC. (NYSE: ZYME), A CLINICAL-STAGE BIOPHARMACEUTICAL COMPANY DEVELOPING MULTIFUNCTIONAL BIOTHERAPEUTICS, TODAY HIGHLIGHTED ITS KEY ACCOMPLISHMENTS IN 2020 AND UPDATED ITS CORPORATE PRIORITIES. “2020 WAS A LEAP FORWARD FOR OUR LEAD CLINICAL PROGRAM IN TERMS OF A P...

ZYMEWORKS HIGHLIGHTS 2020 ACHIEVEMENTS AND ANNOUNCES CORPORATE PRIORITIES

ZYME

a5c0a04e-eb88-4264-9cb2-fb3140e63537

PressRelease

Press Release 0 2CRSI.PA 1 2CRSI.PA 2 2CRSI.PA 3 2CRSI.PA 4 2CRSI.PA ... 83 ZYXI 84 ZYXI 85 ZYXI 0 ZZZ.TO 1 ZZZ.TO Name: symbol, Length: 320040, dtype: object

2020-12-10 08:30:00

null

VANCOUVER, BRITISH COLUMBIA--(BUSINESS WIRE)--ZYMEWORKS INC. (NYSE: ZYME), A CLINICAL-STAGE BIOPHARMACEUTICAL COMPANY DEVELOPING MULTIFUNCTIONAL BIOTHERAPEUTICS, TODAY ANNOUNCED THE SELECTION OF THREE ABSTRACTS FOR PRESENTATION AT THE AMERICAN SOCIETY OF CLINICAL ONCOLOGY (ASCO) GASTROINTESTINAL CANCERS SYMPOSIUM, TAKI...

ZANIDATAMAB CLINICAL DATA SELECTED FOR ORAL PRESENTATION AT THE AMERICAN SOCIETY OF CLINICAL ONCOLOGY (ASCO) GASTROINTESTINAL CANCERS SYMPOSIUM

ZYME

a5c0a04e-eb88-4264-9cb2-fb3140e63537

PressRelease

Press Release 0 2CRSI.PA 1 2CRSI.PA 2 2CRSI.PA 3 2CRSI.PA 4 2CRSI.PA ... 83 ZYXI 84 ZYXI 85 ZYXI 0 ZZZ.TO 1 ZZZ.TO Name: symbol, Length: 320040, dtype: object

2020-11-19 08:30:00

null

VANCOUVER, BRITISH COLUMBIA--(BUSINESS WIRE)--ZYMEWORKS INC. (NYSE:ZYME), A CLINICAL-STAGE BIOPHARMACEUTICAL COMPANY DEVELOPING MULTIFUNCTIONAL BIOTHERAPEUTICS, TODAY ANNOUNCED THAT THE EUROPEAN COMMISSION (EC) HAS GRANTED ORPHAN DRUG DESIGNATION FOR ZANIDATAMAB, THE COMPANY'S INVESTIGATIONAL HER2-TARGETED BISPECIFIC A...

ZYMEWORKS RECEIVES ORPHAN DRUG DESIGNATION FROM THE EUROPEAN COMMISSION FOR HER2-TARGETED BISPECIFIC ANTIBODY ZANIDATAMAB IN PATIENTS WITH GASTRIC CANCER

ZYME

a5c0a04e-eb88-4264-9cb2-fb3140e63537

PressRelease

Press Release 0 2CRSI.PA 1 2CRSI.PA 2 2CRSI.PA 3 2CRSI.PA 4 2CRSI.PA ... 83 ZYXI 84 ZYXI 85 ZYXI 0 ZZZ.TO 1 ZZZ.TO Name: symbol, Length: 320040, dtype: object

2020-11-16 16:15:00

null

VANCOUVER, BRITISH COLUMBIA & BURLINGAME, CALIF.--(BUSINESS WIRE)--ZYMEWORKS INC. (NYSE: ZYME), A CLINICAL-STAGE BIOPHARMACEUTICAL COMPANY DEVELOPING MULTIFUNCTIONAL BIOTHERAPEUTICS, AND ALX ONCOLOGY HOLDINGS INC. (NASDAQ: ALXO), A CLINICAL-STAGE IMMUNO-ONCOLOGY COMPANY DEVELOPING THERAPIES THAT BLOCK THE CD47 CHECKPOI...

ZYMEWORKS AND ALX ONCOLOGY ANNOUNCE CLINICAL COLLABORATION EVALUATING ZANIDATAMAB WITH THE CD47 BLOCKER ALX148 IN PATIENTS WITH ADVANCED HER2‑EXPRESSING BREAST CANCER

ZYME

a5c0a04e-eb88-4264-9cb2-fb3140e63537

PressRelease

Press Release 0 2CRSI.PA 1 2CRSI.PA 2 2CRSI.PA 3 2CRSI.PA 4 2CRSI.PA ... 83 ZYXI 84 ZYXI 85 ZYXI 0 ZZZ.TO 1 ZZZ.TO Name: symbol, Length: 320040, dtype: object

2020-11-03 16:15:00

null

VANCOUVER, BRITISH COLUMBIA--(BUSINESS WIRE)--ZYMEWORKS INC. (NYSE: ZYME), A CLINICAL-STAGE BIOPHARMACEUTICAL COMPANY DEVELOPING MULTIFUNCTIONAL BIOTHERAPEUTICS, TODAY REPORTED FINANCIAL RESULTS FOR THE QUARTER ENDED SEPTEMBER 30, 2020. “ZANIDATAMAB'S CLINICAL DEVELOPMENT CONTINUED TO EXPAND THIS QUARTER, HAVING OPENED...

ZYMEWORKS REPORTS 2020 THIRD QUARTER FINANCIAL RESULTS

ZYME

a5c0a04e-eb88-4264-9cb2-fb3140e63537

PressRelease

Press Release 0 2CRSI.PA 1 2CRSI.PA 2 2CRSI.PA 3 2CRSI.PA 4 2CRSI.PA ... 83 ZYXI 84 ZYXI 85 ZYXI 0 ZZZ.TO 1 ZZZ.TO Name: symbol, Length: 320040, dtype: object

2020-08-05 18:30:00

null

ZYMEWORKS REPORTS 2020 SECOND QUARTER FINANCIAL RESULTS.Q2 REVENUE $12.4 MILLION VERSUS $7.9 MILLION.QTRLY LOSS PER SHARE $0.77.

ZYMEWORKS REPORTS QTRLY LOSS PER SHARE $0.77

ZYME

a5c0a04e-eb88-4264-9cb2-fb3140e63537

PressRelease

Press Release 0 2CRSI.PA 1 2CRSI.PA 2 2CRSI.PA 3 2CRSI.PA 4 2CRSI.PA ... 83 ZYXI 84 ZYXI 85 ZYXI 0 ZZZ.TO 1 ZZZ.TO Name: symbol, Length: 320040, dtype: object

2020-07-08 19:30:00

null

ZYMEWORKS - CO & MERCK SIGNED NEW LICENSE AGREEMENT.ZYMEWORKS - AGREEMENT GRANTS MERCK RIGHT TO DEVELOP ADDITIONAL MULTISPECIFIC ANTIBODY THERAPEUTIC CANDIDATES USING CO'S AZYMETRIC & EFECT PLATFORMS.ZYMEWORKS - TO PROVIDE MERCK WORLDWIDE, ROYALTY-BEARING LICENSE TO RESEARCH, COMMERCIALIZE UP TO 3 NEW MULTISPECIFIC ANT...

ZYMEWORKS & MERCK SIGN NEW LICENSE AGREEMENT

ZYME

a5c0a04e-eb88-4264-9cb2-fb3140e63537

PressRelease

Press Release 0 2CRSI.PA 1 2CRSI.PA 2 2CRSI.PA 3 2CRSI.PA 4 2CRSI.PA ... 83 ZYXI 84 ZYXI 85 ZYXI 0 ZZZ.TO 1 ZZZ.TO Name: symbol, Length: 320040, dtype: object

2020-05-07 19:30:00

null

ZYMEWORKS REPORTS 2020 FIRST QUARTER FINANCIAL RESULTS.Q1 REVENUE $8.3 MILLION VERSUS $11.9 MILLION.EXPECTS TO HAVE CASH TO FUND RESEARCH AND DEVELOPMENT PROGRAMS AND OPERATIONS INTO 2022 AND POTENTIALLY BEYOND.QTRLY LOSS PER SHARE $0.64.

ZYMEWORKS POSTS QUARTERLY LOSS PER SHARE OF $0.64

ZYME

a5c0a04e-eb88-4264-9cb2-fb3140e63537

PressRelease

Press Release 0 2CRSI.PA 1 2CRSI.PA 2 2CRSI.PA 3 2CRSI.PA 4 2CRSI.PA ... 83 ZYXI 84 ZYXI 85 ZYXI 0 ZZZ.TO 1 ZZZ.TO Name: symbol, Length: 320040, dtype: object

2020-01-21 20:30:00

null

ZYMEWORKS FILES PRELIMINARY PROSPECTUS SUPPLEMENTS FOR OFFERING OF COMMON SHARES AND PRE-FUNDED WARRANTS.

ZYMEWORKS FILES PRELIMINARY PROSPECTUS SUPPLEMENTS FOR OFFERING OF COMMON SHARES AND PRE-FUNDED WARRANTS

ZYME

a5c0a04e-eb88-4264-9cb2-fb3140e63537

PressRelease

Press Release 0 2CRSI.PA 1 2CRSI.PA 2 2CRSI.PA 3 2CRSI.PA 4 2CRSI.PA ... 83 ZYXI 84 ZYXI 85 ZYXI 0 ZZZ.TO 1 ZZZ.TO Name: symbol, Length: 320040, dtype: object

2020-01-12 13:30:00

null

ZYMEWORKS ANNOUNCES AGREEMENT WITH PFIZER AND INITIATION OF A NEW PHASE 2 TRIAL EVALUATING ZW25 IN COMBINATION WITH IBRANCE® (PALBOCICLIB).ZYMEWORKS WILL SPONSOR STUDY, AND PFIZER WILL PROVIDE PALBOCICLIB..PLANS TO INITIATE A REGISTRATION-ENABLING PHASE 2 TRIAL IN PREVIOUSLY-TREATED OR RECURRENT HER2-POSITIVE BILIARY T...

ZYMEWORKS ANNOUNCES AGREEMENT WITH PFIZER

ZYME

a5c0a04e-eb88-4264-9cb2-fb3140e63537

PressRelease

Press Release 0 2CRSI.PA 1 2CRSI.PA 2 2CRSI.PA 3 2CRSI.PA 4 2CRSI.PA ... 83 ZYXI 84 ZYXI 85 ZYXI 0 ZZZ.TO 1 ZZZ.TO Name: symbol, Length: 320040, dtype: object

2019-11-21 22:30:00

null

ZYMEWORKS INC. ANNOUNCED UPDATED PHASE 1 DATA FOR SINGLE AGENT ZW25 IN HEAVILY PRETREATED PATIENTS WITH HER2-EXPRESSING SOLID TUMORS IN A MINI ORAL PRESENTATION BY DR. DO-YOUN OH, STUDY INVESTIGATOR AND PROFESSOR AT SEOUL NATIONAL UNIVERSITY, AT THE ESMO ASIA 2019 CONGRESS, TAKING PLACE NOVEMBER 22 - 24 IN SINGAPORE. Z...

ZYMEWORKS INC. ANNOUNCES UPDATED PHASE 1 DATA FOR SINGLE AGENT ZW25

ZYME

a5c0a04e-eb88-4264-9cb2-fb3140e63537

PressRelease

Press Release 0 2CRSI.PA 1 2CRSI.PA 2 2CRSI.PA 3 2CRSI.PA 4 2CRSI.PA ... 83 ZYXI 84 ZYXI 85 ZYXI 0 ZZZ.TO 1 ZZZ.TO Name: symbol, Length: 320040, dtype: object

2019-11-17 22:30:00

null

ZYMEWORKS INC. ANNOUNCED THE SELECTION OF AN ABSTRACT HIGHLIGHTING UPDATED SINGLE AGENT DATA FROM THE PHASE 1 CLINICAL TRIAL EVALUATING THE HER2-TARGETED BISPECIFIC ANTIBODY, ZW25, IN PATIENTS WITH HER2-EXPRESSING SOLID TUMORS FOR A MINI ORAL PRESENTATION AT THE ESMO ASIA 2019 CONGRESS, TAKING PLACE NOVEMBER 22 - 24 IN...

ZYMEWORKS INC. ANNOUNCES SELECTION OF ZW25 ABSTRACT FOR MINI ORAL PRESENTATION AT THE EUROPEAN SOCIETY FOR MEDICAL ONCOLOGY ASIA (ESMO ASIA) CONGRESS

ZYME

a5c0a04e-eb88-4264-9cb2-fb3140e63537

PressRelease

Press Release 0 2CRSI.PA 1 2CRSI.PA 2 2CRSI.PA 3 2CRSI.PA 4 2CRSI.PA ... 83 ZYXI 84 ZYXI 85 ZYXI 0 ZZZ.TO 1 ZZZ.TO Name: symbol, Length: 320040, dtype: object

2019-11-05 21:30:00

null

ZYMEWORKS INC FILES FOR OFFERING OF UP TO $75.0 MILLION OF COMMON SHARES - SEC FILING.

ZYMEWORKS INC FILES FOR OFFERING OF UP TO $75 MLN OF COMMON SHARES

ZYME

a5c0a04e-eb88-4264-9cb2-fb3140e63537

PressRelease

Press Release 0 2CRSI.PA 1 2CRSI.PA 2 2CRSI.PA 3 2CRSI.PA 4 2CRSI.PA ... 83 ZYXI 84 ZYXI 85 ZYXI 0 ZZZ.TO 1 ZZZ.TO Name: symbol, Length: 320040, dtype: object

2019-11-05 19:30:00

null

ZYMEWORKS REPORTS 2019 THIRD QUARTER FINANCIAL RESULTS.Q3 REVENUE $7.9 MILLION VERSUS $2.1 MILLION.QTRLY LOSS PER SHARE $0.70.AS OF SEPTEMBER 30, 2019, ZYMEWORKS HAD $335.1 MILLION IN CASH AND CASH EQUIVALENTS AND SHORT-TERM INVESTMENTS.

ZYMEWORKS REPORTS 2019 THIRD QUARTER FINANCIAL RESULTS

ZYME

a5c0a04e-eb88-4264-9cb2-fb3140e63537

PressRelease

Press Release 0 2CRSI.PA 1 2CRSI.PA 2 2CRSI.PA 3 2CRSI.PA 4 2CRSI.PA ... 83 ZYXI 84 ZYXI 85 ZYXI 0 ZZZ.TO 1 ZZZ.TO Name: symbol, Length: 320040, dtype: object

2019-11-04 22:30:00

null

ZYMEWORKS INC. HAS FILED A SHELF REGISTRATION.

ZYME

a5c0a04e-eb88-4264-9cb2-fb3140e63537

PressRelease

Press Release 0 2CRSI.PA 1 2CRSI.PA 2 2CRSI.PA 3 2CRSI.PA 4 2CRSI.PA ... 83 ZYXI 84 ZYXI 85 ZYXI 0 ZZZ.TO 1 ZZZ.TO Name: symbol, Length: 320040, dtype: object

2019-10-27 22:30:00

null

ZYMEWORKS INC. ANNOUNCED THE FIRST DATA FROM ITS PHASE 1 STUDY EVALUATING NOVEL BISPECIFIC ANTIBODY ZW25 IN COMBINATION WITH CHEMOTHERAPY IN HER2-EXPRESSING GASTROESOPHAGEAL ADENOCARCINOMA (GEA) IN A POSTER PRESENTATION AT THE AACR-NCI-EORTC INTERNATIONAL CONFERENCE ON MOLECULAR TARGETS AND CANCER THERAPEUTICS, TAKING ...

ZYMEWORKS INC. ANNOUNCES PHASE 1 DATA FOR ZW25 IN COMBINATION WITH CHEMOTHERAPY IN ADVANCED GASTROESOPHAGEAL ADENOCARCINOMA AT AACR-NCI-EORTC INTERNATIONAL CONFERENCE

ZYME

a5c0a04e-eb88-4264-9cb2-fb3140e63537

PressRelease

Press Release 0 2CRSI.PA 1 2CRSI.PA 2 2CRSI.PA 3 2CRSI.PA 4 2CRSI.PA ... 83 ZYXI 84 ZYXI 85 ZYXI 0 ZZZ.TO 1 ZZZ.TO Name: symbol, Length: 320040, dtype: object

2019-10-24 22:30:00

null

ZYMEWORKS INC. PRESENTS AT PROTEIN & ANTIBODY ENGINEERING SUMMIT 2019, NOV-18-2019 . VENUE: LISBON CONGRESS CENTER, LISBON, PORTUGAL.

ZYMEWORKS INC. PRESENTS AT PROTEIN & ANTIBODY ENGINEERING SUMMIT 2019, NOV-18-2019

ZYME

a5c0a04e-eb88-4264-9cb2-fb3140e63537

PressRelease

Press Release 0 2CRSI.PA 1 2CRSI.PA 2 2CRSI.PA 3 2CRSI.PA 4 2CRSI.PA ... 83 ZYXI 84 ZYXI 85 ZYXI 0 ZZZ.TO 1 ZZZ.TO Name: symbol, Length: 320040, dtype: object

2019-10-16 22:30:00

null

ZYMEWORKS INC. PRESENTS AT STIFEL 2019 HEALTHCARE CONFERENCE, NOV-19-2019 08:00 AM. VENUE: LOTTE NEW YORK PALACE HOTEL, NEW YORK, NEW YORK, UNITED STATES.

ZYMEWORKS INC. PRESENTS AT STIFEL 2019 HEALTHCARE CONFERENCE, NOV-19-2019 08:00 AM

ZYME

a5c0a04e-eb88-4264-9cb2-fb3140e63537

PressRelease

Press Release 0 2CRSI.PA 1 2CRSI.PA 2 2CRSI.PA 3 2CRSI.PA 4 2CRSI.PA ... 83 ZYXI 84 ZYXI 85 ZYXI 0 ZZZ.TO 1 ZZZ.TO Name: symbol, Length: 320040, dtype: object

2019-10-15 22:30:00

null

ZYMEWORKS INC. ANNOUNCED THE APPOINTMENT OF KATHRYN O’DRISCOLL TO THE EXECUTIVE TEAM AS CHIEF PEOPLE OFFICER (CPO). MS. O'DRISCOLL BRINGS OVER 20 YEARS OF EXPERIENCE AS AN EXECUTIVE-LEVEL HUMAN RESOURCES LEADER ACROSS LARGE GLOBAL ORGANIZATIONS IN THE TECHNOLOGY AND NON-PROFIT SECTORS. IN HER NEW ROLE AS ZYMEWORKS’ CPO...

ZYMEWORKS INC. APPOINTS KATHRYN O’DRISCOLL AS CHIEF PEOPLE OFFICER

ZYME

a5c0a04e-eb88-4264-9cb2-fb3140e63537

PressRelease

Press Release 0 2CRSI.PA 1 2CRSI.PA 2 2CRSI.PA 3 2CRSI.PA 4 2CRSI.PA ... 83 ZYXI 84 ZYXI 85 ZYXI 0 ZZZ.TO 1 ZZZ.TO Name: symbol, Length: 320040, dtype: object

2019-09-27 22:30:00

null

ZYMEWORKS INC. ANNOUNCED UPDATED DATA FROM THE ONGOING MULTI-CENTER PHASE 1 CLINICAL TRIAL EVALUATING ZW25 IN PATIENTS WITH HER2-EXPRESSING SOLID TUMORS, INCLUDING BILIARY TRACT CANCER (BTC), COLORECTAL CANCER (CRC), GYNECOLOGICAL CANCERS, AND GASTROESOPHAGEAL ADENOCARCINOMA (GEA), IN A POSTER DISCUSSION PRESENTATION A...

ZYMEWORKS INC. ANNOUNCES UPDATED SINGLE AGENT DATA FOR HER2-TARGETED BISPECIFIC ANTIBODY ZW25 AT EUROPEAN SOCIETY FOR MEDICAL ONCOLOGY (ESMO) CONGRESS

ZYME

a5c0a04e-eb88-4264-9cb2-fb3140e63537

PressRelease

Press Release 0 2CRSI.PA 1 2CRSI.PA 2 2CRSI.PA 3 2CRSI.PA 4 2CRSI.PA ... 83 ZYXI 84 ZYXI 85 ZYXI 0 ZZZ.TO 1 ZZZ.TO Name: symbol, Length: 320040, dtype: object

2023-06-28 16:05:00

null

ANNUAL MEETING RECONVENED AND ADJOURNED WITHOUT CONDUCTING BUSINESS MEETING TO RECONVENE ON JULY 27, 2023 AT 9:00 AM EDT DEVON, PA., JUNE 28, 2023 (GLOBE NEWSWIRE) -- ZYNERBA PHARMACEUTICALS, INC. (NASDAQ: ZYNE) (THE “COMPANY”), THE LEADER IN INNOVATIVE PHARMACEUTICALLY-PRODUCED TRANSDERMAL CANNABINOID THERAPIES FOR OR...

ZYNERBA PHARMACEUTICALS ANNOUNCES FURTHER ADJOURNMENT OF ANNUAL MEETING

ZYNE

a5c0a04e-eb88-4264-9cb2-fb3140e63537

PressRelease

Press Release 0 2CRSI.PA 1 2CRSI.PA 2 2CRSI.PA 3 2CRSI.PA 4 2CRSI.PA ... 83 ZYXI 84 ZYXI 85 ZYXI 0 ZZZ.TO 1 ZZZ.TO Name: symbol, Length: 320040, dtype: object

2023-06-13 16:05:00

null

MEETING ADJOURNED WITH RESPECT TO PROPOSAL 2, REVERSE STOCK SPLIT; COMPANY ENCOURAGES ADDITIONAL STOCKHOLDERS OF RECORD TO VOTE BEFORE RECONVENED MEETING ON JUNE 28, 2023

ZYNERBA PHARMACEUTICALS ANNOUNCES PARTIAL ADJOURNMENT OF ANNUAL MEETING

ZYNE

a5c0a04e-eb88-4264-9cb2-fb3140e63537

PressRelease

Press Release 0 2CRSI.PA 1 2CRSI.PA 2 2CRSI.PA 3 2CRSI.PA 4 2CRSI.PA ... 83 ZYXI 84 ZYXI 85 ZYXI 0 ZZZ.TO 1 ZZZ.TO Name: symbol, Length: 320040, dtype: object

2023-05-23 07:00:00

null

DEVON, PA., MAY 23, 2023 (GLOBE NEWSWIRE) -- ZYNERBA PHARMACEUTICALS, INC. (NASDAQ: ZYNE), THE LEADER IN INNOVATIVE PHARMACEUTICALLY-PRODUCED TRANSDERMAL CANNABINOID THERAPIES FOR ORPHAN NEUROPSYCHIATRIC DISORDERS, TODAY ANNOUNCED AN ORAL PODIUM PRESENTATION AND POSTER PRESENTATIONS AT THE AMERICAN SOCIETY OF CLINICAL ...

ZYNERBA PHARMACEUTICALS ANNOUNCES PODIUM AND POSTER PRESENTATIONS AT THE AMERICAN SOCIETY OF CLINICAL PSYCHOPHARMACOLOGY ANNUAL MEETING

ZYNE

a5c0a04e-eb88-4264-9cb2-fb3140e63537

PressRelease

Press Release 0 2CRSI.PA 1 2CRSI.PA 2 2CRSI.PA 3 2CRSI.PA 4 2CRSI.PA ... 83 ZYXI 84 ZYXI 85 ZYXI 0 ZZZ.TO 1 ZZZ.TO Name: symbol, Length: 320040, dtype: object

2023-05-15 07:00:00

null

ENROLLMENT CONTINUES IN RECONNECT, A CONFIRMATORY PIVOTAL PHASE 3 TRIAL OF ZYGEL™ IN PATIENTS WITH FRAGILE X SYNDROME; TOPLINE RESULTS EXPECTED FIRST-HALF 2024

ZYNERBA PHARMACEUTICALS REPORTS FIRST QUARTER 2023 FINANCIAL RESULTS AND OPERATIONAL HIGHLIGHTS

ZYNE

a5c0a04e-eb88-4264-9cb2-fb3140e63537

PressRelease

Press Release 0 2CRSI.PA 1 2CRSI.PA 2 2CRSI.PA 3 2CRSI.PA 4 2CRSI.PA ... 83 ZYXI 84 ZYXI 85 ZYXI 0 ZZZ.TO 1 ZZZ.TO Name: symbol, Length: 320040, dtype: object

2023-04-12 07:30:00

null

ZYGEL CONTINUED TO BE WELL-TOLERATED WITH LONG-TERM ADMINISTRATION AND MAINTAINED CLINICALLY MEANINGFUL IMPROVEMENTS IN CHILDREN AND ADOLESCENTS WITH FRAGILE X SYNDROME

ZYNERBA PHARMACEUTICALS PRESENTS DATA ON ZYGEL™ AT THE 55TH GATLINBURG CONFERENCE

ZYNE

a5c0a04e-eb88-4264-9cb2-fb3140e63537

PressRelease

Press Release 0 2CRSI.PA 1 2CRSI.PA 2 2CRSI.PA 3 2CRSI.PA 4 2CRSI.PA ... 83 ZYXI 84 ZYXI 85 ZYXI 0 ZZZ.TO 1 ZZZ.TO Name: symbol, Length: 320040, dtype: object

2023-04-05 07:30:00

null

DEVON, PA., APRIL 05, 2023 (GLOBE NEWSWIRE) -- ZYNERBA PHARMACEUTICALS, INC. (NASDAQ: ZYNE), THE LEADER IN INNOVATIVE PHARMACEUTICALLY-PRODUCED TRANSDERMAL CANNABINOID THERAPIES FOR ORPHAN NEUROPSYCHIATRIC DISORDERS, TODAY ANNOUNCED THE PRESENTATION OF TWO POSTERS AT THE 55TH GATLINBURG CONFERENCE, BEING HELD APRIL 10-...

ZYNERBA PHARMACEUTICALS ANNOUNCES POSTER PRESENTATIONS AT THE 55TH GATLINBURG CONFERENCE

ZYNE

a5c0a04e-eb88-4264-9cb2-fb3140e63537

PressRelease

Press Release 0 2CRSI.PA 1 2CRSI.PA 2 2CRSI.PA 3 2CRSI.PA 4 2CRSI.PA ... 83 ZYXI 84 ZYXI 85 ZYXI 0 ZZZ.TO 1 ZZZ.TO Name: symbol, Length: 320040, dtype: object

2023-03-28 07:30:00

null

ENROLLMENT CONTINUES IN RECONNECT, A CONFIRMATORY PIVOTAL PHASE 3 TRIAL OF ZYGEL™ IN PATIENTS WITH FRAGILE X SYNDROME; TOPLINE RESULTS EXPECTED FIRST-HALF 2024

ZYNERBA PHARMACEUTICALS REPORTS FOURTH QUARTER AND FULL YEAR 2022 FINANCIAL RESULTS AND OPERATIONAL HIGHLIGHTS

ZYNE

a5c0a04e-eb88-4264-9cb2-fb3140e63537

PressRelease

Press Release 0 2CRSI.PA 1 2CRSI.PA 2 2CRSI.PA 3 2CRSI.PA 4 2CRSI.PA ... 83 ZYXI 84 ZYXI 85 ZYXI 0 ZZZ.TO 1 ZZZ.TO Name: symbol, Length: 320040, dtype: object

2023-03-13 16:15:00

null

DEVON, PA., MARCH 13, 2023 (GLOBE NEWSWIRE) -- ZYNERBA PHARMACEUTICALS, INC. (NASDAQ: ZYNE), THE LEADER IN INNOVATIVE PHARMACEUTICALLY-PRODUCED TRANSDERMAL CANNABINOID THERAPIES FOR ORPHAN NEUROPSYCHIATRIC DISORDERS, TODAY ISSUED A STATEMENT CONFIRMING THAT IT DOES NOT HOLD CASH DEPOSITS OR SECURITIES AT SILICON VALLEY...

ZYNERBA PHARMACEUTICALS CONFIRMS NOT HOLDING CASH DEPOSITS OR SECURITIES AT SILICON VALLEY BANK

ZYNE

a5c0a04e-eb88-4264-9cb2-fb3140e63537

PressRelease

Press Release 0 2CRSI.PA 1 2CRSI.PA 2 2CRSI.PA 3 2CRSI.PA 4 2CRSI.PA ... 83 ZYXI 84 ZYXI 85 ZYXI 0 ZZZ.TO 1 ZZZ.TO Name: symbol, Length: 320040, dtype: object

2023-01-11 08:30:00

null

COMPREHENSIVE DATA REVIEW SUGGESTS A CENTRAL ROLE FOR THE ENDOCANNABINOID SYSTEM (ECS) IN NEURONAL DEVELOPMENT, COGNITIVE FUNCTION AND IN THE PATHOGENESIS OF FRAGILE X SYNDROME (FXS)

ZYNERBA PHARMACEUTICALS ANNOUNCES PUBLICATION IN THE JOURNAL OF NEURODEVELOPMENTAL DISORDERS DESCRIBING THE ROLE OF THE ENDOCANNABINOID SYSTEM AND CANNABIDIOL THERAPY IN FRAGILE X SYNDROME

ZYNE

a5c0a04e-eb88-4264-9cb2-fb3140e63537

PressRelease

Press Release 0 2CRSI.PA 1 2CRSI.PA 2 2CRSI.PA 3 2CRSI.PA 4 2CRSI.PA ... 83 ZYXI 84 ZYXI 85 ZYXI 0 ZZZ.TO 1 ZZZ.TO Name: symbol, Length: 320040, dtype: object

2022-12-21 07:00:00

null

RECONNECT INITIAL SCREENING VISITS ARE BEING ADVERSELY IMPACTED BY ENVIRONMENTAL FACTORS, SUCH AS THE “TRIPLEDEMIC” (HIGH RATES OF RSV, INFLUENZA AND COVID-19); TOPLINE RESULTS NOW EXPECTED FIRST HALF OF 2024

ZYNERBA PHARMACEUTICALS ANNOUNCES UPDATE ON RECONNECT, THE PIVOTAL PHASE 3 TRIAL OF ZYGEL™ IN FRAGILE X SYNDROME

ZYNE

a5c0a04e-eb88-4264-9cb2-fb3140e63537

PressRelease

Press Release 0 2CRSI.PA 1 2CRSI.PA 2 2CRSI.PA 3 2CRSI.PA 4 2CRSI.PA ... 83 ZYXI 84 ZYXI 85 ZYXI 0 ZZZ.TO 1 ZZZ.TO Name: symbol, Length: 320040, dtype: object

2022-12-05 07:30:00

null

ZYGEL™ ACHIEVED STATISTICALLY SIGNIFICANT AND CLINICALLY MEANINGFUL IMPROVEMENTS FROM BASELINE IN MULTIPLE EFFICACY ASSESSMENTS AND WAS GENERALLY WELL-TOLERATED THROUGH 38 WEEKS OF TREATMENT

ZYNERBA PHARMACEUTICALS ANNOUNCES POSITIVE LONG-TERM DATA FROM PHASE 2 INSPIRE TRIAL IN 22Q11.2 DELETION SYNDROME AT THE ANNUAL MEETING OF THE AMERICAN COLLEGE OF NEUROPSYCHOPHARMACOLOGY

ZYNE

a5c0a04e-eb88-4264-9cb2-fb3140e63537

PressRelease

Press Release 0 2CRSI.PA 1 2CRSI.PA 2 2CRSI.PA 3 2CRSI.PA 4 2CRSI.PA ... 83 ZYXI 84 ZYXI 85 ZYXI 0 ZZZ.TO 1 ZZZ.TO Name: symbol, Length: 320040, dtype: object

2022-11-29 07:00:00

null

DEVON, PA., NOV. 29, 2022 (GLOBE NEWSWIRE) -- ZYNERBA PHARMACEUTICALS, INC. (NASDAQ: ZYNE), THE LEADER IN INNOVATIVE PHARMACEUTICALLY-PRODUCED TRANSDERMAL CANNABINOID THERAPIES FOR ORPHAN NEUROPSYCHIATRIC DISORDERS, TODAY ANNOUNCED THE PRESENTATION OF A POSTER AT THE 61ST ANNUAL MEETING OF THE AMERICAN COLLEGE OF NEURO...

ZYNERBA PHARMACEUTICALS ANNOUNCES POSTER PRESENTATION AT THE ANNUAL MEETING OF THE AMERICAN COLLEGE OF NEUROPSYCHOPHARMACOLOGY

ZYNE

a5c0a04e-eb88-4264-9cb2-fb3140e63537

PressRelease

Press Release 0 2CRSI.PA 1 2CRSI.PA 2 2CRSI.PA 3 2CRSI.PA 4 2CRSI.PA ... 83 ZYXI 84 ZYXI 85 ZYXI 0 ZZZ.TO 1 ZZZ.TO Name: symbol, Length: 320040, dtype: object

2022-11-28 07:30:00

null

STUDY FINDS PATIENTS WITH FRAGILE X WHO HAVE A HIGHLY METHYLATED FMR1 GENE THAT WERE TREATED WITH ZYGEL SHOWED A SIGNIFICANT REDUCTION IN BEHAVIORAL SYMPTOMS COMPARED TO THOSE TREATED WITH PLACEBO

ZYNERBA PHARMACEUTICALS ANNOUNCES PUBLICATION OF DATA FROM PHASE 3 CONNECT-FX STUDY OF ZYGEL™ IN THE JOURNAL OF NEURODEVELOPMENTAL DISORDERS

ZYNE

a5c0a04e-eb88-4264-9cb2-fb3140e63537

PressRelease

Press Release 0 2CRSI.PA 1 2CRSI.PA 2 2CRSI.PA 3 2CRSI.PA 4 2CRSI.PA ... 83 ZYXI 84 ZYXI 85 ZYXI 0 ZZZ.TO 1 ZZZ.TO Name: symbol, Length: 320040, dtype: object

2022-11-15 07:30:00

null

DEVON, PA., NOV. 15, 2022 (GLOBE NEWSWIRE) -- ZYNERBA PHARMACEUTICALS, INC. (NASDAQ: ZYNE), THE LEADER IN INNOVATIVE PHARMACEUTICALLY-PRODUCED TRANSDERMAL CANNABINOID THERAPIES FOR ORPHAN NEUROPSYCHIATRIC DISORDERS, TODAY ANNOUNCED THAT THE EUROPEAN COMMISSION (EC) HAS GRANTED ORPHAN DRUG DESIGNATION TO CANNABIDIOL, TH...

ZYNERBA PHARMACEUTICALS ANNOUNCES EUROPEAN COMMISSION HAS GRANTED ORPHAN DRUG DESIGNATION FOR ZYGEL™ IN 22Q11.2 DELETION SYNDROME

ZYNE

a5c0a04e-eb88-4264-9cb2-fb3140e63537

PressRelease

Press Release 0 2CRSI.PA 1 2CRSI.PA 2 2CRSI.PA 3 2CRSI.PA 4 2CRSI.PA ... 83 ZYXI 84 ZYXI 85 ZYXI 0 ZZZ.TO 1 ZZZ.TO Name: symbol, Length: 320040, dtype: object

2022-11-14 07:30:00

null

ENROLLMENT CONTINUES IN RECONNECT, A CONFIRMATORY PIVOTAL PHASE 3 TRIAL OF ZYGEL™ IN PATIENTS WITH FRAGILE X SYNDROME (FXS); TOPLINE RESULTS EXPECTED SECOND-HALF 2023

ZYNERBA PHARMACEUTICALS REPORTS THIRD QUARTER 2022 FINANCIAL RESULTS AND OPERATIONAL HIGHLIGHTS

ZYNE

a5c0a04e-eb88-4264-9cb2-fb3140e63537

PressRelease

Press Release 0 2CRSI.PA 1 2CRSI.PA 2 2CRSI.PA 3 2CRSI.PA 4 2CRSI.PA ... 83 ZYXI 84 ZYXI 85 ZYXI 0 ZZZ.TO 1 ZZZ.TO Name: symbol, Length: 320040, dtype: object

2022-11-02 07:30:00

null

DEVON, PA., NOV. 02, 2022 (GLOBE NEWSWIRE) -- ZYNERBA PHARMACEUTICALS, INC. (NASDAQ: ZYNE), THE LEADER IN INNOVATIVE PHARMACEUTICALLY-PRODUCED TRANSDERMAL CANNABINOID THERAPIES FOR ORPHAN NEUROPSYCHIATRIC DISORDERS, TODAY ANNOUNCED THAT THE U.S. PATENT AND TRADEMARK OFFICE HAS ISSUED PATENT NO. 11,458,109, TITLED “TREA...

ZYNERBA PHARMACEUTICALS ANNOUNCES ISSUANCE OF NEW U.S. PATENT FOR ZYGEL™ FOR THE TREATMENT OF 22Q11.2 DELETION SYNDROME

ZYNE

a5c0a04e-eb88-4264-9cb2-fb3140e63537

PressRelease

Press Release 0 2CRSI.PA 1 2CRSI.PA 2 2CRSI.PA 3 2CRSI.PA 4 2CRSI.PA ... 83 ZYXI 84 ZYXI 85 ZYXI 0 ZZZ.TO 1 ZZZ.TO Name: symbol, Length: 320040, dtype: object

2022-10-10 07:00:00

null

DEVON, PA., OCT. 10, 2022 (GLOBE NEWSWIRE) -- ZYNERBA PHARMACEUTICALS, INC. (NASDAQ: ZYNE), THE LEADER IN INNOVATIVE PHARMACEUTICALLY-PRODUCED TRANSDERMAL CANNABINOID THERAPIES FOR ORPHAN NEUROPSYCHIATRIC DISORDERS, TODAY ANNOUNCED THE PRESENTATION OF A POSTER AT THE 2022 NATIONAL ORGANIZATION FOR RARE DISORDERS (NORD)...

ZYNERBA PHARMACEUTICALS ANNOUNCES POSTER PRESENTATION AT THE NATIONAL ORGANIZATION FOR RARE DISORDERS (NORD) RARE DISEASES AND ORPHAN PRODUCTS BREAKTHROUGH SUMMIT

ZYNE

a5c0a04e-eb88-4264-9cb2-fb3140e63537

PressRelease

Press Release 0 2CRSI.PA 1 2CRSI.PA 2 2CRSI.PA 3 2CRSI.PA 4 2CRSI.PA ... 83 ZYXI 84 ZYXI 85 ZYXI 0 ZZZ.TO 1 ZZZ.TO Name: symbol, Length: 320040, dtype: object

2022-10-06 07:00:00

null

DEVON, PA., OCT. 06, 2022 (GLOBE NEWSWIRE) -- ZYNERBA PHARMACEUTICALS, INC. (NASDAQ: ZYNE), THE LEADER IN INNOVATIVE PHARMACEUTICALLY-PRODUCED TRANSDERMAL CANNABINOID THERAPIES FOR ORPHAN NEUROPSYCHIATRIC DISORDERS, TODAY ANNOUNCED THAT THE U.S. PATENT AND TRADEMARK OFFICE HAS ISSUED PATENT NO. 11,458,110, TITLED “TREA...

ZYNERBA PHARMACEUTICALS ANNOUNCES ISSUANCE OF NEW U.S. PATENT FOR ZYGEL™

ZYNE

a5c0a04e-eb88-4264-9cb2-fb3140e63537

PressRelease

Press Release 0 2CRSI.PA 1 2CRSI.PA 2 2CRSI.PA 3 2CRSI.PA 4 2CRSI.PA ... 83 ZYXI 84 ZYXI 85 ZYXI 0 ZZZ.TO 1 ZZZ.TO Name: symbol, Length: 320040, dtype: object

2022-09-29 07:00:00

null

DEVON, PA., SEPT. 29, 2022 (GLOBE NEWSWIRE) -- ZYNERBA PHARMACEUTICALS, INC. (NASDAQ: ZYNE), THE LEADER IN INNOVATIVE PHARMACEUTICALLY-PRODUCED TRANSDERMAL CANNABINOID THERAPIES FOR ORPHAN NEUROPSYCHIATRIC DISORDERS, TODAY ANNOUNCED THAT STEPHEN O'QUINN, PHARM.D., VICE PRESIDENT, MEDICAL AFFAIRS, ZYNERBA PHARMACEUTICAL...

ZYNERBA PHARMACEUTICALS TO PARTICIPATE IN THE CANTOR NEUROLOGY & PSYCHIATRY CONFERENCE

ZYNE

a5c0a04e-eb88-4264-9cb2-fb3140e63537

PressRelease

Press Release 0 2CRSI.PA 1 2CRSI.PA 2 2CRSI.PA 3 2CRSI.PA 4 2CRSI.PA ... 83 ZYXI 84 ZYXI 85 ZYXI 0 ZZZ.TO 1 ZZZ.TO Name: symbol, Length: 320040, dtype: object

2022-09-08 09:15:00

null

INSPIRE TRIAL IN 22Q ACHIEVED STATISTICALLY SIGNIFICANT AND CLINICALLY MEANINGFUL IMPROVEMENTS FROM BASELINE IN MULTIPLE EFFICACY ASSESSMENTS, WITH EXCELLENT TOLERABILITY PROFILE INSPIRE TRIAL IN 22Q ACHIEVED STATISTICALLY SIGNIFICANT AND CLINICALLY MEANINGFUL IMPROVEMENTS FROM BASELINE IN MULTIPLE EFFICACY ASSESSMENTS...

ZYNERBA PHARMACEUTICALS PRESENTS POSITIVE DATA FROM PHASE 2 INSPIRE TRIAL IN 22Q AT THE SOCIETY FOR THE STUDY OF BEHAVIOURAL PHENOTYPES (SSBP) 24TH INTERNATIONAL RESEARCH SYMPOSIUM

ZYNE

a5c0a04e-eb88-4264-9cb2-fb3140e63537

PressRelease

Press Release 0 2CRSI.PA 1 2CRSI.PA 2 2CRSI.PA 3 2CRSI.PA 4 2CRSI.PA ... 83 ZYXI 84 ZYXI 85 ZYXI 0 ZZZ.TO 1 ZZZ.TO Name: symbol, Length: 320040, dtype: object

2022-08-31 07:00:00

null

DEVON, PA., AUG. 31, 2022 (GLOBE NEWSWIRE) -- ZYNERBA PHARMACEUTICALS, INC. (NASDAQ: ZYNE), THE LEADER IN INNOVATIVE PHARMACEUTICALLY-PRODUCED TRANSDERMAL CANNABINOID THERAPIES FOR ORPHAN NEUROPSYCHIATRIC DISORDERS, TODAY ANNOUNCED THE ACCEPTANCE OF AN ORAL PRESENTATION AT THE SOCIETY FOR THE STUDY OF BEHAVIOURAL PHENO...

ZYNERBA PHARMACEUTICALS ANNOUNCES ORAL PRESENTATION AT THE SOCIETY FOR THE STUDY OF BEHAVIOURAL PHENOTYPES (SSBP) 24TH INTERNATIONAL RESEARCH SYMPOSIUM

ZYNE

a5c0a04e-eb88-4264-9cb2-fb3140e63537

PressRelease

Press Release 0 2CRSI.PA 1 2CRSI.PA 2 2CRSI.PA 3 2CRSI.PA 4 2CRSI.PA ... 83 ZYXI 84 ZYXI 85 ZYXI 0 ZZZ.TO 1 ZZZ.TO Name: symbol, Length: 320040, dtype: object

2022-08-10 07:00:00

null

ENROLLMENT CONTINUES IN RECONNECT, A CONFIRMATORY PIVOTAL PHASE 3 TRIAL OF ZYGEL™ IN PATIENTS WITH FRAGILE X SYNDROME (FXS); TOPLINE RESULTS EXPECTED SECOND-HALF 2023

ZYNERBA PHARMACEUTICALS REPORTS SECOND QUARTER 2022 FINANCIAL RESULTS AND OPERATIONAL HIGHLIGHTS

ZYNE

a5c0a04e-eb88-4264-9cb2-fb3140e63537

PressRelease

Press Release 0 2CRSI.PA 1 2CRSI.PA 2 2CRSI.PA 3 2CRSI.PA 4 2CRSI.PA ... 83 ZYXI 84 ZYXI 85 ZYXI 0 ZZZ.TO 1 ZZZ.TO Name: symbol, Length: 320040, dtype: object

2022-07-21 07:00:00

null

DEVON, PA., JULY 21, 2022 (GLOBE NEWSWIRE) -- ZYNERBA PHARMACEUTICALS, INC. (NASDAQ: ZYNE), THE LEADER IN INNOVATIVE PHARMACEUTICALLY-PRODUCED TRANSDERMAL CANNABINOID THERAPIES FOR ORPHAN NEUROPSYCHIATRIC DISORDERS, TODAY ANNOUNCED IT HAS ENTERED INTO AN EQUITY PURCHASE AGREEMENT FOR UP TO $20 MILLION WITH LINCOLN PARK...

ZYNERBA PHARMACEUTICALS ENTERS INTO EQUITY PURCHASE AGREEMENT FOR UP TO $20 MILLION WITH LINCOLN PARK CAPITAL

ZYNE

a5c0a04e-eb88-4264-9cb2-fb3140e63537

PressRelease

Press Release 0 2CRSI.PA 1 2CRSI.PA 2 2CRSI.PA 3 2CRSI.PA 4 2CRSI.PA ... 83 ZYXI 84 ZYXI 85 ZYXI 0 ZZZ.TO 1 ZZZ.TO Name: symbol, Length: 320040, dtype: object

2022-07-07 07:00:00

null

DEVON, PA., JULY 07, 2022 (GLOBE NEWSWIRE) -- ZYNERBA PHARMACEUTICALS, INC. (NASDAQ: ZYNE), THE LEADER IN INNOVATIVE PHARMACEUTICALLY-PRODUCED TRANSDERMAL CANNABINOID THERAPIES FOR RARE AND NEAR-RARE NEUROPSYCHIATRIC DISORDERS, TODAY ANNOUNCED TWO POSTER PRESENTATIONS AT THE 18TH NFXF INTERNATIONAL FRAGILE X CONFERENCE...

ZYNERBA PHARMACEUTICALS ANNOUNCES PANEL PRESENTATION AND POSTER PRESENTATIONS AT THE NFXF INTERNATIONAL FRAGILE X CONFERENCE

ZYNE

a5c0a04e-eb88-4264-9cb2-fb3140e63537

PressRelease

Press Release 0 2CRSI.PA 1 2CRSI.PA 2 2CRSI.PA 3 2CRSI.PA 4 2CRSI.PA ... 83 ZYXI 84 ZYXI 85 ZYXI 0 ZZZ.TO 1 ZZZ.TO Name: symbol, Length: 320040, dtype: object

2022-06-21 20:05:00

null

– THE INSPIRE TRIAL ACHIEVED STATISTICALLY SIGNIFICANT AND CLINICALLY MEANINGFUL IMPROVEMENTS FROM BASELINE IN MULTIPLE EFFICACY ASSESSMENTS –

ZYNERBA PHARMACEUTICALS ANNOUNCES POSITIVE TOP LINE RESULTS FROM OPEN-LABEL PHASE 2 INSPIRE TRIAL OF ZYGEL™ IN 22Q11.2 DELETION SYNDROME

ZYNE

a5c0a04e-eb88-4264-9cb2-fb3140e63537

PressRelease

Press Release 0 2CRSI.PA 1 2CRSI.PA 2 2CRSI.PA 3 2CRSI.PA 4 2CRSI.PA ... 83 ZYXI 84 ZYXI 85 ZYXI 0 ZZZ.TO 1 ZZZ.TO Name: symbol, Length: 320040, dtype: object

2022-06-01 07:00:00

null

– POSTER PRESENTATION HIGHLIGHTS DESIGN ENHANCEMENTS INCORPORATED INTO PIVOTAL RECONNECT TRIAL –

ZYNERBA PHARMACEUTICALS PRESENTS DATA ON ZYGEL™ AT THE AMERICAN SOCIETY OF CLINICAL PSYCHOPHARMACOLOGY ANNUAL MEETING

ZYNE

a5c0a04e-eb88-4264-9cb2-fb3140e63537

PressRelease

Press Release 0 2CRSI.PA 1 2CRSI.PA 2 2CRSI.PA 3 2CRSI.PA 4 2CRSI.PA ... 83 ZYXI 84 ZYXI 85 ZYXI 0 ZZZ.TO 1 ZZZ.TO Name: symbol, Length: 320040, dtype: object

2022-05-16 07:00:00

null

– ENROLLMENT CONTINUES IN RECONNECT, A CONFIRMATORY PIVOTAL PHASE 3 TRIAL OF ZYGEL™ IN PATIENTS WITH FRAGILE X SYNDROME (FXS); TOPLINE RESULTS EXPECTED SECOND-HALF 2023 –

ZYNERBA PHARMACEUTICALS REPORTS FIRST QUARTER 2022 FINANCIAL RESULTS AND OPERATIONAL HIGHLIGHTS

ZYNE

a5c0a04e-eb88-4264-9cb2-fb3140e63537

PressRelease

Press Release 0 2CRSI.PA 1 2CRSI.PA 2 2CRSI.PA 3 2CRSI.PA 4 2CRSI.PA ... 83 ZYXI 84 ZYXI 85 ZYXI 0 ZZZ.TO 1 ZZZ.TO Name: symbol, Length: 320040, dtype: object

2022-05-11 13:30:00

null

– DATA SUPPORT THE LONG-TERM SAFETY AND EFFECTIVENESS OF ZYGEL –

ZYNERBA PHARMACEUTICALS PRESENTS LONG-TERM SAFETY AND EFFICACY DATA OF ZYGEL™ IN CHILDREN AND ADOLESCENTS WITH FRAGILE X SYNDROME (FXS) AT THE INTERNATIONAL SOCIETY FOR AUTISM RESEARCH ANNUAL MEETING

ZYNE

a5c0a04e-eb88-4264-9cb2-fb3140e63537

PressRelease

Press Release 0 2CRSI.PA 1 2CRSI.PA 2 2CRSI.PA 3 2CRSI.PA 4 2CRSI.PA ... 83 ZYXI 84 ZYXI 85 ZYXI 0 ZZZ.TO 1 ZZZ.TO Name: symbol, Length: 320040, dtype: object

2022-05-09 16:57:00

null

DEVON, PA., MAY 09, 2022 (GLOBE NEWSWIRE) -- ZYNERBA PHARMACEUTICALS, INC. (NASDAQ: ZYNE), THE LEADER IN INNOVATIVE PHARMACEUTICALLY-PRODUCED TRANSDERMAL CANNABINOID THERAPIES FOR RARE AND NEAR-RARE NEUROPSYCHIATRIC DISORDERS, TODAY ANNOUNCED AN ORAL PODIUM PRESENTATION AT THE INTERNATIONAL SOCIETY FOR AUTISM RESEARCH ...

ZYNERBA PHARMACEUTICALS ANNOUNCES PODIUM PRESENTATION AT THE INTERNATIONAL SOCIETY FOR AUTISM RESEARCH ANNUAL MEETING

ZYNE

a5c0a04e-eb88-4264-9cb2-fb3140e63537

PressRelease

Press Release 0 2CRSI.PA 1 2CRSI.PA 2 2CRSI.PA 3 2CRSI.PA 4 2CRSI.PA ... 83 ZYXI 84 ZYXI 85 ZYXI 0 ZZZ.TO 1 ZZZ.TO Name: symbol, Length: 320040, dtype: object

2022-05-02 07:00:00

null

DEVON, PA., MAY 02, 2022 (GLOBE NEWSWIRE) -- ZYNERBA PHARMACEUTICALS, INC. (NASDAQ: ZYNE), THE LEADER IN INNOVATIVE PHARMACEUTICALLY-PRODUCED TRANSDERMAL CANNABINOID THERAPIES FOR RARE AND NEAR-RARE NEUROPSYCHIATRIC DISORDERS, PRESENTED A POSTER AT THE 2022 SOCIETY OF BIOLOGICAL PSYCHIATRY (SOBP) ANNUAL MEETING, HELD A...

ZYNERBA PHARMACEUTICALS PRESENTS LONG-TERM SAFETY AND EFFICACY DATA OF ZYGEL™ IN CHILDREN AND ADOLESCENTS WITH FRAGILE X SYNDROME (FXS) AT THE 2022 SOCIETY OF BIOLOGICAL PSYCHIATRY ANNUAL MEETING

ZYNE

a5c0a04e-eb88-4264-9cb2-fb3140e63537

PressRelease

Press Release 0 2CRSI.PA 1 2CRSI.PA 2 2CRSI.PA 3 2CRSI.PA 4 2CRSI.PA ... 83 ZYXI 84 ZYXI 85 ZYXI 0 ZZZ.TO 1 ZZZ.TO Name: symbol, Length: 320040, dtype: object

2022-04-21 07:00:00

null

DEVON, PA., APRIL 21, 2022 (GLOBE NEWSWIRE) -- ZYNERBA PHARMACEUTICALS, INC. (NASDAQ: ZYNE), THE LEADER IN INNOVATIVE PHARMACEUTICALLY-PRODUCED TRANSDERMAL CANNABINOID THERAPIES FOR RARE AND NEAR-RARE NEUROPSYCHIATRIC DISORDERS, TODAY ANNOUNCED THE PRESENTATION OF A POSTER AT THE 2022 SOCIETY OF BIOLOGICAL PSYCHIATRY (...

ZYNERBA PHARMACEUTICALS ANNOUNCES PRESENTATION OF POSTER AT THE 2022 SOCIETY OF BIOLOGICAL PSYCHIATRY ANNUAL MEETING

ZYNE

a5c0a04e-eb88-4264-9cb2-fb3140e63537

PressRelease

Press Release 0 2CRSI.PA 1 2CRSI.PA 2 2CRSI.PA 3 2CRSI.PA 4 2CRSI.PA ... 83 ZYXI 84 ZYXI 85 ZYXI 0 ZZZ.TO 1 ZZZ.TO Name: symbol, Length: 320040, dtype: object

2022-03-22 07:00:00

null

DEVON, PA., MARCH 22, 2022 (GLOBE NEWSWIRE) -- ZYNERBA PHARMACEUTICALS, INC. (NASDAQ: ZYNE), THE LEADER IN INNOVATIVE PHARMACEUTICALLY-PRODUCED TRANSDERMAL CANNABINOID THERAPIES FOR RARE AND NEAR-RARE NEUROPSYCHIATRIC DISORDERS, TODAY ANNOUNCED THAT STEPHEN O'QUINN, VICE PRESIDENT, MEDICAL AFFAIRS, ZYNERBA PHARMACEUTIC...

ZYNERBA PHARMACEUTICALS TO PARTICIPATE IN THE CANTOR RARE ORPHAN DISEASE SUMMIT

ZYNE

a5c0a04e-eb88-4264-9cb2-fb3140e63537

PressRelease

Press Release 0 2CRSI.PA 1 2CRSI.PA 2 2CRSI.PA 3 2CRSI.PA 4 2CRSI.PA ... 83 ZYXI 84 ZYXI 85 ZYXI 0 ZZZ.TO 1 ZZZ.TO Name: symbol, Length: 320040, dtype: object

2022-03-01 06:00:00

null

– EUROPEAN COMMISSION GRANTED ORPHAN DRUG DESIGNATION FOR ZYGEL™ IN FRAGILE X SYNDROME (FXS) –

ZYNERBA PHARMACEUTICALS REPORTS FOURTH QUARTER AND FULL YEAR 2021 FINANCIAL RESULTS AND OPERATIONAL HIGHLIGHTS

ZYNE

a5c0a04e-eb88-4264-9cb2-fb3140e63537

PressRelease

Press Release 0 2CRSI.PA 1 2CRSI.PA 2 2CRSI.PA 3 2CRSI.PA 4 2CRSI.PA ... 83 ZYXI 84 ZYXI 85 ZYXI 0 ZZZ.TO 1 ZZZ.TO Name: symbol, Length: 320040, dtype: object

2022-02-28 07:00:00

null

TOPLINE DATA FROM PHASE 2 INSPIRE TRIAL EXPECTED MID-YEAR 2022 TOPLINE DATA FROM PHASE 2 INSPIRE TRIAL EXPECTED MID-YEAR 2022

ZYNERBA PHARMACEUTICALS ANNOUNCES COMPLETION OF ENROLLMENT IN PHASE 2 TRIAL OF ZYGEL™ IN 22Q11.2 DELETION SYNDROME

ZYNE

a5c0a04e-eb88-4264-9cb2-fb3140e63537

PressRelease

Press Release 0 2CRSI.PA 1 2CRSI.PA 2 2CRSI.PA 3 2CRSI.PA 4 2CRSI.PA ... 83 ZYXI 84 ZYXI 85 ZYXI 0 ZZZ.TO 1 ZZZ.TO Name: symbol, Length: 320040, dtype: object

2022-02-15 07:00:00

null

DEVON, PA., FEB. 15, 2022 (GLOBE NEWSWIRE) -- ZYNERBA PHARMACEUTICALS, INC. (NASDAQ: ZYNE), THE LEADER IN INNOVATIVE PHARMACEUTICALLY-PRODUCED TRANSDERMAL CANNABINOID THERAPIES FOR RARE AND NEAR-RARE NEUROPSYCHIATRIC DISORDERS, TODAY ANNOUNCED THE APPOINTMENT OF ALBERT P. PARKER, AN ACCOMPLISHED INDUSTRY EXECUTIVE WITH...

ZYNERBA PHARMACEUTICALS ANNOUNCES PLANNED RETIREMENT OF SUZANNE HANLON AND APPOINTS ALBERT P. PARKER AS CHIEF LEGAL OFFICER

ZYNE

a5c0a04e-eb88-4264-9cb2-fb3140e63537

PressRelease

Press Release 0 2CRSI.PA 1 2CRSI.PA 2 2CRSI.PA 3 2CRSI.PA 4 2CRSI.PA ... 83 ZYXI 84 ZYXI 85 ZYXI 0 ZZZ.TO 1 ZZZ.TO Name: symbol, Length: 320040, dtype: object

2022-01-04 16:05:00

null

– COMPANY PLANS TO FOCUS DEVELOPMENT OF ZYGEL™ IN FXS, ASD AND 22Q –

ZYNERBA PHARMACEUTICALS ANNOUNCES CLINICAL DEVELOPMENT UPDATES FOR FXS, ASD, 22Q AND DEE

ZYNE

a5c0a04e-eb88-4264-9cb2-fb3140e63537

PressRelease

Press Release 0 2CRSI.PA 1 2CRSI.PA 2 2CRSI.PA 3 2CRSI.PA 4 2CRSI.PA ... 83 ZYXI 84 ZYXI 85 ZYXI 0 ZZZ.TO 1 ZZZ.TO Name: symbol, Length: 320040, dtype: object

2021-12-06 07:00:00

null

DEVON, PA., DEC. 06, 2021 (GLOBE NEWSWIRE) -- ZYNERBA PHARMACEUTICALS, INC. (NASDAQ: ZYNE), THE LEADER IN INNOVATIVE PHARMACEUTICALLY-PRODUCED TRANSDERMAL CANNABINOID THERAPIES FOR RARE AND NEAR-RARE NEUROPSYCHIATRIC DISORDERS, TODAY ANNOUNCED PRESENTATION DETAILS FOR THE BRAIN FOUNDATION SYNCHRONY 2021 SYMPOSIUM, BEIN...

ZYNERBA PHARMACEUTICALS ANNOUNCES PRESENTATION AT THE BRAIN FOUNDATION SYNCHRONY 2021 SYMPOSIUM

ZYNE

a5c0a04e-eb88-4264-9cb2-fb3140e63537

PressRelease

Press Release 0 2CRSI.PA 1 2CRSI.PA 2 2CRSI.PA 3 2CRSI.PA 4 2CRSI.PA ... 83 ZYXI 84 ZYXI 85 ZYXI 0 ZZZ.TO 1 ZZZ.TO Name: symbol, Length: 320040, dtype: object

2021-11-22 07:00:00

null

DEVON, PA., NOV. 22, 2021 (GLOBE NEWSWIRE) -- ZYNERBA PHARMACEUTICALS, INC. (NASDAQ: ZYNE), THE LEADER IN INNOVATIVE PHARMACEUTICALLY-PRODUCED TRANSDERMAL CANNABINOID THERAPIES FOR RARE AND NEAR-RARE NEUROPSYCHIATRIC DISORDERS, TODAY ANNOUNCED THAT THE EUROPEAN PATENT OFFICE HAS ISSUED PATENT NO. 3687513, TITLED “TREAT...

ZYNERBA PHARMACEUTICALS ANNOUNCES ISSUANCE OF NEW PATENT IN EU FOR ZYGEL™

ZYNE

a5c0a04e-eb88-4264-9cb2-fb3140e63537

PressRelease

Press Release 0 2CRSI.PA 1 2CRSI.PA 2 2CRSI.PA 3 2CRSI.PA 4 2CRSI.PA ... 83 ZYXI 84 ZYXI 85 ZYXI 0 ZZZ.TO 1 ZZZ.TO Name: symbol, Length: 320040, dtype: object

2021-10-21 07:00:00

null

DEVON, PA., OCT. 21, 2021 (GLOBE NEWSWIRE) -- ZYNERBA PHARMACEUTICALS, INC. (NASDAQ: ZYNE), THE LEADER IN INNOVATIVE PHARMACEUTICALLY-PRODUCED TRANSDERMAL CANNABINOID THERAPIES FOR RARE AND NEAR-RARE NEUROPSYCHIATRIC DISORDERS, TODAY ANNOUNCED ORAL AND POSTER PRESENTATIONS AT THE SOCIETY FOR DEVELOPMENTAL & BEHAVIORAL ...

ZYNERBA PHARMACEUTICALS ANNOUNCES PRESENTATIONS AT TWO UPCOMING SCIENTIFIC CONFERENCES IN OCTOBER

ZYNE

a5c0a04e-eb88-4264-9cb2-fb3140e63537

PressRelease

Press Release 0 2CRSI.PA 1 2CRSI.PA 2 2CRSI.PA 3 2CRSI.PA 4 2CRSI.PA ... 83 ZYXI 84 ZYXI 85 ZYXI 0 ZZZ.TO 1 ZZZ.TO Name: symbol, Length: 320040, dtype: object

2021-10-19 16:15:00

null

DEVON, PA., OCT. 19, 2021 (GLOBE NEWSWIRE) -- ZYNERBA PHARMACEUTICALS, INC. (NASDAQ: ZYNE), THE LEADER IN INNOVATIVE PHARMACEUTICALLY-PRODUCED TRANSDERMAL CANNABINOID THERAPIES FOR RARE AND NEAR-RARE NEUROPSYCHIATRIC DISORDERS, TODAY ANNOUNCED THE PRESENTATION OF A POSTER AT THE 2021 NATIONAL ORGANIZATION FOR RARE DISO...

ZYNERBA PHARMACEUTICALS ANNOUNCES PRESENTATION OF POSTER AT THE NATIONAL ORGANIZATION FOR RARE DISORDERS (NORD) RARE DISEASES AND ORPHAN PRODUCTS BREAKTHROUGH SUMMIT

ZYNE

a5c0a04e-eb88-4264-9cb2-fb3140e63537

PressRelease

Press Release 0 2CRSI.PA 1 2CRSI.PA 2 2CRSI.PA 3 2CRSI.PA 4 2CRSI.PA ... 83 ZYXI 84 ZYXI 85 ZYXI 0 ZZZ.TO 1 ZZZ.TO Name: symbol, Length: 320040, dtype: object

2021-10-08 07:30:00

null

DEVON, PA., OCT. 08, 2021 (GLOBE NEWSWIRE) -- ZYNERBA PHARMACEUTICALS, INC. (NASDAQ: ZYNE), THE LEADER IN INNOVATIVE PHARMACEUTICALLY-PRODUCED TRANSDERMAL CANNABINOID THERAPIES FOR RARE AND NEAR-RARE NEUROPSYCHIATRIC DISORDERS, TODAY ANNOUNCED THE PRESENTATION OF A POSTER AT THE 2021 AMERICAN ACADEMY OF PEDIATRICS (AAP...

ZYNERBA PHARMACEUTICALS ANNOUNCES PRESENTATION OF POSTER AT THE 2021 AMERICAN ACADEMY OF PEDIATRICS NATIONAL CONFERENCE & EXHIBITION

ZYNE

a5c0a04e-eb88-4264-9cb2-fb3140e63537

PressRelease

Press Release 0 2CRSI.PA 1 2CRSI.PA 2 2CRSI.PA 3 2CRSI.PA 4 2CRSI.PA ... 83 ZYXI 84 ZYXI 85 ZYXI 0 ZZZ.TO 1 ZZZ.TO Name: symbol, Length: 320040, dtype: object

2021-09-20 07:00:00

null

DEVON, PA., SEPT. 20, 2021 (GLOBE NEWSWIRE) -- ZYNERBA PHARMACEUTICALS, INC. (NASDAQ: ZYNE), THE LEADER IN INNOVATIVE PHARMACEUTICALLY-PRODUCED TRANSDERMAL CANNABINOID THERAPIES FOR RARE AND NEAR-RARE NEUROPSYCHIATRIC DISORDERS, TODAY ANNOUNCED THAT ARMANDO ANIDO, CHAIRMAN AND CHIEF EXECUTIVE OFFICER OF ZYNERBA, WILL P...

ZYNERBA PHARMACEUTICALS TO PRESENT AT THE CANTOR VIRTUAL GLOBAL HEALTHCARE CONFERENCE

ZYNE

a5c0a04e-eb88-4264-9cb2-fb3140e63537

PressRelease

Press Release 0 2CRSI.PA 1 2CRSI.PA 2 2CRSI.PA 3 2CRSI.PA 4 2CRSI.PA ... 83 ZYXI 84 ZYXI 85 ZYXI 0 ZZZ.TO 1 ZZZ.TO Name: symbol, Length: 320040, dtype: object

2021-09-09 07:00:00

null

DEVON, PA., SEPT. 09, 2021 (GLOBE NEWSWIRE) -- ZYNERBA PHARMACEUTICALS, INC. (NASDAQ: ZYNE), THE LEADER IN INNOVATIVE PHARMACEUTICALLY-PRODUCED TRANSDERMAL CANNABINOID THERAPIES FOR RARE AND NEAR-RARE NEUROPSYCHIATRIC DISORDERS, TODAY PRESENTED DATA FROM THE PHASE 2 BRIGHT TRIAL DESCRIBING TOLERABILITY AND EFFICACY OF ...

ZYNERBA PHARMACEUTICALS PRESENTS LONGER TERM TOLERABILITY AND EFFICACY DATA OF ZYGEL™ IN CHILDREN AND ADOLESCENTS WITH AUTISM SPECTRUM DISORDER (ASD) AT THE SOCIETY FOR THE STUDY OF BEHAVIOURAL PHENOTYPES (SSBP) CONFERENCE 2021

ZYNE

a5c0a04e-eb88-4264-9cb2-fb3140e63537

PressRelease

Press Release 0 2CRSI.PA 1 2CRSI.PA 2 2CRSI.PA 3 2CRSI.PA 4 2CRSI.PA ... 83 ZYXI 84 ZYXI 85 ZYXI 0 ZZZ.TO 1 ZZZ.TO Name: symbol, Length: 320040, dtype: object

2021-09-02 07:30:00

null

DEVON, PA., SEPT. 02, 2021 (GLOBE NEWSWIRE) -- ZYNERBA PHARMACEUTICALS, INC. (NASDAQ: ZYNE), THE LEADER IN INNOVATIVE PHARMACEUTICALLY-PRODUCED TRANSDERMAL CANNABINOID THERAPIES FOR RARE AND NEAR-RARE NEUROPSYCHIATRIC DISORDERS, TODAY ANNOUNCED THAT ARMANDO ANIDO, CHAIRMAN AND CHIEF EXECUTIVE OFFICER OF ZYNERBA, WILL P...

ZYNERBA PHARMACEUTICALS TO PRESENT AT THE H.C. WAINWRIGHT GLOBAL INVESTMENT CONFERENCE

ZYNE

a5c0a04e-eb88-4264-9cb2-fb3140e63537

PressRelease

Press Release 0 2CRSI.PA 1 2CRSI.PA 2 2CRSI.PA 3 2CRSI.PA 4 2CRSI.PA ... 83 ZYXI 84 ZYXI 85 ZYXI 0 ZZZ.TO 1 ZZZ.TO Name: symbol, Length: 320040, dtype: object

2021-08-09 07:00:00

null

DEVON, PA., AUG. 09, 2021 (GLOBE NEWSWIRE) -- ZYNERBA PHARMACEUTICALS, INC. (NASDAQ: ZYNE), THE LEADER IN INNOVATIVE PHARMACEUTICALLY-PRODUCED TRANSDERMAL CANNABINOID THERAPIES FOR RARE AND NEAR-RARE NEUROPSYCHIATRIC DISORDERS, TODAY REPORTED FINANCIAL RESULTS FOR THE SECOND QUARTER ENDED JUNE 30, 2021, AND PROVIDED AN...

ZYNERBA PHARMACEUTICALS REPORTS SECOND QUARTER 2021 FINANCIAL RESULTS AND OPERATIONAL HIGHLIGHTS

ZYNE

a5c0a04e-eb88-4264-9cb2-fb3140e63537

PressRelease

Press Release 0 2CRSI.PA 1 2CRSI.PA 2 2CRSI.PA 3 2CRSI.PA 4 2CRSI.PA ... 83 ZYXI 84 ZYXI 85 ZYXI 0 ZZZ.TO 1 ZZZ.TO Name: symbol, Length: 320040, dtype: object

2021-08-04 07:30:00

null

DEVON, PA., AUG. 04, 2021 (GLOBE NEWSWIRE) -- ZYNERBA PHARMACEUTICALS, INC. (NASDAQ: ZYNE), THE LEADER IN INNOVATIVE PHARMACEUTICALLY-PRODUCED TRANSDERMAL CANNABINOID THERAPIES FOR RARE AND NEAR-RARE NEUROPSYCHIATRIC DISORDERS, TODAY ANNOUNCED THAT COMPANY MANAGEMENT WILL PARTICIPATE IN A FIRESIDE CHAT DURING THE CANAC...

ZYNERBA PHARMACEUTICALS TO PRESENT AT THE CANACCORD GENUITY 41ST ANNUAL GROWTH CONFERENCE

ZYNE

a5c0a04e-eb88-4264-9cb2-fb3140e63537

PressRelease

Press Release 0 2CRSI.PA 1 2CRSI.PA 2 2CRSI.PA 3 2CRSI.PA 4 2CRSI.PA ... 83 ZYXI 84 ZYXI 85 ZYXI 0 ZZZ.TO 1 ZZZ.TO Name: symbol, Length: 320040, dtype: object

2021-07-07 07:30:00

null

DEVON, PA., JULY 07, 2021 (GLOBE NEWSWIRE) -- ZYNERBA PHARMACEUTICALS, INC. (NASDAQ: ZYNE), THE LEADER IN INNOVATIVE PHARMACEUTICALLY-PRODUCED TRANSDERMAL CANNABINOID THERAPIES FOR RARE AND NEAR-RARE NEUROPSYCHIATRIC DISORDERS, TODAY ANNOUNCED THAT ARMANDO ANIDO, CHAIRMAN AND CHIEF EXECUTIVE OFFICER OF ZYNERBA, WILL PR...

ZYNERBA PHARMACEUTICALS TO PRESENT AT THE LADENBURG THALMANN VIRTUAL HEALTHCARE CONFERENCE

ZYNE

a5c0a04e-eb88-4264-9cb2-fb3140e63537

PressRelease

Press Release 0 2CRSI.PA 1 2CRSI.PA 2 2CRSI.PA 3 2CRSI.PA 4 2CRSI.PA ... 83 ZYXI 84 ZYXI 85 ZYXI 0 ZZZ.TO 1 ZZZ.TO Name: symbol, Length: 320040, dtype: object

2021-06-11 12:30:00

null

DEVON, PA., JUNE 11, 2021 (GLOBE NEWSWIRE) -- ZYNERBA PHARMACEUTICALS, INC. (NASDAQ: ZYNE), THE LEADER IN INNOVATIVE PHARMACEUTICALLY-PRODUCED TRANSDERMAL CANNABINOID THERAPIES FOR RARE AND NEAR-RARE NEUROPSYCHIATRIC DISORDERS, PRESENTED A POSTER TODAY AT SLEEP 2021, THE 35TH ANNUAL MEETING OF THE ASSOCIATED PROFESSION...

ZYNERBA PHARMACEUTICALS PRESENTS SLEEP DATA FROM STUDY OF ZYGEL™ IN CHILDREN AND ADOLESCENTS WITH BOTH DEVELOPMENTAL AND EPILEPTIC ENCEPHALOPATHIES (DEE) AND AUTISM SPECTRUM DISORDER (ASD) AT THE ASSOCIATED PROFESSIONAL SLEEP SOCIETIES SLEEP 2021 ANNUAL MEETING

ZYNE

a5c0a04e-eb88-4264-9cb2-fb3140e63537

PressRelease

Press Release 0 2CRSI.PA 1 2CRSI.PA 2 2CRSI.PA 3 2CRSI.PA 4 2CRSI.PA ... 83 ZYXI 84 ZYXI 85 ZYXI 0 ZZZ.TO 1 ZZZ.TO Name: symbol, Length: 320040, dtype: object

2021-06-09 16:05:00

null

– 46.4% OF SHARES VOTED, QUORUM NOT ESTABLISHED TO HOLD ANNUAL MEETING –

ZYNERBA PHARMACEUTICALS ANNOUNCES ADJOURNMENT OF ANNUAL MEETING

ZYNE

a5c0a04e-eb88-4264-9cb2-fb3140e63537

PressRelease

Press Release 0 2CRSI.PA 1 2CRSI.PA 2 2CRSI.PA 3 2CRSI.PA 4 2CRSI.PA ... 83 ZYXI 84 ZYXI 85 ZYXI 0 ZZZ.TO 1 ZZZ.TO Name: symbol, Length: 320040, dtype: object

2021-06-04 07:30:00

null

DEVON, PA., JUNE 04, 2021 (GLOBE NEWSWIRE) -- ZYNERBA PHARMACEUTICALS, INC. (NASDAQ: ZYNE), THE LEADER IN INNOVATIVE PHARMACEUTICALLY-PRODUCED TRANSDERMAL CANNABINOID THERAPIES FOR RARE AND NEAR-RARE NEUROPSYCHIATRIC DISORDERS, TODAY ANNOUNCED THE ACCEPTANCE AND PRESENTATION DETAILS OF A POSTER AT SLEEP 2021, THE 35TH ...

ZYNERBA PHARMACEUTICALS ANNOUNCES ACCEPTANCE OF POSTER AT THE ASSOCIATED PROFESSIONAL SLEEP SOCIETIES SLEEP 2021 ANNUAL MEETING

ZYNE

a5c0a04e-eb88-4264-9cb2-fb3140e63537

PressRelease

Press Release 0 2CRSI.PA 1 2CRSI.PA 2 2CRSI.PA 3 2CRSI.PA 4 2CRSI.PA ... 83 ZYXI 84 ZYXI 85 ZYXI 0 ZZZ.TO 1 ZZZ.TO Name: symbol, Length: 320040, dtype: object

2021-06-03 10:00:00

null

DEVON, PA., JUNE 03, 2021 (GLOBE NEWSWIRE) -- ZYNERBA PHARMACEUTICALS, INC. (NASDAQ: ZYNE), THE LEADER IN INNOVATIVE PHARMACEUTICALLY-PRODUCED TRANSDERMAL CANNABINOID THERAPIES FOR RARE AND NEAR-RARE NEUROPSYCHIATRIC DISORDERS, IS PRESENTING A POSTER TODAY FROM 10:00 A.M. – 11:00 A.M. ET IN POSTER SESSION II AT THE 202...

ZYNERBA PHARMACEUTICALS ANNOUNCES PRESENTATION OF EFFICACY AND SAFETY FINDINGS IN CHILDREN AND ADOLESCENTS WITH AUTISM SPECTRUM DISORDER (ASD) AND RELATED DISORDERS AT THE 2021 AMERICAN SOCIETY OF CLINICAL PSYCHOPHARMACOLOGY (ASCP) ANNUAL MEETING

ZYNE

a5c0a04e-eb88-4264-9cb2-fb3140e63537

PressRelease

Press Release 0 2CRSI.PA 1 2CRSI.PA 2 2CRSI.PA 3 2CRSI.PA 4 2CRSI.PA ... 83 ZYXI 84 ZYXI 85 ZYXI 0 ZZZ.TO 1 ZZZ.TO Name: symbol, Length: 320040, dtype: object

2021-05-27 07:30:00

null

DEVON, PA., MAY 27, 2021 (GLOBE NEWSWIRE) -- ZYNERBA PHARMACEUTICALS, INC. (NASDAQ: ZYNE), THE LEADER IN INNOVATIVE PHARMACEUTICALLY-PRODUCED TRANSDERMAL CANNABINOID THERAPIES FOR RARE AND NEAR-RARE NEUROPSYCHIATRIC DISORDERS, TODAY ANNOUNCED THE ACCEPTANCE AND PRESENTATION DETAILS OF A POSTER AT THE 2021 AMERICAN SOCI...

ZYNERBA PHARMACEUTICALS ANNOUNCES ACCEPTANCE OF POSTER AT THE 2021 AMERICAN SOCIETY OF CLINICAL PSYCHOPHARMACOLOGY (ASCP) ANNUAL MEETING

ZYNE

a5c0a04e-eb88-4264-9cb2-fb3140e63537

PressRelease

Press Release 0 2CRSI.PA 1 2CRSI.PA 2 2CRSI.PA 3 2CRSI.PA 4 2CRSI.PA ... 83 ZYXI 84 ZYXI 85 ZYXI 0 ZZZ.TO 1 ZZZ.TO Name: symbol, Length: 320040, dtype: object

2021-05-26 07:30:00

null

DEVON, PA., MAY 26, 2021 (GLOBE NEWSWIRE) -- ZYNERBA PHARMACEUTICALS, INC. (NASDAQ: ZYNE), THE LEADER IN INNOVATIVE PHARMACEUTICALLY-PRODUCED TRANSDERMAL CANNABINOID THERAPIES FOR RARE AND NEAR-RARE NEUROPSYCHIATRIC DISORDERS, TODAY ANNOUNCED THAT ARMANDO ANIDO, CHAIRMAN AND CHIEF EXECUTIVE OFFICER OF ZYNERBA, WILL PRE...

ZYNERBA PHARMACEUTICALS TO PRESENT AT THE JEFFERIES VIRTUAL HEALTHCARE CONFERENCE

ZYNE

a5c0a04e-eb88-4264-9cb2-fb3140e63537

PressRelease

Press Release 0 2CRSI.PA 1 2CRSI.PA 2 2CRSI.PA 3 2CRSI.PA 4 2CRSI.PA ... 83 ZYXI 84 ZYXI 85 ZYXI 0 ZZZ.TO 1 ZZZ.TO Name: symbol, Length: 320040, dtype: object

2021-04-29 14:00:00

null

DEVON, PA., APRIL 29, 2021 (GLOBE NEWSWIRE) -- ZYNERBA PHARMACEUTICALS, INC. (NASDAQ: ZYNE), THE LEADER IN INNOVATIVE PHARMACEUTICALLY-PRODUCED TRANSDERMAL CANNABINOID THERAPIES FOR RARE AND NEAR-RARE NEUROPSYCHIATRIC DISORDERS, IS PRESENTING TWO POSTERS AT THE SOCIETY OF BIOLOGICAL PSYCHIATRY (SOBP) 2021 VIRTUAL MEETI...

ZYNERBA PHARMACEUTICALS PRESENTS TWO POSTERS AT THE SOCIETY OF BIOLOGICAL PSYCHIATRY 2021 VIRTUAL MEETING

ZYNE

a5c0a04e-eb88-4264-9cb2-fb3140e63537

PressRelease

Press Release 0 2CRSI.PA 1 2CRSI.PA 2 2CRSI.PA 3 2CRSI.PA 4 2CRSI.PA ... 83 ZYXI 84 ZYXI 85 ZYXI 0 ZZZ.TO 1 ZZZ.TO Name: symbol, Length: 320040, dtype: object

2021-04-15 07:30:00

null

DEVON, PA., APRIL 15, 2021 (GLOBE NEWSWIRE) -- ZYNERBA PHARMACEUTICALS, INC. (NASDAQ: ZYNE), THE LEADER IN INNOVATIVE PHARMACEUTICALLY-PRODUCED TRANSDERMAL CANNABINOID THERAPIES FOR RARE AND NEAR-RARE NEUROPSYCHIATRIC DISORDERS, TODAY ANNOUNCED THE ACCEPTANCE AND PRESENTATION DETAILS OF TWO POSTERS AT THE SOCIETY OF BI...

ZYNERBA PHARMACEUTICALS ANNOUNCES THE ACCEPTANCE OF TWO POSTERS AT THE SOCIETY OF BIOLOGICAL PSYCHIATRY 2021 VIRTUAL MEETING

ZYNE

a5c0a04e-eb88-4264-9cb2-fb3140e63537

PressRelease

Press Release 0 2CRSI.PA 1 2CRSI.PA 2 2CRSI.PA 3 2CRSI.PA 4 2CRSI.PA ... 83 ZYXI 84 ZYXI 85 ZYXI 0 ZZZ.TO 1 ZZZ.TO Name: symbol, Length: 320040, dtype: object

2021-04-06 07:30:00

null

DEVON, PA., APRIL 06, 2021 (GLOBE NEWSWIRE) -- ZYNERBA PHARMACEUTICALS, INC. (NASDAQ: ZYNE), THE LEADER IN INNOVATIVE PHARMACEUTICALLY-PRODUCED TRANSDERMAL CANNABINOID THERAPIES FOR RARE AND NEAR-RARE NEUROPSYCHIATRIC DISORDERS, TODAY ANNOUNCED THAT ARMANDO ANIDO, CHIEF EXECUTIVE OFFICER OF ZYNERBA, WILL PRESENT A COMP...

ZYNERBA PHARMACEUTICALS TO PRESENT AT THE NEEDHAM VIRTUAL HEALTHCARE CONFERENCE

ZYNE

a5c0a04e-eb88-4264-9cb2-fb3140e63537

PressRelease

Press Release 0 2CRSI.PA 1 2CRSI.PA 2 2CRSI.PA 3 2CRSI.PA 4 2CRSI.PA ... 83 ZYXI 84 ZYXI 85 ZYXI 0 ZZZ.TO 1 ZZZ.TO Name: symbol, Length: 320040, dtype: object

2021-03-28 08:15:00

null

SAN DIEGO, MARCH 28, 2021 /PRNEWSWIRE/ -- JOHNSON FISTEL, LLP IS INVESTIGATING POTENTIAL CLAIMS ON BEHALF OF ZYNERBA PHARMACEUTICALS, INC. (NASDAQ: ZYNE) ("ZYNERBA " OR THE "COMPANY") AGAINST CERTAIN OF ITS OFFICERS AND DIRECTORS. SPECIFICALLY, A CLASS-ACTION LAWSUIT PENDING IN THE EASTERN DISTRICT OF PENNSYLVANIA AGAI...

ZYNERBA (ZYNE) ALERT: SHAREHOLDER CLASS ACTION SURVIVES MOTION TO DISMISS; SHOULD MANAGEMENT BE HELD ACCOUNTABLE FOR INVESTORS LOSSES? CONTACT JOHNSON FISTEL

ZYNE

a5c0a04e-eb88-4264-9cb2-fb3140e63537

PressRelease

Press Release 0 2CRSI.PA 1 2CRSI.PA 2 2CRSI.PA 3 2CRSI.PA 4 2CRSI.PA ... 83 ZYXI 84 ZYXI 85 ZYXI 0 ZZZ.TO 1 ZZZ.TO Name: symbol, Length: 320040, dtype: object

2021-03-10 06:45:00

null

DEVON, PA., MARCH 10, 2021 (GLOBE NEWSWIRE) -- ZYNERBA PHARMACEUTICALS, INC. (NASDAQ: ZYNE), THE LEADER IN INNOVATIVE PHARMACEUTICALLY-PRODUCED TRANSDERMAL CANNABINOID THERAPIES FOR RARE AND NEAR-RARE NEUROPSYCHIATRIC DISORDERS, TODAY REPORTED FINANCIAL RESULTS FOR THE FOURTH QUARTER AND FULL YEAR ENDED DECEMBER 31, 20...

ZYNERBA PHARMACEUTICALS REPORTS FOURTH QUARTER AND FULL YEAR 2020 FINANCIAL RESULTS AND OPERATIONAL HIGHLIGHTS

ZYNE

a5c0a04e-eb88-4264-9cb2-fb3140e63537

PressRelease

Press Release 0 2CRSI.PA 1 2CRSI.PA 2 2CRSI.PA 3 2CRSI.PA 4 2CRSI.PA ... 83 ZYXI 84 ZYXI 85 ZYXI 0 ZZZ.TO 1 ZZZ.TO Name: symbol, Length: 320040, dtype: object

2021-03-04 08:00:00

null

DEVON, PA., MARCH 04, 2021 (GLOBE NEWSWIRE) -- ZYNERBA PHARMACEUTICALS, INC. (NASDAQ: ZYNE), THE LEADER IN INNOVATIVE PHARMACEUTICALLY-PRODUCED TRANSDERMAL CANNABINOID THERAPIES FOR RARE AND NEAR-RARE NEUROPSYCHIATRIC DISORDERS, TODAY ANNOUNCED THAT COMPANY MANAGEMENT WILL PARTICIPATE IN THE 33RD ANNUAL ROTH CONFERENCE...

ZYNERBA PHARMACEUTICALS TO PARTICIPATE IN THE 33RD ANNUAL ROTH CONFERENCE

ZYNE

a5c0a04e-eb88-4264-9cb2-fb3140e63537

PressRelease

Press Release 0 2CRSI.PA 1 2CRSI.PA 2 2CRSI.PA 3 2CRSI.PA 4 2CRSI.PA ... 83 ZYXI 84 ZYXI 85 ZYXI 0 ZZZ.TO 1 ZZZ.TO Name: symbol, Length: 320040, dtype: object

2020-12-17 06:30:00

null

- SINGLE TRIAL TO BE CONDUCTED IN PATIENTS WITH FRAGILE X SYNDROME TO CONFIRM POSITIVE RESULTS SEEN IN THE POPULATION OF RESPONDERS IN THE CONNECT-FX TRIAL -

ZYNERBA PHARMACEUTICALS PROVIDES REGULATORY UPDATE ON ZYGEL™ IN FRAGILE X SYNDROME

ZYNE

a5c0a04e-eb88-4264-9cb2-fb3140e63537

PressRelease

Press Release 0 2CRSI.PA 1 2CRSI.PA 2 2CRSI.PA 3 2CRSI.PA 4 2CRSI.PA ... 83 ZYXI 84 ZYXI 85 ZYXI 0 ZZZ.TO 1 ZZZ.TO Name: symbol, Length: 320040, dtype: object

2020-12-09 15:49:00

null

DENVER--(BUSINESS WIRE)--SHUMAN, GLENN & STECKER INVESTIGATES ZYNERBA PHARMACEUTICALS, INC. (ZYNE)

SHUMAN, GLENN & STECKER INVESTIGATES ZYNERBA PHARMACEUTICALS, INC.

ZYNE

a5c0a04e-eb88-4264-9cb2-fb3140e63537

PressRelease